WO2020208842A1 - 遺伝子組換え微生物及びこれを用いた目的物質の生産方法 - Google Patents
遺伝子組換え微生物及びこれを用いた目的物質の生産方法 Download PDFInfo
- Publication number
- WO2020208842A1 WO2020208842A1 PCT/JP2019/035286 JP2019035286W WO2020208842A1 WO 2020208842 A1 WO2020208842 A1 WO 2020208842A1 JP 2019035286 W JP2019035286 W JP 2019035286W WO 2020208842 A1 WO2020208842 A1 WO 2020208842A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino acid
- microorganism
- wild
- genetically modified
- activity
- Prior art date
Links
- 244000005700 microbiome Species 0.000 title claims abstract description 306
- 239000013076 target substance Substances 0.000 title claims description 80
- 238000004519 manufacturing process Methods 0.000 title description 91
- 108091000041 Phosphoenolpyruvate Carboxylase Proteins 0.000 claims abstract description 193
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims abstract description 170
- 235000003704 aspartic acid Nutrition 0.000 claims abstract description 159
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims abstract description 159
- 230000000694 effects Effects 0.000 claims abstract description 149
- 230000005764 inhibitory process Effects 0.000 claims abstract description 42
- 108010012901 Succinate Dehydrogenase Proteins 0.000 claims abstract description 25
- 102000019259 Succinate Dehydrogenase Human genes 0.000 claims abstract description 22
- 108700023483 L-lactate dehydrogenases Proteins 0.000 claims abstract description 21
- 102000003855 L-lactate dehydrogenase Human genes 0.000 claims abstract description 17
- 101710157142 2-methylene-furan-3-one reductase Proteins 0.000 claims abstract description 10
- 101710189291 Quinone oxidoreductase Proteins 0.000 claims abstract description 10
- 102100034576 Quinone oxidoreductase Human genes 0.000 claims abstract description 10
- DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical class OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 claims abstract description 5
- 150000001413 amino acids Chemical class 0.000 claims description 357
- 235000001014 amino acid Nutrition 0.000 claims description 257
- 229940024606 amino acid Drugs 0.000 claims description 162
- 229960005261 aspartic acid Drugs 0.000 claims description 157
- 238000006467 substitution reaction Methods 0.000 claims description 151
- 238000000034 method Methods 0.000 claims description 128
- 108090000623 proteins and genes Proteins 0.000 claims description 122
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 68
- 241000894006 Bacteria Species 0.000 claims description 51
- 239000002207 metabolite Substances 0.000 claims description 51
- 239000012634 fragment Substances 0.000 claims description 41
- 239000012429 reaction media Substances 0.000 claims description 39
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 34
- 239000001530 fumaric acid Substances 0.000 claims description 34
- 230000035772 mutation Effects 0.000 claims description 34
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 34
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 32
- 235000009582 asparagine Nutrition 0.000 claims description 32
- 229960001230 asparagine Drugs 0.000 claims description 32
- 239000004472 Lysine Substances 0.000 claims description 31
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 31
- 108090000854 Oxidoreductases Proteins 0.000 claims description 27
- 102000039446 nucleic acids Human genes 0.000 claims description 27
- 108020004707 nucleic acids Proteins 0.000 claims description 27
- 150000007523 nucleic acids Chemical class 0.000 claims description 27
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 26
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 24
- 239000008103 glucose Substances 0.000 claims description 24
- 102000004316 Oxidoreductases Human genes 0.000 claims description 22
- 241000186254 coryneform bacterium Species 0.000 claims description 21
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 claims description 20
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 15
- 150000001720 carbohydrates Chemical class 0.000 claims description 15
- 238000012258 culturing Methods 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical group OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 claims description 11
- 235000018102 proteins Nutrition 0.000 claims description 11
- 108090000856 Lyases Proteins 0.000 claims description 10
- 102000004317 Lyases Human genes 0.000 claims description 10
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 10
- 235000011090 malic acid Nutrition 0.000 claims description 10
- 229940107700 pyruvic acid Drugs 0.000 claims description 10
- 230000009261 transgenic effect Effects 0.000 claims description 9
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims description 8
- 241000588722 Escherichia Species 0.000 claims description 6
- 239000001630 malic acid Substances 0.000 claims description 6
- 230000006696 biosynthetic metabolic pathway Effects 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 229940000635 beta-alanine Drugs 0.000 claims description 4
- 230000000644 propagated effect Effects 0.000 claims description 4
- 229930029653 phosphoenolpyruvate Natural products 0.000 claims description 2
- 150000003893 lactate salts Chemical class 0.000 abstract 1
- 150000004728 pyruvic acid derivatives Chemical class 0.000 abstract 1
- 150000003890 succinate salts Chemical class 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 description 86
- 239000002609 medium Substances 0.000 description 75
- 238000006243 chemical reaction Methods 0.000 description 72
- 102000004190 Enzymes Human genes 0.000 description 66
- 108020004414 DNA Proteins 0.000 description 48
- 102000053602 DNA Human genes 0.000 description 48
- 210000004027 cell Anatomy 0.000 description 47
- 108091026890 Coding region Proteins 0.000 description 44
- 241000588724 Escherichia coli Species 0.000 description 39
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 39
- 239000013612 plasmid Substances 0.000 description 39
- 239000000243 solution Substances 0.000 description 38
- 239000000126 substance Substances 0.000 description 35
- 238000012360 testing method Methods 0.000 description 34
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 30
- 235000004400 serine Nutrition 0.000 description 30
- 235000018977 lysine Nutrition 0.000 description 29
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 26
- 241000186216 Corynebacterium Species 0.000 description 24
- 239000000047 product Substances 0.000 description 24
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 23
- 241000186226 Corynebacterium glutamicum Species 0.000 description 22
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 20
- 238000011144 upstream manufacturing Methods 0.000 description 20
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 19
- 239000004471 Glycine Substances 0.000 description 19
- 101150104734 ldh gene Proteins 0.000 description 19
- 230000001580 bacterial effect Effects 0.000 description 18
- 235000004279 alanine Nutrition 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 17
- 238000010367 cloning Methods 0.000 description 17
- 230000002950 deficient Effects 0.000 description 16
- 230000014509 gene expression Effects 0.000 description 16
- 229940076788 pyruvate Drugs 0.000 description 16
- 241000186031 Corynebacteriaceae Species 0.000 description 15
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 15
- 238000009776 industrial production Methods 0.000 description 15
- 229930027917 kanamycin Natural products 0.000 description 15
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 15
- 229960000318 kanamycin Drugs 0.000 description 15
- 229930182823 kanamycin A Natural products 0.000 description 15
- 101150023641 ppc gene Proteins 0.000 description 15
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 14
- 108010063172 Aspartate dehydrogenase Proteins 0.000 description 14
- 238000002744 homologous recombination Methods 0.000 description 14
- 230000006801 homologous recombination Effects 0.000 description 14
- 230000002503 metabolic effect Effects 0.000 description 14
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 13
- 239000013600 plasmid vector Substances 0.000 description 13
- 241000894007 species Species 0.000 description 13
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 12
- 238000005516 engineering process Methods 0.000 description 12
- 229910052799 carbon Inorganic materials 0.000 description 11
- 238000005119 centrifugation Methods 0.000 description 11
- 239000002773 nucleotide Substances 0.000 description 11
- 125000003729 nucleotide group Chemical group 0.000 description 11
- 150000007524 organic acids Chemical class 0.000 description 11
- DTBNBXWJWCWCIK-UHFFFAOYSA-K phosphonatoenolpyruvate Chemical class [O-]C(=O)C(=C)OP([O-])([O-])=O DTBNBXWJWCWCIK-UHFFFAOYSA-K 0.000 description 11
- 230000010076 replication Effects 0.000 description 11
- 239000004475 Arginine Substances 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 10
- 235000009697 arginine Nutrition 0.000 description 10
- 238000012262 fermentative production Methods 0.000 description 10
- 230000000813 microbial effect Effects 0.000 description 10
- 108091008146 restriction endonucleases Proteins 0.000 description 10
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 9
- 241000196324 Embryophyta Species 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 9
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 9
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 9
- 229930006000 Sucrose Natural products 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- 101150111581 pflB gene Proteins 0.000 description 9
- 239000007858 starting material Substances 0.000 description 9
- 239000001384 succinic acid Substances 0.000 description 9
- 239000005720 sucrose Substances 0.000 description 9
- 235000000346 sugar Nutrition 0.000 description 9
- 239000013598 vector Substances 0.000 description 9
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 8
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 8
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 8
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 8
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
- 239000013611 chromosomal DNA Substances 0.000 description 8
- 230000002255 enzymatic effect Effects 0.000 description 8
- 238000000855 fermentation Methods 0.000 description 8
- 230000004151 fermentation Effects 0.000 description 8
- 230000037353 metabolic pathway Effects 0.000 description 8
- -1 nitrogen-containing organic compounds Chemical class 0.000 description 8
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 8
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 8
- 241001485655 Corynebacterium glutamicum ATCC 13032 Species 0.000 description 7
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 7
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 7
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 7
- 210000004899 c-terminal region Anatomy 0.000 description 7
- 235000013922 glutamic acid Nutrition 0.000 description 7
- 239000004220 glutamic acid Substances 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 230000004060 metabolic process Effects 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 241000186146 Brevibacterium Species 0.000 description 6
- 108020004705 Codon Proteins 0.000 description 6
- 206010059866 Drug resistance Diseases 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 108700026244 Open Reading Frames Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 238000010353 genetic engineering Methods 0.000 description 6
- 229910017053 inorganic salt Inorganic materials 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 101150041530 ldha gene Proteins 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 238000005215 recombination Methods 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- 241000233866 Fungi Species 0.000 description 5
- 241000192041 Micrococcus Species 0.000 description 5
- 240000008042 Zea mays Species 0.000 description 5
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 5
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 5
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 5
- 229940041514 candida albicans extract Drugs 0.000 description 5
- 235000005822 corn Nutrition 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 108010008221 formate C-acetyltransferase Proteins 0.000 description 5
- 101150075213 frdA gene Proteins 0.000 description 5
- 101150091570 gapA gene Proteins 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 230000000415 inactivating effect Effects 0.000 description 5
- 229940099690 malic acid Drugs 0.000 description 5
- 150000002772 monosaccharides Chemical class 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- 150000004804 polysaccharides Chemical class 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000006798 recombination Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000012138 yeast extract Substances 0.000 description 5
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 239000004473 Threonine Substances 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- HWXBTNAVRSUOJR-UHFFFAOYSA-N alpha-hydroxyglutaric acid Natural products OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 description 4
- 229940009533 alpha-ketoglutaric acid Drugs 0.000 description 4
- 239000002518 antifoaming agent Substances 0.000 description 4
- 229940009098 aspartate Drugs 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 229940093915 gynecological organic acid Drugs 0.000 description 4
- 229940116298 l- malic acid Drugs 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 235000005985 organic acids Nutrition 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 4
- 239000013605 shuttle vector Substances 0.000 description 4
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- 229960003495 thiamine Drugs 0.000 description 4
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 4
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 4
- 229960002898 threonine Drugs 0.000 description 4
- 229940011671 vitamin b6 Drugs 0.000 description 4
- 239000002028 Biomass Substances 0.000 description 3
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 3
- 241000186145 Corynebacterium ammoniagenes Species 0.000 description 3
- ODBLHEXUDAPZAU-ZAFYKAAXSA-N D-threo-isocitric acid Chemical compound OC(=O)[C@H](O)[C@@H](C(O)=O)CC(O)=O ODBLHEXUDAPZAU-ZAFYKAAXSA-N 0.000 description 3
- 101710088194 Dehydrogenase Proteins 0.000 description 3
- 150000008575 L-amino acids Chemical class 0.000 description 3
- 239000006142 Luria-Bertani Agar Substances 0.000 description 3
- 239000001888 Peptone Substances 0.000 description 3
- 108010080698 Peptones Proteins 0.000 description 3
- 108091081021 Sense strand Proteins 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 210000004900 c-terminal fragment Anatomy 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 150000002016 disaccharides Chemical class 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000004898 n-terminal fragment Anatomy 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 235000019319 peptone Nutrition 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 101150060030 poxB gene Proteins 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 229920002477 rna polymer Polymers 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 210000001082 somatic cell Anatomy 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- VNOYUJKHFWYWIR-ITIYDSSPSA-N succinyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 VNOYUJKHFWYWIR-ITIYDSSPSA-N 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- LGQKSQQRKHFMLI-SJYYZXOBSA-N (2s,3r,4s,5r)-2-[(3r,4r,5r,6r)-4,5,6-trihydroxyoxan-3-yl]oxyoxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)CO[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)OC1 LGQKSQQRKHFMLI-SJYYZXOBSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 2
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- LGQKSQQRKHFMLI-UHFFFAOYSA-N 4-O-beta-D-xylopyranosyl-beta-D-xylopyranose Natural products OC1C(O)C(O)COC1OC1C(O)C(O)C(O)OC1 LGQKSQQRKHFMLI-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 2
- 241000193403 Clostridium Species 0.000 description 2
- 241001644925 Corynebacterium efficiens Species 0.000 description 2
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- SQNRKWHRVIAKLP-UHFFFAOYSA-N D-xylobiose Natural products O=CC(O)C(O)C(CO)OC1OCC(O)C(O)C1O SQNRKWHRVIAKLP-UHFFFAOYSA-N 0.000 description 2
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000235058 Komagataella pastoris Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241001467578 Microbacterium Species 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229920000805 Polyaspartic acid Polymers 0.000 description 2
- 241000192142 Proteobacteria Species 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 108010053763 Pyruvate Carboxylase Proteins 0.000 description 2
- 102100039895 Pyruvate carboxylase, mitochondrial Human genes 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 101150053469 SDHC gene Proteins 0.000 description 2
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 229930003451 Vitamin B1 Natural products 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 241000235013 Yarrowia Species 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000002154 agricultural waste Substances 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 150000003862 amino acid derivatives Chemical class 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 239000001099 ammonium carbonate Substances 0.000 description 2
- 235000012501 ammonium carbonate Nutrition 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
- 239000008122 artificial sweetener Substances 0.000 description 2
- 235000021311 artificial sweeteners Nutrition 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 229920006167 biodegradable resin Polymers 0.000 description 2
- 235000010633 broth Nutrition 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 229960003563 calcium carbonate Drugs 0.000 description 2
- 235000013877 carbamide Nutrition 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- GTZCVFVGUGFEME-HNQUOIGGSA-N cis-Aconitic acid Natural products OC(=O)C\C(C(O)=O)=C/C(O)=O GTZCVFVGUGFEME-HNQUOIGGSA-N 0.000 description 2
- GTZCVFVGUGFEME-IWQZZHSRSA-N cis-aconitic acid Chemical compound OC(=O)C\C(C(O)=O)=C\C(O)=O GTZCVFVGUGFEME-IWQZZHSRSA-N 0.000 description 2
- 229910000361 cobalt sulfate Inorganic materials 0.000 description 2
- 229940044175 cobalt sulfate Drugs 0.000 description 2
- KTVIXTQDYHMGHF-UHFFFAOYSA-L cobalt(2+) sulfate Chemical compound [Co+2].[O-]S([O-])(=O)=O KTVIXTQDYHMGHF-UHFFFAOYSA-L 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 2
- 235000019797 dipotassium phosphate Nutrition 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 238000003028 enzyme activity measurement method Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 239000000174 gluconic acid Substances 0.000 description 2
- 235000012208 gluconic acid Nutrition 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 150000002484 inorganic compounds Chemical class 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 238000007852 inverse PCR Methods 0.000 description 2
- SURQXAFEQWPFPV-UHFFFAOYSA-L iron(2+) sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Fe+2].[O-]S([O-])(=O)=O SURQXAFEQWPFPV-UHFFFAOYSA-L 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 229940099596 manganese sulfate Drugs 0.000 description 2
- 239000011702 manganese sulphate Substances 0.000 description 2
- 235000007079 manganese sulphate Nutrition 0.000 description 2
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229940127554 medical product Drugs 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 229910017464 nitrogen compound Inorganic materials 0.000 description 2
- 150000002830 nitrogen compounds Chemical class 0.000 description 2
- 150000003867 organic ammonium compounds Chemical class 0.000 description 2
- 230000033116 oxidation-reduction process Effects 0.000 description 2
- 229940055726 pantothenic acid Drugs 0.000 description 2
- 235000019161 pantothenic acid Nutrition 0.000 description 2
- 239000011713 pantothenic acid Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 108010064470 polyaspartate Proteins 0.000 description 2
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2
- 239000004323 potassium nitrate Substances 0.000 description 2
- 235000010333 potassium nitrate Nutrition 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 239000003531 protein hydrolysate Substances 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- 235000008160 pyridoxine Nutrition 0.000 description 2
- 239000011677 pyridoxine Substances 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 101150047761 sdhA gene Proteins 0.000 description 2
- 101150108347 sdhB gene Proteins 0.000 description 2
- 101150114996 sdhd gene Proteins 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- JXOHGGNKMLTUBP-HSUXUTPPSA-N shikimic acid Chemical compound O[C@@H]1CC(C(O)=O)=C[C@@H](O)[C@H]1O JXOHGGNKMLTUBP-HSUXUTPPSA-N 0.000 description 2
- JXOHGGNKMLTUBP-JKUQZMGJSA-N shikimic acid Natural products O[C@@H]1CC(C(O)=O)=C[C@H](O)[C@@H]1O JXOHGGNKMLTUBP-JKUQZMGJSA-N 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 239000004317 sodium nitrate Substances 0.000 description 2
- 235000010344 sodium nitrate Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000010907 stover Substances 0.000 description 2
- 239000010902 straw Substances 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 235000019157 thiamine Nutrition 0.000 description 2
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 2
- 239000011721 thiamine Substances 0.000 description 2
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 2
- 239000011747 thiamine hydrochloride Substances 0.000 description 2
- 229960000344 thiamine hydrochloride Drugs 0.000 description 2
- GTZCVFVGUGFEME-UHFFFAOYSA-N trans-aconitic acid Natural products OC(=O)CC(C(O)=O)=CC(O)=O GTZCVFVGUGFEME-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000012137 tryptone Substances 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 235000014393 valine Nutrition 0.000 description 2
- 235000010374 vitamin B1 Nutrition 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- 235000019158 vitamin B6 Nutrition 0.000 description 2
- 239000011726 vitamin B6 Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 2
- 229910000368 zinc sulfate Inorganic materials 0.000 description 2
- 229960001763 zinc sulfate Drugs 0.000 description 2
- IOCJWNPYGRVHLN-MMALYQPHSA-N (2r)-2-amino-3-[[(2r)-2-amino-2-carboxyethyl]disulfanyl]propanoic acid;hydrochloride Chemical compound Cl.OC(=O)[C@@H](N)CSSC[C@H](N)C(O)=O IOCJWNPYGRVHLN-MMALYQPHSA-N 0.000 description 1
- LXJXRIRHZLFYRP-VKHMYHEASA-L (R)-2-Hydroxy-3-(phosphonooxy)-propanal Natural products O=C[C@H](O)COP([O-])([O-])=O LXJXRIRHZLFYRP-VKHMYHEASA-L 0.000 description 1
- FECNVDHIIJYRIA-UHFFFAOYSA-N 2-oxopentanedioic acid Chemical compound OC(=O)CCC(=O)C(O)=O.OC(=O)CCC(=O)C(O)=O FECNVDHIIJYRIA-UHFFFAOYSA-N 0.000 description 1
- WVMWZWGZRAXUBK-JLEYCGRDSA-N 3-dehydroquinic acid Chemical compound O[C@H]1C[C@](O)(C(O)=O)CC(=O)[C@@H]1O WVMWZWGZRAXUBK-JLEYCGRDSA-N 0.000 description 1
- WVMWZWGZRAXUBK-UHFFFAOYSA-N 3-dehydroquinic acid Natural products OC1CC(O)(C(O)=O)CC(=O)C1O WVMWZWGZRAXUBK-UHFFFAOYSA-N 0.000 description 1
- SLWWJZMPHJJOPH-PHDIDXHHSA-N 3-dehydroshikimic acid Chemical compound O[C@@H]1CC(C(O)=O)=CC(=O)[C@H]1O SLWWJZMPHJJOPH-PHDIDXHHSA-N 0.000 description 1
- ALYNCZNDIQEVRV-PZFLKRBQSA-N 4-amino-3,5-ditritiobenzoic acid Chemical compound [3H]c1cc(cc([3H])c1N)C(O)=O ALYNCZNDIQEVRV-PZFLKRBQSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- GVUOPSNMFBICMM-UHFFFAOYSA-N 5-bromo-6-morpholin-4-yl-1h-pyrimidine-2,4-dione Chemical compound OC1=NC(O)=C(Br)C(N2CCOCC2)=N1 GVUOPSNMFBICMM-UHFFFAOYSA-N 0.000 description 1
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 101150030347 ASPDH gene Proteins 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 102000006589 Alpha-ketoglutarate dehydrogenase Human genes 0.000 description 1
- 108020004306 Alpha-ketoglutarate dehydrogenase Proteins 0.000 description 1
- 241001135756 Alphaproteobacteria Species 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 241000186063 Arthrobacter Species 0.000 description 1
- 241000186074 Arthrobacter globiformis Species 0.000 description 1
- 241000783679 Arthrobacter globiformis NBRC 12137 Species 0.000 description 1
- 108700016171 Aspartate ammonia-lyases Proteins 0.000 description 1
- 102100032948 Aspartoacylase Human genes 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 240000006439 Aspergillus oryzae Species 0.000 description 1
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 1
- 108010023063 Bacto-peptone Proteins 0.000 description 1
- 241001135755 Betaproteobacteria Species 0.000 description 1
- 241001025270 Brevibacterium album Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- RZZPDXZPRHQOCG-OJAKKHQRSA-O CDP-choline(1+) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-O 0.000 description 1
- 108091033409 CRISPR Proteins 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- 241000193401 Clostridium acetobutylicum Species 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- 241000595586 Coryne Species 0.000 description 1
- 241001517047 Corynebacterium acetoacidophilum Species 0.000 description 1
- 241001584962 Corynebacterium ammoniagenes DSM 20306 Species 0.000 description 1
- 241000272947 Corynebacterium callunae DSM 20147 Species 0.000 description 1
- 241000446654 Corynebacterium deserti Species 0.000 description 1
- 241000243347 Corynebacterium deserti GIMN1.010 Species 0.000 description 1
- 241000272936 Corynebacterium doosanense Species 0.000 description 1
- 241000549500 Corynebacterium doosanense CAU 212 = DSM 45436 Species 0.000 description 1
- 241001487058 Corynebacterium efficiens YS-314 Species 0.000 description 1
- 241000291063 Corynebacterium halotolerans Species 0.000 description 1
- 241000272969 Corynebacterium halotolerans YIM 70093 = DSM 44683 Species 0.000 description 1
- 241000015585 Corynebacterium humireducens Species 0.000 description 1
- 241000015586 Corynebacterium humireducens NBRC 106098 = DSM 45392 Species 0.000 description 1
- 241000778959 Corynebacterium marinum Species 0.000 description 1
- 241000012542 Corynebacterium marinum DSM 44953 Species 0.000 description 1
- 241001236603 Corynebacterium maris Species 0.000 description 1
- 241000012543 Corynebacterium maris DSM 45190 Species 0.000 description 1
- 241000133018 Corynebacterium melassecola Species 0.000 description 1
- 241000337023 Corynebacterium thermoaminogenes Species 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- 241000003367 Cryptococcus sp. S-2 Species 0.000 description 1
- 241000252867 Cupriavidus metallidurans Species 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 235000000638 D-biotin Nutrition 0.000 description 1
- 239000011665 D-biotin Substances 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- LXJXRIRHZLFYRP-VKHMYHEASA-N D-glyceraldehyde 3-phosphate Chemical compound O=C[C@H](O)COP(O)(O)=O LXJXRIRHZLFYRP-VKHMYHEASA-N 0.000 description 1
- SLWWJZMPHJJOPH-UHFFFAOYSA-N DHS Natural products OC1CC(C(O)=O)=CC(=O)C1O SLWWJZMPHJJOPH-UHFFFAOYSA-N 0.000 description 1
- 101100170485 Danio rerio sdhdb gene Proteins 0.000 description 1
- 108020005199 Dehydrogenases Proteins 0.000 description 1
- 241001135761 Deltaproteobacteria Species 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241000741267 Enterobacteriaceae bacterium Species 0.000 description 1
- 241001148568 Epsilonproteobacteria Species 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- 108010046276 FLP recombinase Proteins 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000192128 Gammaproteobacteria Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 101000797251 Homo sapiens Aspartoacylase Proteins 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- 241001138401 Kluyveromyces lactis Species 0.000 description 1
- 241000191948 Kocuria rosea Species 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 1
- 101100179119 Methanopyrus kandleri (strain AV19 / DSM 6324 / JCM 9639 / NBRC 100938) fni gene Proteins 0.000 description 1
- 241000191938 Micrococcus luteus Species 0.000 description 1
- 240000003433 Miscanthus floridulus Species 0.000 description 1
- 241001661345 Moesziomyces antarcticus Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 description 1
- 241000320412 Ogataea angusta Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 241000947836 Pseudomonadaceae Species 0.000 description 1
- 241000893045 Pseudozyma Species 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
- 241000191025 Rhodobacter Species 0.000 description 1
- 241000190932 Rhodopseudomonas Species 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 241000193448 Ruminiclostridium thermocellum Species 0.000 description 1
- 241000235346 Schizosaccharomyces Species 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 101100398785 Streptococcus agalactiae serotype V (strain ATCC BAA-611 / 2603 V/R) ldhD gene Proteins 0.000 description 1
- 241000204666 Thermotoga maritima Species 0.000 description 1
- 241000656145 Thyrsites atun Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 101100023132 Wolinella succinogenes (strain ATCC 29543 / DSM 1740 / LMG 7466 / NCTC 11488 / FDC 602W) sdhE gene Proteins 0.000 description 1
- 241000235015 Yarrowia lipolytica Species 0.000 description 1
- 241001561178 Zetaproteobacteria Species 0.000 description 1
- 101100386830 Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4) ddh gene Proteins 0.000 description 1
- 241000319304 [Brevibacterium] flavum Species 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000006757 chemical reactions by type Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- DUYAAUVXQSMXQP-UHFFFAOYSA-N ethanethioic S-acid Chemical compound CC(S)=O DUYAAUVXQSMXQP-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 235000014705 isoleucine Nutrition 0.000 description 1
- 101150109249 lacI gene Proteins 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 101150026107 ldh1 gene Proteins 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 235000005772 leucine Nutrition 0.000 description 1
- 101150082109 lldD gene Proteins 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 238000006241 metabolic reaction Methods 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000018791 negative regulation of catalytic activity Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 101150094986 pepC gene Proteins 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000013930 proline Nutrition 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 229940079889 pyrrolidonecarboxylic acid Drugs 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 229910052979 sodium sulfide Inorganic materials 0.000 description 1
- GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 241001446247 uncultured actinomycete Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/77—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Corynebacterium; for Brevibacterium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0008—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/001—Oxidoreductases (1.) acting on the CH-CH group of donors (1.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
- C12P13/06—Alanine; Leucine; Isoleucine; Serine; Homoserine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
- C12P13/20—Aspartic acid; Asparagine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
- C12P13/22—Tryptophan; Tyrosine; Phenylalanine; 3,4-Dihydroxyphenylalanine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
- C12P7/42—Hydroxy-carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
- C12P7/44—Polycarboxylic acids
- C12P7/46—Dicarboxylic acids having four or less carbon atoms, e.g. fumaric acid, maleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01028—D-Lactate dehydrogenase (1.1.1.28)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y103/00—Oxidoreductases acting on the CH-CH group of donors (1.3)
- C12Y103/99—Oxidoreductases acting on the CH-CH group of donors (1.3) with other acceptors (1.3.99)
- C12Y103/99001—Succinate dehydrogenase (1.3.99.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/15—Corynebacterium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/185—Escherichia
- C12R2001/19—Escherichia coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01027—L-Lactate dehydrogenase (1.1.1.27)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
- C12Y102/05—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with a quinone or similar compound as acceptor (1.2.5)
- C12Y102/05001—Pyruvate dehydrogenase (quinone) (1.2.5.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y103/00—Oxidoreductases acting on the CH-CH group of donors (1.3)
- C12Y103/01—Oxidoreductases acting on the CH-CH group of donors (1.3) with NAD+ or NADP+ as acceptor (1.3.1)
- C12Y103/01006—Fumarate reductase (NADH) (1.3.1.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y103/00—Oxidoreductases acting on the CH-CH group of donors (1.3)
- C12Y103/05—Oxidoreductases acting on the CH-CH group of donors (1.3) with a quinone or related compound as acceptor (1.3.5)
- C12Y103/05001—Succinate dehydrogenase (ubiquinone) (1.3.5.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y103/00—Oxidoreductases acting on the CH-CH group of donors (1.3)
- C12Y103/05—Oxidoreductases acting on the CH-CH group of donors (1.3) with a quinone or related compound as acceptor (1.3.5)
- C12Y103/05004—Fumarate reductase (menaquinone) (1.3.5.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y401/00—Carbon-carbon lyases (4.1)
- C12Y401/01—Carboxy-lyases (4.1.1)
- C12Y401/01031—Phosphoenolpyruvate carboxylase (4.1.1.31)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y401/00—Carbon-carbon lyases (4.1)
- C12Y401/01—Carboxy-lyases (4.1.1)
- C12Y401/01032—Phosphoenolpyruvate carboxykinase (GTP) (4.1.1.32)
Definitions
- the present invention is a modified phosphoenols that reduce or inactivate certain enzymatic activities such as lactate dehydrogenase enzyme activity, succinate dehydrogenase enzyme activity or fumaric acid reductase activity and are resistant to feedback inhibition by aspartic acid.
- the present invention relates to a recombinant microorganism having pyruvate carboxylase activity and a method for producing a substance using the same. This application is based on the Japanese Patent Application No. submitted to the Japan Patent Office on April 12, 2019. Priority is claimed based on JP2019-76629 (Japanese Patent Application No. 2019-76629), and the contents of the above-mentioned Japanese patent application are incorporated herein by reference for all purposes.
- amino acids made from petroleum-derived raw materials there are also amino acids made from petroleum-derived raw materials.
- aspartame which is widely used in medical products, food additives, artificial sweeteners, etc.
- aspartic acid which is widely used as a raw material for polyaspartic acid, which is a biodegradable resin
- Fumaric acid synthesized in is used as a raw material. More specifically, a method of synthesizing aspartic acid by adding ammonia to fumaric acid synthesized from petroleum and allowing an aspartate enzyme produced by a microorganism to act on the fumaric acid is adopted.
- Patent Document 1 describes a mutant aspartic acid dehirogenase in which the enzyme activity is enhanced by introducing a mutation into aspartic acid dehirogenase derived from Bacillus subtilis, and a method for producing L-aspartic acid using the same. ing.
- the method for producing L-aspartic acid described in Patent Document 1 actually purifies the above-mentioned mutant aspartic acid dehydrogenase expressed in Escherichia coli, and produces aspartic acid in an in vitro enzyme reaction system using the purified mutant enzyme. The method of making it is adopted. Therefore, strictly speaking, the method described in Patent Document 1 cannot be said to be a fermentation production technique for aspartic acid.
- Patent Document 2 aspartic acid derived from Pseudomonas erginoza PA01 strain and Ralstonia eutropha JM134 strain, which exhibit high catalytic activity even at room temperature. A dehirogenase has been found, and a method for producing L-aspartic acid using these aspartic acid dehydrogenases is disclosed. More specifically, in Patent Document 2, an enzyme mixture was prepared by treating Escherichia coli expressing the above-mentioned predetermined aspartate dehydrogenase with toluene, and aspartic acid was produced by an in vitro enzyme method using the enzyme mixture.
- Patent Document 4 describes an Enterobacteriaceae bacterium that produces L-aspartic acid or a metabolite derived from it by introducing aspartate dehydrogenase, and L-aspartic acid using the bacterium or derived from it. A method for producing a metabolite is disclosed.
- the bacteria disclosed in Patent Document 4 are specifically obtained by introducing various heterologous aspartate dehydrogenase genes derived from Thermotoga maritima, Corynebacterium glutamicum, etc. into Escherichia coli (Escherichia coli) or the like. It is a recombinant.
- Patent Document 4 shows that L-aspartic acid and its downstream metabolites can be increased to a certain extent according to Escherichia coli imparted with the enzyme activity by introducing such a heterologous aspartate dehydrogenase gene. ..
- aspartic acid is widely used as a raw material for medical products, food additives, aspartame used as an artificial sweetener, and polyaspartic acid which is a biodegradable resin.
- aspartic acid has an important role in microorganisms as an intermediate for additional metabolites such as ⁇ -alanine and asparagine, and strengthening the metabolic system to aspartic acid is aspartic acid. It can be said that it is also important in the development of fermentation production technology for the above metabolites derived from.
- the subject of the present invention is to enable the production of aspartic acid or a metabolite derived from it from a sugar source by direct fermentation by a microorganism instead of the above-mentioned conventional method using aspartate dehydrogenase, and can be applied to industrial production.
- the purpose is to provide technology that can achieve a certain level of production efficiency.
- Patent Document 4 describes a method for producing L-aspartic acid or a metabolite downstream thereof using Escherichia coli or the like modified to have various heterogeneous aspartate dehydrogenases, and additionally.
- Some metabolizing enzymes such as ⁇ -ketoglutarate dehydrogenase and further strengthening some metabolizing enzymes such as phosphoenolpyruvate carboxylase.
- Patent Document 4 since the technique disclosed in Patent Document 4 is a technique that depends on the expression of various heterologous aspartate dehydrogenases in Escherichia coli or the like, a sufficient expression level of the heterologous enzyme protein in the cells. It can be said that it is difficult to realize. Therefore, Patent Document 4 does not suggest any knowledge regarding the fermentative production of aspartic acid and related metabolites that can be applied to industrial production.
- Patent Document 5 discloses a method for producing an amino acid using a coryneform bacterium inactivated by lactate dehydrogenase. However, in the first place, Patent Document 5 is a technique focusing on the production of total amino acids, and the patent document does not describe or suggest findings on the fermentative production of aspartic acid and related metabolites that can be applied to industrial production. ..
- Patent Document 6 Escherichia coli and corynebacterium into which a mutant phosphoenolpyruvate carboxylase having a mutation that releases feedback inhibition of phosphoenolpyruvate carboxylase by aspartic acid in phosphoenolpyruvate carboxylase derived from Escherichia coli was introduced. -It is disclosed that glutamicum was produced and that various amino acids were produced using these. However, Patent Document 6 only describes that glutamic acid and lysine were actually produced, and neither describes nor suggests the findings regarding the fermentative production of aspartic acid and related metabolites that can be applied to industrial production.
- Patent Document 7 introduces a modified phosphoenolpyruvate carboxylase gene derived from alfalfa, which does not require acetyl-CoA as a coenzyme and has a property desensitized to feedback inhibition by aspartic acid.
- Recombinant bacteria such as Corinebacterium glutamicum have been disclosed, and formally, a method for producing an amino acid using the recombinant bacterium is also described.
- Patent Document 7 only describes that lysine was actually produced, and does not describe or suggest any knowledge regarding the fermentative production of aspartic acid or related metabolites that can be applied to industrial production.
- Non-Patent Document 1 predetermined metabolic enzymes such as succinate dehydrogenase (SDH) and pyruvate: quinone oxide reductase (PQO) were inactivated and a predetermined single amino acid substitution was introduced in corinebacterium glutamicum. Overexpression of mutant pyruvate carboxylase and wild phosphoenolpyruvate carboxylase has been shown to improve succinate production. Since Non-Patent Document 7 discloses a technique focusing on the production of succinic acid, neither description nor suggestion is made regarding the fermentative production of aspartic acid and related metabolites that can be applied to industrial production.
- SDH succinate dehydrogenase
- PQO quinone oxide reductase
- Non-Patent Document 2 when a predetermined one amino acid substitution such as N917G is applied to phosphoenolpyruvate carboxylase derived from corinebacterium glutamicum, the enzyme activity is maintained and compared with the wild type. Therefore, it has been shown that feedback inhibition by aspartic acid and the like is reduced, and that the amount of lysine produced is improved in corynebacterium glutamicum into which the mutant ppc having the above-mentioned one amino acid mutation is introduced. Since Non-Patent Document 2 only shows the production of ricin using the above-mentioned mutant ppc, the findings on the fermentative production of aspartic acid and related metabolites that can be applied to industrial production are described and suggested. Absent.
- Non-Patent Document 3 when a predetermined one amino acid substitution such as D299N is applied to phosphoenolpyruvate carboxylase derived from corinebacterium glutamic acid, the enzyme activity is maintained and compared with the wild type. , Feedback inhibition by aspartic acid, ⁇ -ketoglutaric acid, etc. can be reduced, and the production of glutamic acid and aspartic acid can be improved in corinebacterium glutamicum introduced with the above-mentioned monoamino acid-substituted mutant ppc. It is shown.
- a predetermined one amino acid substitution such as D299N
- Non-Patent Document 3 is not a document that describes findings on fermentative production of aspartic acid and related metabolites that can be applied to industrial production.
- Non-Patent Document 4 states that, with respect to phosphoenolpyruvate carboxylase derived from Escherichia coli, the mutant enzyme in which the 620th lysine is replaced with serine has the property that the feedback inhibition by aspartic acid and malic acid is reduced. It is stated to show.
- Non-Patent Document 4 is a mere academic study in which the effect of amino acid mutation on the above feedback inhibition on phosphoenolpyruvate carboxylase derived from Escherichia coli was investigated by an in vitro assay using a purified recombinant enzyme from the viewpoint of enzyme kinetics. This is a paper. Therefore, Non-Patent Document 4 is not a document that describes findings on fermentative production of aspartic acid and related metabolites that can be applied to industrial production.
- the present inventor inactivates predetermined enzyme activities such as succinate dehydrogenase activity or fumaric acid reductase activity and lactate dehydrogenase activity in microorganisms, and inhibits feedback by aspartic acid. It was found that the production efficiency of aspartic acid and its related metabolites was improved by imparting modified phosphoenolpyruvate carboxylase activity showing resistance to aspartic acid. The present invention has been completed based on such findings.
- Condition (IV) The pyruvate: quinone oxidoreductase activity is reduced or inactivated as compared with the wild-type microorganism described above.
- at least two of the conditions (I), (II) and (IV) may be satisfied, and in certain embodiments, the conditions (I) and (II). ), Both of the conditions (I) and (IV), or both of the conditions (II) and (IV) may be satisfied.
- a nucleic acid encoding a mutant phosphoenolpyruvate carboxylase derived from a bacterium has been introduced in a form capable of expressing the mutant phosphoenolpyruvate carboxylase, and the mutant phosphoenolpyruvate carboxylase is the above gene.
- nucleic acid encoding mutant phosphoenolpyruvate carboxylase derived from bacteria is referred to as "nucleic acid encoding exogenous phosphoenolpyruvate carboxylase derived from microorganisms, plants, prokaryotes or bacteria”.
- An embodiment can also be adopted by reading ".
- the at least one amino acid mutation in the mutant phosphoenolpyruvate carboxylase is selected from the group consisting of the amino acid substitutions shown in the following (a) to (f) based on the amino acid sequence shown in SEQ ID NO: 2.
- the at least one amino acid mutation in the mutant phosphoenolpyruvate carboxylase is selected from the group consisting of the amino acid substitutions shown in (g) to (l) below with reference to the amino acid sequence shown in SEQ ID NO: 2.
- the at least one amino acid mutation in the mutant phosphoenolpyruvate carboxylase includes the amino acid substitution shown in (g) above and at least one of the amino acid substitutions shown in (h) to (l) above. , [8].
- the at least one amino acid mutation in the mutant phosphoenolpyruvate carboxylase comprises the amino acid substitution shown in (g) above and the amino acid substitution shown in (i) or (l) above, [8] or The transgenic microorganism according to [9].
- any one of [4] to [10], wherein the mutant phosphoenolpyruvate carboxylase has an amino acid sequence shown in any one of (A), (B) and (C) below.
- the amino acid sequence of wild-type phosphoenolpyruvate carboxylase possessed by a microorganism belonging to a coryneform bacterium has an amino acid mutation capable of reducing feedback inhibition by aspartic acid in the wild-type phosphoenolpyruvate carboxylase activity.
- the amino acid mutation is based on the amino acid sequence shown in SEQ ID NO: 2.
- II Substitution of the amino acid corresponding to the 813th lysine to a predetermined amino acid (however, the amino acid after the substitution is not lysine); or (l) the amino acid corresponding to the 917th asparagine.
- Amino acid substitution to a given amino acid (however, the amino acid after substitution shall not be asparagin), Including at least To the amino acid sequence of the wild-type phosphoenolpyruvate carboxylase, resistance to feedback inhibition by aspartic acid is higher than that of a protein having only the amino acid substitutions specified in (g), (i) or (l). Is high, Mutant phosphoenolpyruvate carboxylase.
- the amino acid corresponding to the 813th lysine is preferably replaced with alanine, asparagine, glycine or serine.
- the amino acid corresponding to the 917th asparagine is preferably replaced with alanine, phenylalanine, glycine or serine, and more preferably replaced with phenylalanine or glycine.
- [16] The mutant phosphoenolpyruvate carboxylase according to [14] or [15], which has the amino acid sequence shown in any one of (J), (K) and (L) below:
- (J) An amino acid sequence obtained by introducing the above amino acid substitution into the amino acid sequence shown in any one of SEQ ID NOs: 2 to 13 (preferably SEQ ID NOs: 2 to 12, more preferably SEQ ID NO: 2 to 11);
- (K) An amino acid sequence in which one or more amino acids are deleted, substituted and / or added in the amino acid sequence specified in (J) above (provided that the amino acid substitution is maintained);
- (L) An amino acid sequence having at least 60% sequence identity with respect to the amino acid sequence specified in (J) above (provided that the amino acid substitution is maintained).
- [19] A nucleic acid encoding the mutant phosphoenolpyruvate carboxylase according to any one of [14] to [18]. [20] The nucleic acid according to [19], which is a DNA fragment.
- Condition (IV) satisfies that pyruvic acid: quinone oxidase reductase is reduced or inactivated as compared with the wild-type microorganism corresponding to the above-mentioned recombinant microorganism, [1] to [ 13] and the genetically modified microorganism according to any one of [21] to [24].
- [26] The genetically modified microorganism according to any one of [1] to [13] and [21] to [25], which is a genetically modified microorganism belonging to a bacterium.
- the genetically modified microorganism according to [28] which is a genetically modified microorganism belonging to the genus Corynebacterium.
- the genetically modified microorganism according to [31] which is a genetically modified microorganism belonging to the genus Escherichia.
- the genetically modified microorganism according to [32] which is a genetically modified microorganism of Escherichia coli.
- any one of [31] to [33] satisfies that the pyruvate formic acid lyase activity is reduced or inactivated as compared with the wild-type microorganism.
- condition (I) and / or condition (II) and / or condition (IV) and / or condition (V) in the above-mentioned genetically modified microorganism is satisfied on the chromosomal DNA of the above-mentioned genetically modified microorganism.
- the coding region of the acid dehydrogenase gene or the fumaric acid reductase gene and / or the lactate dehydrogenase gene coding region and / or the pyruvate: quinone oxide reductase gene coding region and / or the pyruvate formate lyase gene coding region is completely or The genetically modified microorganism according to any one of [1] to [13] and [21] to [34], which is realized by being partially destroyed.
- condition (I) and / or condition (II) and / or condition (IV) and / or condition (V) in the genetically modified microorganism is a succinate dehydrogenase on the chromosomal DNA of the recombinant microorganism.
- Gene or fumarate reductase gene coding region and / or lactate dehydrogenase gene coding region and / or pyruvate quinone oxide reductase gene coding region and / or pyruvate formate lyase gene coding region upstream of each gene
- the genetically modified microorganism according to any one of [1] to [13] and [21] to [35], which is realized by completely or partially disrupting the expression control region.
- a target substance is produced using the cells of the recombinant microorganism according to any one of [1] to [13] and [21] to [36] or a processed product thereof. That; and (q) recovering the above-mentioned target substance, A method of producing a target substance, including.
- step (p) the cells of the recombinant microorganism or a processed product thereof are reacted in the reaction medium (X) under reducing conditions in which the recombinant microorganism does not substantially grow.
- the redox potential of the reaction medium (X) is a predetermined value in the range of ⁇ 200 millivolts to ⁇ 500 millivolts.
- the reaction medium (X) contains a saccharide.
- step (P') Culturing and growing the recombinant microorganism in a predetermined medium (Y) under aerobic conditions.
- Y a predetermined medium
- the cells of the genetically modified microorganism or the processed product thereof, which are further contained and propagated in the step (p') are subjected to the test in the step (p). The method described.
- the present invention it is possible to improve the production efficiency of aspartic acid and metabolites produced by metabolic pathways derived from the aspartic acid, and as a result, the yield of the target substance can be improved.
- the efficiency of conversion of a starting substrate such as a saccharide to a target substance can be improved, and as a result, energy saving of a bioprocess, cost reduction, and efficient substance production can be realized.
- Genetically modified microorganisms that satisfy at least one of the following conditions (I), (II) and (IV) and satisfy the following condition (III):
- Condition (I) The succinate dehydrogenase activity or the fumaric acid reductase activity is reduced or inactivated as compared with the wild-type microorganism corresponding to the above-mentioned recombinant microorganism;
- Condition (II) Lactate dehydrogenase activity is reduced or inactivated as compared with the above wild-type microorganisms;
- the following genetically modified microorganisms are also provided. Genetically modified microorganisms that satisfy all of the following conditions (I) to (III): Condition (I) The succinate dehydrogenase activity or the fumaric acid reductase activity is reduced or inactivated as compared with the wild-type microorganism corresponding to the above-mentioned recombinant microorganism; Condition (II) Lactate dehydrogenase activity is reduced or inactivated as compared with the above wild-type microorganisms; Condition (III) More than modified phosphoenolpyruvate carboxylase activity showing resistance to feedback inhibition by aspartic acid in wild phosphoenolpyruvate carboxylase activity, or wild phosphoenolpyruvate carboxylase activity shown by the above wild microorganisms.
- Condition (I) The succinate dehydrogenase activity or the fumaric acid reductase activity is reduced or inactivated as compared with the wild-type microorganism
- the genetically modified microorganism according to the first aspect of the present invention and the genetically modified microorganism according to the second aspect of the invention are collectively referred to as “the genetically modified microorganism of the present invention” or “the present invention. Such genetically modified microorganisms "may be referred to.
- microorganism may be interpreted literally, and more specifically, in the present invention, "microorganism” or “genetically modified microorganism” is a prokaryote of a bacterium, an archaea, a cyanobacterial bacterium, or the like. It can be a living thing.
- the "microorganism” or “genetically modified microorganism” is preferably a fungus or a bacterium, and more preferably a bacterium.
- Saccharomyces yeast e.g., Saccharomyces cerevisiae
- Schizosaccharomyces Romi KES genus yeasts e.g., Schizosaccharomyces pombe
- Pichia yeast e.g., Pichia pastoris
- click Louis web b Kluyveromyces yeast Kluyveromyces lactis
- Hansenula polymorpha Yarrowia yeasts (e.g., Yarrowia lipolytica)
- Cryptococcus fungi e.g., Cryptococcus sp.
- Saccharomyces cerevisiae Schizosaccharomyces pombe , Pichia pastoris and the like can be conveniently used in the present invention because gene recombination technology and a heterologous protein expression system have been established.
- the bacteria e.g., Escherichia (e.g., Escherichia coli), Bacillus (e.g., Bacillus subtilis), Lactobacillus spp (e.g., Lactobacillus acidophilus), clostridium bacteria (e.g., Clostridium thermocellum, Clostridium acetobutylicum) Rod Examples include the genus Pseudomonas (eg, Rhodopseudomonas pulustris ), the genus Rhodopseudom ( Rhodobacter capsaturus ), and the bacteria belonging to the corine-type bacteria described in detail below.
- Escherichia e.g., Escherichia coli
- Bacillus e.g., Bacillus subtilis
- Lactobacillus spp e.g., Lactobacillus acidophilus
- clostridium bacteria e.g., Clostridium thermocellum, Clo
- microorganism or “genetically modified microorganism” in the present invention has already established a gene recombination technique and a protein expression system, and enables substance production under reducing conditions in which cells do not substantially proliferate. It is preferably a bacterium or a coryneform bacterium, more preferably an Escherichia coli or a coryneform bacterium, and most preferably a Corynebacterium spp.
- the recombinant microorganism according to the present invention is a microorganism belonging to a Gram-positive bacterium (for example, actinomycete).
- the recombinant microorganism according to the present invention may be a microorganism belonging to a Gram-negative bacterium.
- Gram-negative bacteria are specifically microorganisms belonging to the phylum Proteobacteria, and more specifically, microorganisms belonging to the Alpha-, Beta-, Gamma-, Delta-, Epsilon- or Zeta-Proteobacteria, and oligos. Includes microorganisms belonging to the Proteobacteria.
- Examples of Gram-negative bacteria that can be preferably used in the present invention include microorganisms belonging to the family Enterobacteriaceae, Vibrio or Pseudomonadaceae.
- coryneform bacterium refers to a group of microorganisms defined in Bergey's Manual of Determinative Bacteriology (Vol. 8, p. 599, 1974). More specifically, as coryneform bacteria, Corynebacterium spp., Brevibacterium spp., Arthrobacter spp., Mycobacterium spp., Micrococcus ( Examples thereof include Micrococcus spp., Microbacterium spp.
- Corynebacterium spp. include the following species and strains.
- Corynebacterium glutamicum eg, FERM P-18976 strain, ATCC13032 strain, ATCC31831 strain, ATCC13058 strain, ATCC13059 strain, ATCC13060 strain, ATCC13232 strain, ATCC13286 strain, ATCC13287 strain, ATCC1375 strain, ATCC1373 strain , ATCC13761 strain, ATCC14020 strain
- Corynebacterium acetoglutamicum eg, ATCC15806 strain
- Corynebacterium acetoacidophilum eg, ATCC13870 strain
- Corynebacterium melassecola eg, ATCC17965 strain
- Corynebacterium efficiens eg, YS-314 strain, YS-314 T strain (NBRC100395 T strain)
- Corynebacterium alkanoliticum eg, ATCC21511 strain
- Corynebacterium marinum eg, DSM44953 strain
- Corynebacterium humireducens eg, NBRC106098 strain
- Corynebacterium halotolerans eg, YIM70093 strain
- Brevibacterium divaricatum (Brevibacterium divaricatum) (for example ATCC14020 shares); Brevibacterium flavum [for example, MJ-233 (FERM BP-1497) strain, MJ-233AB-41 (FERM BP-1498) strain, ATCC13826 strain, ATCC14067 strain, ATCC13826 strain]; Brevibacterium imariophyllum (eg, ATCC14068 strain); Brevibacterium lactofermentum (Corynebacterium glutamicum) (Brevibacterium lactofermentum (Corynebacterium glutamicum) ) ( for example ATCC13869 shares); Brevibacterium roseum (eg, ATCC13825 strain); Brevibacterium saccharoliticum (eg, ATCC14066 strain); Brevibacterium thiogenitalis (eg, ATCC19240 strain); Brevibacterium album (eg, ATCC15111 strain); Brevibacterium cer
- genus Earthrobacter include the following species and strains.
- examples thereof include Arthrobacter globiformis (ATCC8010 strain, ATCC4336 strain, ATCC21056 strain, ATCC31250 strain, ATCC31738 strain, ATCC35698 strain, NBRC3062 strain, NBRC12137T strain) and the like.
- Micrococcus spp. are Micrococcus freudenreichi [for example, No. 239 (FERM P-13221) strain]; Micrococcus luteus [eg, NCTC2665 strain, No. 240 (FERM P-13222) strain]; Micrococcus ureae (for example, IAM1010 strain); Micrococcus roseus (for example, IFO3764 strain) and the like.
- Microbacterium spp Are Microbacteriaium ammoniaphilum (eg, ATCC15354 strain).
- coryneform bacterial strain is, for example, an ATCC strain, it is sold from the American Type Culture Collection (PO Box 1549 Manassas, VA 20108 USA) that provides the strain. Can receive. Other strains can also be sold from each microbial preservation institution that provides these strains.
- the genetically modified microorganism according to the present invention can be produced by subjecting the microorganisms exemplified above to a predetermined genetic manipulation.
- the activity of pyruvate: quinone oxidoreductase is reduced or inactivated as compared with the wild-type microorganism
- the recombinant microorganism according to the present invention is prepared.
- the pyruvate: quinone oxidoreductase activity is significantly reduced or completely inactivated compared to the wild-type microorganisms used as starting materials.
- the TCA cycle (citric acid cycle) shown in FIG. 1 generally metabolizes clockwise under aerobic conditions.
- the TCA cycle metabolizes counterclockwise. That is, when the embodiment satisfying the condition (I) is adopted in the present invention, the conversion of succinic acid to fumaric acid is suppressed under aerobic conditions, so that a larger amount of citric acid, cis-aconitic acid, is used.
- Acids, D-isocitric acid, ⁇ -ketoglutaric acid, succinyl-CoA, succinic acid or additional metabolites derived from it can be efficiently produced, while under reducing or anaerobic conditions, higher amounts of oxalo Acetic acid, L-citric acid, fumaric acid or additional metabolites derived from it can be efficiently produced.
- the further metabolites derived from the above metabolites in the TCA cycle are biosynthesized in the genetically modified microorganism of the present invention satisfying the condition (I) via the metabolic system originally retained by the wild-type microorganisms. It may be one that is biosynthesized via a newly constructed metabolic system by introducing a predetermined gene.
- the embodiment satisfying the condition (IV) when the embodiment satisfying the condition (IV) is adopted in the present invention, the conversion from pyruvic acid to acetic acid is suppressed, so that the pyruvic acid is used as in the embodiment satisfying the condition (II).
- the metabolic pathway to oxaloacetate proceeds efficiently.
- the production of oxaloacetate, L-malic acid, fumaric acid or further metabolites derived thereto can be efficiently carried out. Therefore, in the embodiment satisfying both the conditions (II) and (IV), the production efficiency of oxaloacetate, L-malic acid, fumaric acid or further metabolites derived thereto can be further improved.
- Embodiments can be preferably adopted in the present invention.
- the recombinant microorganism according to the present invention satisfies at least two of the conditions (I), (II) and (IV).
- the recombinant microorganism according to the present invention preferably satisfies both the conditions (I) and (II), both the conditions (I) and (IV), or the conditions (II) and (IV). , It is more preferable that all of the conditions (I), (II) and (IV) are satisfied.
- the metabolic pathway from pyruvate to the TCA cycle and metabolism in the TCA cycle proceed efficiently, with oxaloacetate, L-apple acid, fumaric acid or derived metabolites in the TCA cycle, or citric acid.
- downstream metabolites such as acid, cis-aconitric acid, D-isocitric acid, ⁇ -ketoglutaric acid, succinyl CoA, and succinic acid can be efficiently produced, these metabolites and further metabolism from these metabolites This is because the production of the induced substance can be efficiently achieved.
- a downstream metabolite such as succinic acid or a metabolite derived thereto (for example, a metabolite derived from glutamic acid or glutamic acid).
- a downstream metabolite such as succinic acid or a metabolite derived thereto (for example, a metabolite derived from glutamic acid or glutamic acid).
- Efficient production is possible, and under reducing conditions, it is possible to efficiently produce downstream metabolites such as fumaric acid or metabolites derived from them (for example, aspartic acid or metabolites derived from aspartic acid).
- downstream metabolites such as fumaric acid or metabolites derived from them (for example, aspartic acid or metabolites derived from aspartic acid).
- condition (V) The pyruvate formic acid lyase activity is reduced or inactivated as compared with the wild-type microorganism.
- condition (V) "the activity of pyruvate lyase lyase is reduced or inactivated as compared with the wild-type microorganism” means that the recombinant microorganism according to the present invention is produced. It means that the pyruvate lyase activity is significantly reduced or completely inactivated compared to the wild-type microorganism used as a starting material.
- the genetically modified microorganism according to the present invention is a microorganism belonging to a Gram-negative bacterium, it is preferable that the condition (V) is satisfied.
- the reason is as follows. Wild-type microorganisms belonging to Gram-negative bacteria express pyruvate formic acid lyase activity that is not normally found in Gram-positive bacteria. As described below, this pyruvate formic acid lyase activity creates a secondary biosynthetic pathway for synthesizing organic acids such as formic acid and acetic acid from pyruvate, as described below.
- the pyruvate succinate lyase activity is originally an enzyme activity that can be exhibited by a wild-type microorganism used as a starting material in producing the recombinant microorganism according to the present invention. More specifically, it can be described by a systematic classification according to the type of reaction between the substrate and the enzyme and an EC number recognized as an international enzyme classification based on the reaction type, and the enzyme activity under each condition is described below. It contains the enzyme activity shown in Table 1.
- the satisfaction of the conditions (I) and / or (II) and / or (IV) and / or (V) may be realized by using various methods of genetic engineering and molecular biology.
- a method by gene disruption or mutagenesis targeting these genes on the genome, a method by antisense inhibition at the mRNA expression level (antisense RNA), or the like can be adopted.
- a genetically modified microorganism that has been genetically engineered to express a peptide or protein that inhibits the activity of each enzyme is also included in the present invention.
- the enzyme protein that can impart each enzyme activity requires a process of activation by a predetermined endogenous activator, the endogenous activator. By inactivating the enzyme, the expression of each enzyme activity may be suppressed and each condition may be satisfied.
- amino acid mutations means amino acid mutations that can cause reduction or inactivation of each enzyme activity.
- the condition (I) is that the endogenous activator that activates the enzymatic activity of the enzyme protein that can impart each enzymatic activity is inactivated by the method according to the above embodiments (I) to (III). ) And / or (II) and / or (IV) and / or (V).
- embodiments (I) to (IV) can be independently adopted in order to reduce or inactivate each enzyme activity specified in each condition.
- at least two embodiments of embodiments (I) to (IV) may be adopted as long as there is no particular contradiction.
- both the conditions (I) and (II) may be adopted, and more specifically, both the coding region and the gene expression regulation region of each gene are microbial. May be disrupted in the genome of.
- both embodiments (I) and (II) may be adopted to satisfy condition (I)
- embodiment (III) may be adopted to satisfy condition (II).
- the disruption of the gene coding region and the gene expression regulation region (target region) in the genetically modified microorganism can be described by, for example, a homologous recombination method, a genome editing technology (CRISPR / CAS system), a transposon method, a mutation introduction method, or the like. Can be realized by. Among these methods, it is convenient to adopt the homologous recombination method in that the destruction of the target region can be achieved relatively inexpensively and efficiently.
- the following is an example of a gene disruption method by homologous recombination.
- the method for producing a genetically modified microorganism according to the present invention is not limited to the methods shown below, and any method can be adopted.
- Corynebacterium glutamicum which is one of the microorganisms that can be preferably used in the present invention
- the entire genome sequence has been determined in a large number of strains such as ATCC13032 strain, R strain, ATCC21831 strain, and ATCC14067 strain, and their nucleotide sequences have been determined. Etc. are known.
- the entire genome sequence has been determined for Corynebacterium strains such as Corynebacterium maris DSM45190 strain; Corynebacterium doosanense CAU212 strain (DSM45436 strain), and their nucleotide sequences and the like are known.
- nucleotide sequence of each enzyme gene that imparts the activity of each enzyme according to the conditions (I), (II), (IV) and (V) and the amino acid sequence of the enzyme.
- NCBI National Center for Biotechnology Information Support Center
- Tables 2 to 10 below show the conditions (I) and / or (II) and / or (IV) and / or the microorganisms used as starting materials and those microorganisms in producing the recombinant microorganisms according to the present invention. Information on genes and the like that can be destroyed in order to reduce or inactivate the enzyme activity according to (V) is illustrated. Needless to say, the information on the microorganisms that can be used in the present invention and the genes that can be targeted for reducing or inactivating the activity of each enzyme is limited to those shown in the table below. is not.
- the proteins related to these enzymes include sdhCAB (sdhCABD depending on the bacterial species), ldhA, ld and lldD (genes encoding enzyme proteins exhibiting lactate dehydrogenase activity), pokeB (pqo), genes described as pflABCD, etc. It can be encoded in (see Tables 2-10).
- succinate dehydrogenase (Sdh) is classified into the transmembrane protein (subunit C) encoded by the sdhC gene, the flavin protein subunit (subunit A) encoded by the sdhA gene, and the sdhB gene.
- the microorganism that can be used as a starting material in producing the recombinant microorganism according to the present invention is not limited to such a microorganism whose genomic nucleotide sequence and the like are known, and the enzyme protein. Microorganisms for which the coding region and its surrounding regions are unknown are also available.
- the coding region of each enzyme gene should be appropriately cloned by various genetic engineering techniques, and the nucleotide sequence should be determined as necessary. For example, the area to be destroyed can be identified and cloned. For example, when an alignment analysis is performed on the amino acid sequences of known homologous enzyme proteins (Tables 2 to 10), a plurality of constant amino acid storage regions are found.
- a degenerate primer is designed in each of the amino acid storage regions found on the N-terminal side and the C-terminal side of the enzyme protein, and the genomic DNA of the microorganism to be cloned is used as a template and the degenerate primer is used as a pair.
- the nucleotide sequence of this partial coding region is appropriately determined, and the cloned partial coding region is targeted for gene disruption based on the method for producing a gene-disrupted strain described later, and the conditions (I) and (II) , (IV) and (V) may be satisfied, and the recombinant microorganism according to the present invention may be prepared.
- primers may be appropriately designed in the opposite direction, the coding region of the full length of the target enzyme gene and its peripheral region may be cloned using a method such as inverse PCR, and the nucleotide sequence of those regions may be determined. Good.
- Such a PCR-based cloning method is convenient in that the genomic region to be disrupted can be easily cloned, but as another method, a gene library of the target microorganism is prepared and an appropriate probe is designed. Then, the enzyme genes to be disrupted and their peripheral regions may be cloned by various hybridization methods, and their nucleotide sequences may be determined. Furthermore, for microbial species for which the homolog gene sequence cannot be used, the protein purification technique and each enzyme activity measurement method are combined according to the conventional method, the target enzyme is identified, the peptide sequence is partially determined, and the like. The target enzyme gene may be cloned by the above-mentioned various genetic engineering techniques.
- a drug resistance gene such as a canamycin resistance gene is inserted into the region to be disrupted.
- a plasmid vector for gene disruption can be mentioned. According to such a plasmid vector for gene disruption, there are regions on both sides of the drug resistance gene that are homologous to the region to be disrupted on the genome of the microorganism.
- homologous recombination occurs between the microbial genome and the gene disruption plasmid in the form in which the drug resistance gene is inserted into the region to be disrupted on the microbial genome, so that the target enzyme gene can be disrupted. Become.
- a plasmid vector for gene disruption a fragment in which regions located on both sides of a portion of the microbial genome to be disrupted (that is, 5'upstream and 3'upstream of the region to be removed from the genome) are tandemly linked. It is also possible to utilize the plasmid vector containing it.
- a disruption plasmid is, for example, a plasmid vector in which the 5'upstream region and the 3'downstream region of the enzyme gene targeted for destruction are amplified by the PCR method and the fragments are tandemly linked. It can be obtained by inserting it at a predetermined location such as a multi-cloning site.
- the entire area from 5'upstream to 3'downstream of the enzyme gene to be disrupted is amplified by the PCR method, cloned using various plasmid vectors, and then a reverse primer is designed inside the cloned region, and inverse PCR is performed.
- a plasmid vector for gene disruption into which a deletion mutation of the enzyme gene has been introduced may be prepared.
- the sequence length of the region homologous to the microbial genome sequence to be gene disrupted is not limited as long as homologous recombination can occur, but is generally about 500 bp or more, preferably about about 500 bp or more. It is better to have about 1000 bp. Further, it is convenient to use a plasmid having a replication origin of Escherichia coli because the construction work becomes simple if the plasmid for gene disruption can be constructed using Escherichia coli for cloning. Further, it is preferable that the plasmid for gene disruption does not have an origin of replication capable of autonomous replication in the microorganism targeted for gene disruption.
- gene disruption plasmid has an origin of replication of the microorganism, it is recommended to remove the origin of replication by restriction enzyme treatment or the like before introducing it into a coryneform bacterium.
- gene disruption plasmids are lethal, allowing for positive selection of drug resistance genes that allow drug selection and SacB genes that can produce toxins that inhibit the growth of Gram-negative bacteria in the presence of sucrose.
- a combination with a sex gene may be used.
- a gene disruption plasmid is used, a strain that has undergone homologous recombination by selection with a drug is isolated, and then selection is performed by culturing in a medium containing sucrose, and the vector is subjected to the second homologous recombination. Since it is possible to isolate a gene-disrupted strain in which a portion has been eliminated, it is possible to efficiently obtain a gene-disrupted strain.
- the introduction of the plasmid vector for gene disruption into a microorganism is not particularly limited, but a transformation method established for various microorganisms may be used.
- the coryneform bacterium preferably adopted in the present invention can be carried out by using an electric pulse method (for example, the method described in Van der Rest et al. Appl. Microbiol Biotechnol 52, pp541-545, 1999). It is convenient. This is because the electric pulse method enables efficient introduction of nucleic acid into coryneform bacterial cells. The destruction of the target region on the genome of the recombinant microorganism can be confirmed based on the PCR method, the Southern hybridization method, various enzyme activity measurement methods, and the like.
- the recombinant microorganism according to the present invention further comprises, as condition (III), "modified phosphoenolpyruvate carboxylase activity exhibiting resistance to feedback inhibition by aspartic acid in wild phosphoenolpyruvate carboxylase activity, or the above-mentioned wild type phosphoenolpyruvate carboxylase activity. Having an exogenous phosphoenolpyruvate carboxylase activity that is more resistant to feedback inhibition by aspartic acid than the wild phosphoenolpyruvate carboxylase activity exhibited by type microorganisms ”can be satisfied.
- phosphoenolpyruvate carboxylase activity specifically refers to an enzymatic activity that catalyzes a reaction defined in EC 4.11.31, and is widely possessed by a wide variety of plants and microorganisms.
- Phosphoenolpyruvate carboxylase (PEPC) exerts enzymatic activity. The metabolic reactions catalyzed by PEPC are shown below.
- Non-Patent Documents 2-4 that is, the "modified phosphoenolpyruvate carboxylase activity" in the present invention is different from that of the corresponding wild-type microorganism or the wild-type phosphoenolpyruvate carboxylase possessed by the microorganism. It is defined by an enzymatic property that exhibits phosphoenolpyruvate carboxylase activity but has significantly reduced feedback inhibition by aspartic acid in the enzymatic activity.
- the meaning of the term "extrinsic phosphoenolpyruvate carboxylase activity, which is more resistant to feedback inhibition by aspartic acid than the wild-type phosphoenolpyruvate carboxylase activity exhibited by wild-type microorganisms,” is as follows. That is, the above term is possessed by a wild-type microorganism corresponding to the species to which the genetically modified microorganism according to the present invention belongs, or a wild-type microorganism used as a starting material in producing the genetically modified microorganism according to the present invention.
- exogenous phosphoenolpyruvate carboxylase activity that is more resistant to feedback inhibition by aspartic acid as compared with "resistance to feedback inhibition by aspartic acid” shown by wild-type phosphoenolpyruvate carboxylase.
- exogenous phosphoenolpyruvate carboxylase activity is specifically imparted by a heterologous phosphoenolpyruvate carboxylase possessed by a strain line or species different from the above-mentioned "corresponding wild-type host microorganism”. obtain.
- the "species different from the wild-type host microorganism” includes various species such as microorganisms (for example, fungi, prokaryotes such as individual bacteria and bacteria), plants, and animals such as mammals. Furthermore, the addition of “foreign phosphoenolpyruvate carboxylase activity" in the recombinant microorganism according to the present invention is more specifically PEPC isolated from "a strain line or species different from the wild-type host microorganism". This can be achieved by introducing a nucleic acid encoding a gene.
- modified phosphoenolpyruvate carboxylase (activity) shows resistance to feedback inhibition by aspartic acid in wild-type phosphoenolpyruvate carboxylase activity” and “foreign phosphoenolpyruvate carboxylase (activity)”.
- the resistance to feedback inhibition by aspartic acid is higher than that of wild-type phosphoenolpyruvate carboxylase activity exhibited by wild-type microorganisms, for example, the measurement methods described in Non-Patent Documents 2 to 4, Yoshinaga, T. .. Izui, Kand Katsuki, HJ. It can be confirmed by using the measuring method or the like described in Biochem, 68, 747-750 (1970).
- phosphoenolpyruvate carboxylase may be referred to as "PEPC” or "ppc".
- condition (III) is not particularly limited, but can be realized in the following embodiments. That is, by introducing an amino acid mutation into the protein sequence of wild-type phosphoenolpyruvate carboxylase held by various microorganisms by a genetic engineering method, "phosphoenolpyruvate carboxylase activity" is maintained while “wild". A gene encoding a mutant enzyme that has acquired "resistance to feedback inhibition by aspartic acid in type phosphoenolpyruvate carboxylase activity" may be artificially prepared.
- a base substitution technique such as a random mutagenesis method based on error-prone PCR or a PCR-based site-specific mutagenesis method using a mutagen primer may be used.
- a molecular evolution method such as DNA shuffling to a plurality of types of wild-type PEPC-encoding DNA, a mutant PEPC having higher superiority may be prepared.
- the nucleic acid encoding the mutant PEPC obtained as described above can be introduced into various microorganisms to prepare a genetically modified microorganism satisfying (III). More specifically, a nucleic acid encoding the mutant PEPC may be introduced into various microorganisms in a form capable of expressing the mutant PEPC.
- a gene expression system suitable for each microbial species has already been established in many microbial species including coryneform bacteria.
- the known technology may be used for introducing the above-mentioned mutant PEPC into the microorganism.
- gene recombination technology and gene expression system technology may be independently developed and used for introducing mutant PEPC into microorganisms.
- the mutant PEPC satisfying (III) is not particularly limited, but is a mutant obtained by introducing a predetermined mutation into a wild-type PEPC derived from a bacterium. It is preferably an enzyme. Further, such a mutant PEPC is a mutant enzyme obtained by introducing a predetermined mutation into a wild-type PEPC derived from a Corynebacterium, more preferably a Corynebacterium genus.
- Table 11 lists examples of bacterially derived PEPCs preferably used in the present invention.
- the following embodiments (i) and (ii) are assumed as specific configurations of the mutant PEPC satisfying the condition (III), for example.
- (I) A mutant PEPC in which one or more amino acids are deleted, substituted or added to the amino acid sequence of wild-type PEPC.
- the range of "one or more” is, for example, 1 to 100, 1 to 50, 1 to 30, preferably at least 2 or more, 2 to 20, more preferably 2 to 10, and even more. It is preferably 2 to 5, particularly preferably 2 to 4, 2 to 3, for example 2.
- a chimeric PEPC composed by combining a part of the amino acid sequences of two or more wild-type PEPCs.
- a nucleic acid encoding a mutant phosphoenolpyruvate carboxylase derived from a bacterium has been introduced in a form capable of expressing the mutant phosphoenolpyruvate carboxylase.
- Mutant phosphoenolpyruvate carboxylase has at least one amino acid mutation that satisfies condition (III) for the recombinant microorganism.
- the above-mentioned mutant phosphoenolpyruvate carboxylase is preferably a mutant PEPC derived from a coryneform bacterium or a Corynebacterium spp. Or an Escherichia spp., And more preferably a mutant PEPC derived from a Corynebacterium spp. , Particularly preferably a mutant PEPC derived from Corynebacterium glutamicum.
- the at least one amino acid mutation in the mutant phosphoenolpyruvate carboxylase is based on the amino acid substitutions shown in (a) to (f) below with reference to the amino acid sequence shown in SEQ ID NO: 2.
- amino acids shown in (a) to (f) above are intended to specify the amino acid substitution site in the PEPC amino acid sequence to be introduced into the mutation based on the amino acid contained in the amino acid sequence shown in SEQ ID NO: 2.
- the "corresponding amino acids" in the above (a) to (f) are more specifically referred to as Clustal W and Clustal X (Bioinformatics, Vol. 23, Issue 21, November 2008, pp. 2947-2948; Bioinformatics, Volume 23, Issue 21, 1 Noveller 2007, pp2497-2948), etc., 1: 1 based on the identity of the PEPC amino acid sequence to be introduced into the amino acid sequence shown in SEQ ID NO: 2.
- 3A to 3B show the wild-type PEPC proteins of 11 other Corynebacterium spp. As shown in Table 11 with respect to the amino acid sequence (SEQ ID NO: 2) of wild-type PEPC derived from the Corynebacterium glutamicum ATCC13032 strain. An example is shown in which multiple alignment analysis is performed on the sequences (SEQ ID NOs: 3 to 13) by BluestalW and the amino acids substituted in the above (a) to (f) are identified.
- the "amino acid corresponding to the 299th aspartic acid" in the above (a) is aspartic acid (D) in all nine wild PEPCs belonging to the genus Corynebacterium, and coryne. It is threonine (T) in the wild-type PEPC of the Arthrobacter globiformis NBRC12137 strain, which is a type of bacterium, and glutamic acid (E) in the wild-type PEPC of the Escherichia coli K-12 strain. Further, as shown in FIG.
- the “amino acid corresponding to the 653rd lysine” in the above (b) is used for the nine wild-type PEPCs belonging to the genus Corynebacterium . In ammoniagenes, it is arginine (R), and C.I. In doosanense, it is histidine (H), but in all other bacterial species, it is identical to lysine (K) in the reference sequence. Further, as shown in FIG. 3C, the "amino acid corresponding to the 813th lysine" in the above (c) is the same for the lysine (K) in the reference sequence in all bacterial species. Further, as shown in FIG.
- the "amino acid corresponding to the 869th serine” in the above (d) is the same for the serine (S) in the reference sequence in all bacterial species.
- the "amino acid corresponding to the 873rd arginine” in the above (e) is the same for arginine (R) in the reference sequence in all bacterial species.
- the "amino acid corresponding to the 917th asparagine” in the above (f) is C.I. In ammoniagenes, it is "threonine", and C.I.
- valine (V) in doosanense is identical to asparagine (N) in the reference sequence in all other strains.
- the 299th aspartic acid is expressed as “D299” by using the one-letter notation of the amino acid
- amino acid substitution of the 299th aspartic acid with asparagine is expressed as "D299N”.
- Other amino acids and amino acid substitutions may be expressed in a similar manner.
- the at least one amino acid mutation in the mutant phosphoenolpyruvate carboxylase is a group consisting of the amino acid substitutions shown in the following (g) to (l) with reference to the amino acid sequence shown in SEQ ID NO: 2. Includes at least one selected from.
- the at least one amino acid mutation in the mutant phosphoenolpyruvate carboxylase is one of the amino acid substitutions shown in (g) above and the amino acid substitutions shown in (h) to (l) above. Includes at least one.
- the at least one amino acid mutation in the mutant phosphoenolpyruvate carboxylase is the amino acid substitution shown in (g) above and the amino acid substitution shown in (i) to (l) above. Includes at least one of them.
- the at least one amino acid mutation in the mutant phosphoenolpyruvate carboxylase comprises the amino acid substitution shown in (g) above and the amino acid substitution shown in (i) or (l) above. including.
- the mutant phosphoenolpyruvate carboxylase may be a mutant PEPC having the amino acid sequence shown in any one of (A) to (C) below.
- A In the amino acid sequence shown in any one of SEQ ID NOs: 2 to 13 (preferably SEQ ID NOs: 2 to 12, more preferably SEQ ID NO: 2 to 11), from the amino acid substitutions shown in (a) to (l) above. Amino acid sequence obtained by introducing at least one selected from the group (provided that the amino acid before substitution and the amino acid after substitution are different);
- B In the amino acid sequence defined in (A) above, an amino acid sequence in which one or more amino acids are deleted, substituted and / or added (provided that at least one amino acid substitution is maintained. );
- C An amino acid sequence having at least 60% sequence identity to the amino acid sequence specified in (A) above (provided that at least one amino acid substitution is maintained).
- the mutant phosphoenolpyruvate carboxylase may be a mutant PEPC having the amino acid sequence shown in any one of (D) to (F) below.
- D In the amino acid sequence shown in any one of SEQ ID NOs: 2 to 13 (preferably SEQ ID NOs: 2 to 12, more preferably SEQ ID NO: 2 to 11), the amino acid substitution shown in (g) above and the above (h) )-Amino acid sequence obtained by introducing at least one of the amino acid substitutions shown in (l) (however, the amino acid before the substitution and the amino acid after the substitution are different);
- E An amino acid sequence in which one or more amino acids are deleted, substituted and / or added in the amino acid sequence specified in (D) above (provided that each of the above amino acid substitutions is maintained);
- F An amino acid sequence having at least 60% sequence identity to the amino acid sequence specified in (D) above (provided that each of the above amino acid substitutions is maintained).
- the mutant phosphoenolpyruvate carboxylase may be a mutant PEPC having the amino acid sequence shown in any one of (G) to (I) below.
- G In the amino acid sequence shown in any one of SEQ ID NOs: 2 to 13 (preferably SEQ ID NOs: 2 to 12, more preferably SEQ ID NO: 2 to 11), the amino acid substitution shown in (g) above and the above (i).
- the mutant phosphoenolpyruvate carboxylase may be a mutant PEPC having the amino acid sequence shown in any one of (J) to (L) below.
- (J) In the amino acid sequence shown in any one of SEQ ID NOs: 2 to 13 (preferably SEQ ID NOs: 2 to 12, more preferably SEQ ID NO: 2 to 11), the amino acid substitution shown in (g) above and the above (i).
- the range of "1 or more” is, for example, 1 to 100, 1 to 50, 1 to 30, preferably 1 to 1. 20, 1 to 15, 1 to 10, more preferably 1 to 9, 1 to 8, 1 to 7, 1 to 6, 1 to 5, 1 to 4, 1 to 3, One or two.
- "at least 60%” is preferably at least 70%, more preferably at least 80%, even more preferably at least 85%, 90. It can be read as%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%.
- any one of “SEQ ID NOs: 2 to 13 preferably SEQ ID NOs: 2 to 12, more preferably SEQ ID NO: 2 to 11)).
- the embodiment in which "the amino acid sequence shown in one" is read as "the amino acid sequence shown in SEQ ID NO: 2" is particularly preferable.
- the mutant PEPC having the specified amino acid sequence in any of the above (A) to (L) retains the phosphoenolpyruvate carboxylase activity and satisfies the condition (III). There is no change in the purpose.
- aspartate dehydrogenase (AspDH, EC 1.4.1.21), aspartate amino group transfer enzyme (AspC, EC2.6) .1.1) and the aspartate ammonia-lyase (Aspartate EC4.3.1.1,) (see FIG. 1)
- aspartate dehydrogenase (AspDH, EC 1.4.1.21)
- aspartate amino group transfer enzyme (AspC, EC2.6) .1.1)
- aspartate ammonia-lyase (Aspartate EC4.3.1.1,) (see FIG. 1)
- Genes encoding these enzymes may be additionally introduced for the enhancement of these enzymes.
- Examples of the enzyme gene introduced into the recombinant coryneform bacterium of the present invention include enzyme genes disclosed in Patent Documents 2 and 2, and other Japanese Patent Application Laid-Open No. 2016-516435. The disclosure contents of these prior art documents are also incorporated in the present specification.
- a starting substrate such as a saccharide can be used more efficiently for the production of a substance, and aspartic acid or a metabolite derived from the aspartic acid can be used. It can be expected that the production efficiency of target substances such as these will be significantly improved.
- a method for producing the following target substance is provided.
- (P) Producing a target substance using a bacterial cell of a genetically modified microorganism according to the present invention or a processed product thereof; and (q) Recovering the target substance.
- a method of producing a target substance including.
- the transgenic microorganism according to the present invention may be cultured under aerobic conditions in which it can grow substantially to produce the target substance.
- aerobic conditions in coryneform bacteria, the TCA cycle shown in FIG. 1 proceeds in a clockwise direction. Therefore, taking this into consideration, it is aerobic according to the type of target substance to be produced as a target. If the embodiment relating to substance production under the conditions is suitable, the embodiment may be selected.
- E.I. Microorganisms such as Escherichia spp. And coryneform bacteria such as cory do not grow substantially in the medium or reaction solution under the reducing conditions, and the unique metabolic system under the reducing conditions functions. Therefore, when the coryneform bacterium according to the present invention and its cell-treated product are reacted in a medium or reaction solution under reducing conditions in this way, it becomes possible to eliminate waste of nutrient sources due to proliferation and division of bacterial cells. It is possible to improve the efficiency of conversion of nutrient sources into target substances.
- the recombinant microorganism according to the present invention has reduced or inactivated one or more enzyme activities under the conditions (I), (II) and (IV), and has resistance to feedback inhibition by metabolites. Since it retains the phosphoenolpyruvate carboxylase activity shown, it is expected that the efficiency of conversion of nutrient sources into target substances will be significantly improved. Furthermore, according to an embodiment in which the reaction proceeds under reducing conditions in which such microorganisms do not substantially proliferate, the generation of heat of fermentation is generated as compared with the bioprocess under aerobic conditions accompanied by cell division / proliferation. Since it can be prevented and it is not necessary to secure sufficient aeration during culturing, it is possible to simplify the equipment required for the bioprocess and reduce the energy, which is friendly to the global environment and leads to cost reduction.
- the object is to react the cells of the recombinant microorganism or the processed product thereof in the reaction medium (X) under the reducing condition in which the recombinant microorganism does not substantially grow. It is preferable to produce a substance.
- Step (p') In a more preferred embodiment, the method according to the invention is performed prior to Step (p). (P') Further comprising pre-culturing and growing the recombinant microorganism in a predetermined medium (Y) under aerobic conditions. The cells of the genetically modified microorganism grown in the step (p') or a processed product thereof are tested in the step (p).
- the embodiment in which the step (p') is included in the method of the present invention is also assumed in the embodiment relating to the production of substances under aerobic conditions, and in particular, the recombinant microorganism is substantially substantially. It is preferably applied when the substance is produced in the reaction medium (X) under reducing conditions that do not proliferate.
- the genetically modified microorganism is previously grown to a certain degree under aerobic conditions, and then, in the step (p), a sufficient amount of the grown genetically modified microorganism is subjected to the genetic recombination.
- the genetically modified microorganism can be used as if it were a chemical catalyst to efficiently produce the substance.
- the recombinant microorganism may be recovered from the reaction medium (X) after production of the substance in the reaction medium (X) and reused for the reaction in the step (p) after two cycles. It is possible.
- specific configurations and elements that can be adopted in these steps will be described in detail in the order of step (p'), step (p), and step (q).
- the medium (Y) is not particularly limited, and an appropriate medium (Y) may be selected and used according to the type of the recombinant microorganism used in the method.
- an appropriate medium (Y) may be selected and used according to the type of the recombinant microorganism used in the method.
- a natural medium or a synthetic medium containing a carbon source, a nitrogen source, inorganic salts and other nutritional substances can be used as the medium (Y).
- the components contained in the medium are, for example, as follows.
- Examples of the carbon source include carbohydrates, more specifically carbon-containing substances such as polysaccharides and saccharides containing monosaccharides, and various materials containing these, and examples thereof include the following components.
- Monosaccharides such as glucose, fructose, mannose, xylose, arabinose, galactose; disaccharides such as sucrose, maltose, lactose, cellobiose, xylobiose, trehalose; polysaccharides such as cellulose, starch, glycogen, agarose, pectin, alginic acid; sugar honey Etc .; non-edible agricultural waste such as rice straw, forest residue, bagas, corn stover, etc.
- non-edible biomass sources made from non-edible herbaceous plants and woody plants
- switch glass napier glass
- a saccharified solution containing multiple sugars such as glucose and xylose obtained by saccharifying energy crops such as misscansus with saccharifying enzymes; sugar alcohols such as mannitol, sorbitol, xylitol and glycerin; , Organic acids such as gluconic acid; alcohols such as ethanol, propanol and butanol; hydrocarbons such as normal paraffin.
- the carbon source may be used alone or in combination of two or more.
- inorganic or organic ammonium compounds such as ammonium carbonate ((NH 4 ) 2 CO 3 ), ammonium chloride, ammonium sulfate, ammonium nitrate and ammonium acetate, urea, aqueous ammonia, sodium nitrate, potassium nitrate and the like can be used.
- corn steep liquor, meat extract, protein hydrolyzate (casamino acid, tryptone, peptone, NZ-amine, etc.), nitrogen-containing organic compounds such as amino acids, and the like can also be used.
- one type can be used alone or two or more types can be used in combination.
- the concentration of the nitrogen source in the medium may be appropriately adjusted according to conditions such as the type and properties of the genetically modified microorganism to be adopted, the type of nitrogen compound, and the like, and is not particularly limited, but is not particularly limited, for example, about 0.1. It can be up to 10 w / v%.
- Inorganic salts include monopotassium phosphate, dipotassium phosphate, magnesium sulfate (hydrate), sodium chloride, iron (II) sulfate heptahydrate, ferrous nitrate, manganese sulfate, zinc sulfate, cobalt sulfate, Calcium carbonate and the like can be mentioned.
- the inorganic salt may be used alone or in combination of two or more.
- the concentration of the inorganic salt in the medium may be appropriately adjusted according to conditions such as the type and properties of the genetically modified microorganism to be adopted, the type of the inorganic salt, and the like, and is not particularly limited, but is, for example, about 0.01. It may be set to ⁇ 1 (w / v%).
- other nutritional substances include meat extract, peptone, polypeptone, yeast extract, dried yeast, corn steep liquor, skim milk powder, skim soybean hydrochloric acid hydrolyzate, animal and plant or microbial cell extracts and their decomposition products. Be done.
- concentration of other nutritional substances in the medium may be appropriately adjusted according to conditions such as the type and properties of the genetically modified microorganism to be adopted, the type of nutritional substance, and the like, and is not particularly limited. For example, about 0. It may be 1 to 10 (w / v%).
- vitamins can be added as needed.
- vitamins include biotin, thiamine (vitamin B1), pyridoxine (vitamin B6), pantothenic acid, inositol and the like.
- a defoaming agent such as a silicone-based defoaming agent or a polyether-based defoaming agent may be added, and various defoaming agents for bacterial media are commercially available. You may use it.
- the pH of the medium (Y) is not particularly limited as long as the genetically modified microorganism to be adopted can grow, but is preferably about 6 to 8.
- the medium (Y) is medium A [Inui, M. et al. Et al. , Metabolic analysis of Corynebacterium glutamicum lutating lactitate and succinate products under oxygen development connections. J. Mol. Microbiol. Biotechnol. 7: 182-196 (2004)], BT medium [Omumasaba, C.I. A. Et al. , Corynebacterium glutamicum glyceraldehyde-3-phosphate dehydogenase isoforms with opposite, ATP-dependent regulation. J. Mol. Microbiol. Biotechnol. 8: 91-103 (2004)], the NA medium and the like described in Examples of the present specification can be preferably used.
- the bacterial cells obtained by culturing and growing the recombinant microorganism of the present invention in the medium (Y) as described above or the bacterial cell-treated product thereof may be subjected to the step (p).
- the culture conditions of the genetically modified microorganism are appropriately set so that the genetically modified microorganism can sufficiently grow and a sufficient amount of bacterial cells or a processed product thereof can be obtained.
- the culture can be carried out under aerobic conditions at a culture temperature of about 25 ° C. to 38 ° C. and a culture time of about 12 hours to 48 hours.
- the specific form of the "bacteria or a processed product thereof" is not particularly limited as long as it can produce the target substance.
- the recombinant microorganism in step (p'), is cultivated and propagated in the medium (Y), and then the recombinant microorganism is recovered or separated from the medium (Y).
- the medium (Y) containing the genetically modified microorganism may be used as it is in the step (p), and the target substance may be produced using the cells of the genetically modified microorganism.
- a carbon source that can be a component of the reaction medium (X) described later is added to the medium (Y) containing the recombinant microorganism obtained in the step (p'), if necessary.
- Nitrogen source, inorganic salts, vitamins, reducing agent, etc. may be added and used in the reaction for producing the target substance in step (p).
- the cell itself obtained by separating and recovering the recombinant microorganism cultured and propagated in the medium (Y) in the step (p') from the medium (Y), or the bacterium thereof.
- the cell-treated product obtained by subjecting the body to a predetermined physical or chemical treatment may be used in the step (p). Examples of the method for separating and recovering the recombinant microorganism from the medium (Y) include centrifugation, separation by various filters, decantation and the like.
- the "treated cell product" is not particularly limited as long as the reaction for producing the target substance in step (p) can be realized, but more specifically, for example, with respect to the recovered cell cells. Examples thereof include those subjected to various chemical treatments, those immobilized on carriers such as acrylamide, carrageenan, and other suitable polymers.
- composition of reaction medium (X) realizes a reaction medium (X) under reducing conditions in which the recombinant microorganism does not substantially proliferate and the production reaction of the target substance by the recombinant microorganism proceeds.
- the reaction medium (X) may contain, for example, a carbon source, a nitrogen source, an inorganic salt, or the like, and may be a natural one derived from an organism or the like, or an artificially synthesized one.
- the components contained in the reaction medium (X) are, for example, as follows.
- Examples of the carbon source include carbohydrates, more specifically polysaccharides, saccharides containing monosaccharides, and various materials containing these, and examples thereof include the following components.
- Monosaccharides such as glucose, fructose, mannose, xylose, arabinose, galactose; disaccharides such as sucrose, maltose, lactose, cellobiose, xylobiose, trehalose; polysaccharides such as cellulose, starch, glycogen, agarose, pectin, alginic acid; Sugar honey, etc .;
- Non-edible agricultural waste such as rice straw, forest residue, bagas, corn stover, etc.
- Non-edible biomass sources made from non-edible herbaceous plants and woody plants
- Switch glass Napier glass
- a saccharified solution containing multiple sugars such as glucose and xylose obtained by saccharifying energy crops such as miscanthus with saccharifying enzymes; sugar alcohols such as mannitol, sorbitol, xylitol and glycerin; Organic acids such as acid and gluconic acid; alcohols such as ethanol, propanol and butanol; hydrocarbons such as normal paraffin.
- the carbon source one type may be used alone or two or more types may be used in combination.
- the concentration of the carbon source in the reaction medium (X) is preferably about 1 to 20 (w / v%), more preferably about 2 to 10 (w / v%), and about 2 to 5 (w / v%). v%) is even more preferable.
- the concentration of saccharides in the reaction medium (X) is, for example, about 1-20 (w / v%), more preferably about 2-10 (w / v%), even more preferably about 2-5 (w). / V%).
- inorganic or organic ammonium compounds such as ammonium carbonate ((NH 4 ) 2 CO 3 ), ammonium chloride, ammonium sulfate, ammonium nitrate and ammonium acetate, urea, aqueous ammonia, sodium nitrate, potassium nitrate and the like can be used.
- nitrogen-containing organic compounds such as corn steep liquor, meat extract, peptone, NZ-amine, protein hydrolyzate, and amino acid can also be used.
- one type can be used alone or two or more types can be used in combination.
- the concentration of the nitrogen source in the reaction solution may be appropriately adjusted according to the type of the recombinant microorganism to be used, the type and properties of the desired target substance, the reaction conditions, the type of the nitrogen compound, etc., and is particularly limited. Although it is not a compound, it can be adjusted to, for example, about 0.1 to 10 (w / v%).
- Inorganic salts include monopotassium phosphate, dipotassium phosphate, magnesium sulfate (hydrate), sodium chloride, iron (II) sulfate heptahydrate, ferrous nitrate, manganese sulfate, zinc sulfate, cobalt sulfate, Calcium carbonate and the like can be mentioned.
- Inorganic salts may be used alone or in combination of two or more.
- the concentration of the inorganic salt in the reaction solution may be appropriately adjusted according to the type of the recombinant microorganism to be used, the type and properties of the desired target substance, the reaction conditions, the type of the inorganic salt, etc., and is particularly limited. Although it is not a substance, it may be, for example, about 0.01 to 1 (w / v%).
- vitamins can be added to the reaction medium (X) as needed.
- vitamins include biotin, thiamine (vitamin B1), pyridoxine (vitamin B6), pantothenic acid, inositol and the like.
- the pH of the reaction medium (X) is not particularly limited as long as the reaction for producing the desired target substance proceeds, but is generally preferably about 6.0 to 8.0. More preferably, it is 6.5 to 8.0, for example, around 7.5.
- specific preferred basic compositions of the reaction medium (X) include the above-mentioned BT medium and the like, and based on the composition of these media, as described above, the concentration of the carbon source (sugar) and nicotinic acid.
- the reaction medium (X) can be prepared by appropriately adjusting the concentration (xn), biotin concentration (xb), and the like of at least one of the above and its derivatives.
- the reduction condition in which the coryneform bacterium does not substantially grow means that the reaction medium is in a reduced state to the extent that the recombinant microorganism does not actually grow, but more specifically, the reaction. It is defined by the redox potential of the medium.
- the redox potential of the reaction medium (X) is preferably about ⁇ 200 mV to ⁇ 500 mV, more preferably about ⁇ 250 mV to ⁇ 500 mV.
- the redox potential of the reaction medium (X) can be measured using an oxidation-reduction potential meter. Since there are commercially available redox potential meters, those commercially available products may be used for measuring the redox potential of the reaction medium (X) in the present invention.
- the reduced state of the reaction medium can be estimated with a resazurin indicator (decolorization from blue to colorless in the reduced state) as a simple method, but if more accurate control is desired, a redox potentiometer (for example, BROADLEY) It may be measured using ORP Electrodes) manufactured by JAMES.
- the method for adjusting the reaction medium (X) under the reducing conditions is not particularly limited, and various methods can be used.
- the following known method for preparing an aqueous solution for a reaction solution can be used. it can. That is, as the solvent of the reaction medium, an aqueous solution for a reaction solution may be used instead of distilled water or the like, and the method for adjusting the aqueous solution for the reaction solution is, for example, a method for preparing a culture solution for an absolutely anaerobic microorganism such as a sulfate-reducing microorganism. (Pfennig, N.
- an aqueous solution for a reaction solution under reducing conditions can be obtained by heat-treating or depressurizing distilled water or the like to remove the dissolved gas.
- it is dissolved by treating distilled water or the like for about 1 to 60 minutes, preferably about 5 to 40 minutes under reduced pressure of about 10 mmHg or less, preferably about 5 mmHg or less, more preferably about 3 mmHg or less.
- the gas, especially the dissolved oxygen, can be removed to prepare an aqueous solution for the reaction solution under reducing conditions (anaerobic state).
- an appropriate reducing agent for example, thioglycolic acid, ascorbic acid, cystine hydrochloride, mercaptoacetic acid, thiol acetic acid, glutathione, sodium sulfide, etc.
- an appropriate reducing agent for example, thioglycolic acid, ascorbic acid, cystine hydrochloride, mercaptoacetic acid, thiol acetic acid, glutathione, sodium sulfide, etc.
- An appropriate combination of these methods is also a method for preparing an aqueous solution for a reaction solution under effective reducing conditions.
- the reaction system is made of nitrogen gas or the like. Examples thereof include a method of encapsulating with an inert gas or carbon dioxide gas.
- the pH maintenance adjusting solution of the reaction system is added or various nutrient dissolving solutions are added. In some cases, it may be necessary to add oxygen as appropriate. In such a case, it is effective to remove oxygen from the added solution in advance.
- the method of the present invention includes a step (p')
- the above-mentioned predetermined operation is performed on the medium (Y) in which the gene-recombinant microorganism of the present invention has grown in the step (p').
- the medium (Y) adjusted so as to satisfy the reduction conditions in which the transgenic microorganism does not substantially proliferate by adding a reducing agent or the like is used as the reaction medium (X) in the step (p). You may.
- the reaction temperature in the step (p) may be any range as long as it produces a desired target substance, and may be appropriately set according to the properties of the genetically modified microorganism to be adopted, and is not particularly limited. Typically, it is about 20 to 50 ° C., preferably about 25 to 47 ° C., more preferably about 27 to 37 ° C., and the target substance can be efficiently produced within such a temperature range.
- the reaction time may be appropriately adjusted so as to obtain the desired target substance, and is not particularly limited, but is, for example, about 1 hour to about 7 days, and from the viewpoint of a more efficient target substance, about 1 hour to. It is preferably about 3 days, for example, about 1 hour to 48 hours.
- the reaction may be a batch type, a fed-batch type, or a continuous type. Of these, the batch type is preferable.
- step (p) After the reaction in step (p) is completed, the recombinant microorganism and its cell-treated product are recovered from the reaction medium (X) by an appropriate operation such as centrifugation, and the recovered genetically modified microorganism is reused in the step. (P) may be repeated a plurality of times. Such a configuration in which the step (p) is repeated a plurality of times by reusing the genetically modified microorganism leads to a reduction in production cost and can realize efficient production of the target substance, and thus is a preferred embodiment in the present invention. is there.
- step (q) After producing the target substance in step (p), the target substance is recovered as step (q).
- the term "recovering the target substance (that)” is used by collecting a genetically modified microorganism containing the target substance and / or a culture solution or a reaction medium. It is a concept that includes the recovery of substances.
- the target substance may be recovered by collecting the transgenic microorganism containing the target substance and / or the culture solution or the reaction medium, but the target substance is contained.
- the target substance may be recovered by separating and / or purifying the target substance from the culture solution or reaction medium (X), the recombinant microbial cell, or the processed product thereof.
- the separation and / or purification process of the target substance In the embodiment in which the separation and / or purification process of the target substance is adopted, the purity and the like required for the separation and purification process of the target substance in consideration of the type of the target substance and the use of the target substance are obtained. Appropriate separation / purification techniques may be adopted accordingly. Although not particularly limited, for example, various filtration techniques such as various crystallization methods and ultrafiltration methods, various chromatography techniques such as ion exchange chromatography, affinity chromatography, hydrophobic chromatography, and reverse phase chromatography. , Concentration method, dialysis, activated charcoal adsorption method, etc. can be appropriately combined to recover the target substance. Since various techniques for separating and purifying these substances are known, they may be appropriately used. Further, the method of the present invention may further include steps such as optionally washing, drying, crushing, powdering or granulating, and / or packing the target substance.
- ⁇ Type of target substance> various target substances can be produced in high yield by utilizing the genetically modified microorganism according to the present invention.
- the type of target substance varies depending on the type of recombinant microorganism to be adopted, but specifically, nucleic acid-related compounds (for example, adenine, guanine, shikimic acid, timine, uracil, 5'-guanylate, adenosine, etc.
- ATP ATP, CDP-choline
- various physiologically active substances such as hormone substances; carbohydrates and sugars; vitamin-related substances and coenzymes (for example, vitamin C, vitamin B2, B12, sorbose, NAD, FAD, coenzyme A); proteins, Peptides, amino acids; amino acid derivatives such as L-3,4-dihydroxyphenylalanine (L-DOAP), 5-hydroxytryptophane, pyrrolidone carboxylic acid; alcohols such as ethanol, butanol, isopropanol; phenol, catechol, 4-hydroxybenzoic acid , 4-Aminobenzoic acid, anthranilic acid, gallic acid, succinic acid, fumaric acid, malic acid, shikimic acid, 3-dehydroshikimic acid, 3-dehydroquinic acid, protocatechuic acid, corrismic acid and other various organic compounds. ..
- the target substance is at least one selected from the group consisting of amino acids, alcohols, aromatic compounds, and organic acids.
- the target substance is preferably an L-amino acid or a derivative thereof.
- the amino acids are valine, leucine, isoleucine, glutamine, aspartic acid, glutamic acid, arginine, alanine, proline, cysteine, lysine (lysine), threonine, asparagine, phenylalanine, serine, methionine, glycine, tyrosine, histidine, Contains tryptophan, cystine and theanin.
- the L-amino acid derivative is specifically a metabolite derived from the L-amino acid in the metabolic system of a recombinant microorganism.
- the target substance is preferably L-aspartic acid or a metabolite derived from it.
- Metabolites derived from L-aspartic acid include amino acids and amino acid derivatives such as L-threonine, L-lysine, L-arginine and L-homoserin.
- the substance of interest is citric acid, cis-aconitic acid, D-isocitric acid, ⁇ -ketoglutaric acid, succinyl-CoA, succinic acid or additional metabolites derived from it.
- these metabolites can be efficiently produced by culturing or reacting the recombinant microorganism according to the present invention under aerobic conditions (Fig. 1).
- the target substance is oxaloacetate, L-malic acid, fumaric acid or a metabolite derived from it. These metabolites can be efficiently produced by reacting the genetically modified microorganism according to the present invention under reducing conditions in which the recombinant microorganism does not substantially proliferate (FIG. 1).
- the substance of interest is oxaloacetate, malic acid or a metabolite via these compounds on the biosynthetic pathway.
- the target substance is aspartic acid or a metabolite derived from it.
- the target substance is aspartic acid, beta-alanine, or asparagine.
- the target substance may be one produced by a genetically modified microorganism by a metabolic system inherited from the wild type under the conditions prescribed in the present invention, or further artificially produced by genetic manipulation, mutation treatment, or the like. It may be produced in a metabolic system, or it may be produced by a combination of these two metabolic systems. Furthermore, in the method for producing the target substance according to the present invention, the final target substance is synthesized from the substance produced by the recombinant microorganism by a chemical synthesis process or a bioprocess by a cell-free enzyme metabolism. Embodiments that further include steps are also envisioned.
- target substance produced in the present invention is not limited in any way, and examples thereof include pharmaceutical use, food use, industrial use, fuel use, and cosmetic use.
- target substance produced in the present invention may be a substance actually used for various purposes, or may be an intermediate raw material for use in producing a final product.
- the following mutant phosphoenolpyruvate carboxylase has an amino acid mutation in the amino acid sequence of wild-type phosphoenolpyruvate carboxylase possessed by a microorganism belonging to a coryneform bacterium, which can reduce feedback inhibition by aspartic acid in the wild-type phosphoenolpyruvate carboxylase activity.
- the amino acid mutation is based on the amino acid sequence shown in SEQ ID NO: 2.
- the mutant phosphoenolpyruvate carboxylase is a mutant PEPC having the amino acid sequence shown in any one of (J) to (L) below.
- (J) In the amino acid sequence shown in any one of SEQ ID NOs: 2 to 13 (preferably SEQ ID NOs: 2 to 12, more preferably SEQ ID NO: 2 to 11), the amino acid substitution shown in (g) above and the above (i).
- the range of "1 or more” is, for example, 1 to 100, 1 to 50, 1 to 30, preferably 1 to 20, 1 to 15, 1 to 10. More preferably, it is 1 to 9, 1 to 8, 1 to 7, 1 to 6, 1 to 5, 1 to 4, 1 to 3, 1 to 2.
- "at least 60%” is preferably at least 70%, more preferably at least 80%, even more preferably at least 85%, 90%, 91%, 92%, 93%, 94. It can be read as%, 95%, 96%, 97%, 98%, 99%.
- amino acid sequence shown in any one of SEQ ID NOs: 2 to 13 is “SEQ ID NO: 2".
- the embodiment to be read as “the amino acid sequence shown in” is particularly preferable.
- nucleic acid encoding mutant PEPC ⁇ Nucleic acid encoding mutant PEPC> According to the fifth aspect of the present invention, the nucleic acid encoding the mutant phosphoenolpyruvate carboxylase according to the fourth aspect is provided.
- the "nucleic acid” may be provided in any form of DNA (deoxyribonucleic acid) and RNA (ribonucleic acid). Furthermore, the nucleic acid according to the present invention may be in the form of a single strand or a double strand.
- the nucleic acid is specifically an isolated nucleic acid, cDNA or cRNA. Considering that DNA is chemically more stable than RNA, the nucleic acid of the present invention is preferably provided in the form of DNA. In addition, in the present invention, the nucleic acid may be chemically modified such as methylation.
- the nucleic acid according to the present invention may be provided in the form of a plasmid, which includes an origin of replication and the like so as to enable autonomous replication in cells of a specific microorganism, although not necessarily essential.
- a promoter sequence, Shine-Dalgarno sequence, etc. are used so that the mutant PEPC according to the present invention can be expressed in the cells of the microorganism. It may contain a gene regulatory sequence. May include the mutant PEPC coding region.
- the genetically modified microorganism into which the nucleic acid according to the present invention has been introduced is included in the present invention as a part of the genetically modified microorganism according to the first or second aspect of the present invention.
- the method for producing the target substance using the genetically modified microorganism into which the nucleic acid according to the present invention has been introduced is also a part of the method for producing the target substance according to the third aspect of the present invention. Is included in the present invention.
- the amplified DNA fragment and plasmid pHSG299 (Takara Bio Inc.) were treated with restriction enzymes BamHI and HindIII, and then DNA ligation Kit Ver. 2 (Takara Bio Inc.) was used for ligation to obtain plasmid pGE015. Furthermore, by PCR reaction, the region of about 1000 bp upstream of the ldh gene coding region and the region of about 1000 bp downstream of the gene coding region were amplified by using the genomic DNA of the Corynebacterium glutamicum ATCC13032 strain as a template. In these PCR reactions, a pair of primers F2 and R2 was used for the upstream region, and primers F3 and R3 were used for the downstream region (Table 13). Note that FIG. 2A schematically shows the positional relationship between each primer and the gene coding region.
- thermal cycler T100TM (BIO-RAD) was used for each PCR reaction, and PrimeStar MAX (Takara Bio Inc.) was used as the PCR enzyme reagent. The same applies to the PCR reaction in the procedure described below unless otherwise specified.
- the DNA fragments in the upstream and downstream regions of the ldh gene amplified as described above were ligated to a pGE15 vector linearized by restriction enzyme treatment with EcoRI using an In-Fusion cloning kit (Takara Bio Co., Ltd.). It was cloned.
- the plasmid thus obtained was named pGE033.
- pGE33 In the plasmid pGE33, the upstream fragment of the ldh gene and the downstream fragment of the gene are in the form of being tandemly linked and inserted into the multicloning site, but the coding region of the ldh gene is deleted.
- pGE33 is a plasmid that can replicate in E. coli but not in the cells of coryneform bacteria.
- the plasmid pGE33 was introduced into the Corynebacterium glutamicum ATCC13032 strain by the electrical pulse method (2500V, 25 ⁇ F, 200 ⁇ ; Van der Rest et al. Appl. Microbiol Biotechnol 52, pp541-545, 1999).
- the sample after the electric pulse method was A agar medium containing 25 ⁇ g / ml of casamino acid (composition in 1 L of medium: urea: 2 g, (NH 4 ) 2 SO 4 : 7 g, KH 2 PO 4 : 0.5 g, K 2 HPO.
- pGE33 has a kanamycin resistance gene as a drug resistance marker, as described above, in the growth strain grown on the A agar medium containing kanamycin, pGE33 has one point with the wild-type ldh gene on the chromosome. It is a strain that has undergone homologous recombination and has been integrated into genomic DNA together with the plasmid.
- the growth strain thus obtained was applied to an LB agar medium (composition in 1 L of medium: bactopeptone: 10 g, yeast extract: 5 g, sodium chloride: 10 g, agar: 16 g) to which 10% sucrose was added. It was cultured by the method.
- the transformant carrying the SacB gene derived from pGE33 cannot survive on the medium supplemented with sucrose because a toxic substance is produced.
- the transformant in which the plasmid-derived region containing the SacB gene was lost due to the homologous recombination again can survive on the medium to which sucrose was added, so that the plasmid-derived region was lost and the ldh gene was deleted.
- the transformant is obtained as a growing strain.
- the homologous recombination is performed again, the complete pGE33 form in which the entire plasmid region is removed returns to the trait of the wild-type ATCC13032 strain that carries the ldh gene in intact.
- primers F2 and R3 are primers designed at the 5'end of the region about 1000 bp upstream of the ldh gene and the 3'end of the region about 1000 bp downstream of the gene, respectively, they may be strains lacking the ldh gene. For example, a DNA fragment of about 2 kb should be obtained. Using this as an index, agarose gel electrophoresis (Molecular Cloning, Sambrook et al., 1989 Cold Spring Harbor Laboratory Press) was performed on the product obtained by the above colony PCR, and colony cells in which a deletion of the ldh gene was confirmed were obtained. It was obtained as an ldh gene-deficient strain (GES168).
- the sdhCAB gene was further deleted from the ldh gene-deficient strain (ATCC13032 ⁇ ldh strain) (GES168) according to the method for obtaining the ldh gene-deficient strain. That is, using the genomic DNA of the Corynebacterium glutamicum ATCC13032 strain as a template, a region of about 1000 bp upstream of the sdhCAB gene coding region and a region of about 1000 bp downstream of the gene coding region were amplified. In these PCR reactions, a pair of primers F4 and R4 was used for the upstream region, and primers F5 and R5 were used for the downstream region (Table 14).
- sdhCAB constitutes an operon on the genome by the sdhC coding region, the sdhA coding region, and the sdhB coding region.
- the positional relationship between each primer and each coding region is shown in FIG. 2B. Has been done.
- the upstream and downstream DNA fragments of the SdhCAB gene amplified as described above were ligated to a pGE15 vector linearized by restriction enzyme treatment with EcoRI using an In-Fusion cloning kit (Takara Bio Co., Ltd.). , Cloned.
- the plasmid thus obtained was named pGE020.
- the plasmid pGE020 was introduced into the ATCC13032 ⁇ ldh strain (GES168) according to the above-mentioned electric pulse method in the same manner as when the ATCC13032 ⁇ ldh strain (GES168) was obtained, and ATCC13032 ⁇ ldh ⁇ sdh was screened by colony PCR and selection using a kanamycin-containing medium and a sucrose-containing medium. Acquired the stock (GES439)
- the poxB gene was further deleted from the ATCC13032 ⁇ ldh ⁇ sdh strain (GES439). That is, using the genomic DNA of the Corynebacterium glutamicum ATCC13032 strain as a template, a region of about 1000 bp upstream of the pokeB gene coding region and a region of about 1000 bp downstream of the gene coding region were amplified. In these PCR reactions, a pair of primers F6 and R6 was used for the upstream region, and primers F7 and R7 were used for the downstream region (Table 15). Note that FIG. 2C schematically shows the positional relationship between each primer and the gene coding region.
- the upstream and downstream DNA fragments of the pokeB gene amplified as described above were ligated to a pGE15 vector linearized by restriction enzyme treatment with EcoRI using an In-Fusion cloning kit (Takara Bio Co., Ltd.). , Cloned.
- the plasmid thus obtained was named pGE191.
- the plasmid pGE191 was introduced into the ATCC13032 ⁇ ldh ⁇ sdh strain (GES439) according to the above-mentioned electric pulse method in the same manner as when the ATCC13032 ⁇ ldh strain (GES168) was obtained, and ATCC13032 ⁇ ldh ⁇ sdh ⁇ pox by selection with a kanamycin-containing medium and a sucrose-containing medium and screening by colony PCR. Acquired the stock (GES524)
- the DNA fragment related to the origin of replication of Escherichia coli was amplified by the PCR method using pMW119 (Takara Bio Inc.) as a template and the pair of primers F9 and R9 shown in Table 16. Further, the kanamycin resistance gene DNA fragment was amplified by the PCR method using pHSG299 (Takara Bio Inc.) as a template and the pair of primers F10 and R10 shown in Table 16.
- plasmid pGEK004 was named a shuttle vector for Corynebacterium glutamicum ATCC13032.
- the region of about 900 bp corresponding to the N-terminal side of PEPC was amplified by the PCR method using the ATCC13032 strain genomic DNA as a template and the pair of primers F12 and R12-1 shown in Table 18.
- the region of about 3500 bp including the C-terminal region of PEPC was amplified by using the pair of primers F13-1 and R13 shown in Table 18 using the ATCC13032 strain genomic DNA as a template.
- the primer R12-1 (reverse primer) used for amplifying the N-terminal fragment of PEPC and the primer F13-1 (forward primer) used for amplifying the C-terminal fragment of PEPC are the coding regions of PEPC. It overlaps in and contains the mutant codons associated with D299N (“GTT” / “AAC”, respectively, underlined in Table 18).
- the corresponding wild-type codon is "GAC" (sense strand).
- the three DNA fragments obtained as described above are cyclized by ligating them in tandem using an In-Fusion cloning kit (Takara Bio Inc.) to a vector fragment linearized by treating pGEK004 with a restriction enzyme with BamHI. , The plasmid pGE320 was obtained.
- the C-terminal region of PEPC can be obtained.
- the region containing about 530 bp was amplified.
- the primer R12-2 reverse primer used for amplifying the N-terminal fragment of PEPC and the primer F13-2 (forward primer) used for amplifying the C-terminal fragment of PEPC are the coding regions of PEPC. It overlaps in and contains the mutant codons associated with K813S (“CGA” / “TCG”, respectively, underlined in Table 19). The corresponding wild-type codon is "AAG" (sense strand).
- pGE321 (ppcN917G gene)
- a DNA fragment containing the gapA gene promoter region was amplified by a PCR reaction in the same manner as in the preparation of pGE320.
- the PEPC coding region first, by using the PCR method, using the ATCC13032 strain genomic DNA as a template and using the pair of the primer F12 shown in Table 18 and the primer R12-3 shown in Table 20, the N-terminal side of PEPC was used.
- the C-terminal region of PEPC can be obtained.
- the region containing about 530 bp was amplified.
- the primer R12-3 reverse primer used for amplifying the N-terminal fragment of PEPC and the primer F13-3 (forward primer) used for amplifying the C-terminal fragment of PEPC are the coding regions of PEPC. It overlaps in and contains mutant codons relating to N917G (“GCC” / “GGC”, respectively, underlined in Table 20). The corresponding wild-type codon is "AAC" (sense strand).
- the two DNA fragments obtained as described above are cyclized by ligating them in tandem using an In-Fusion cloning kit (Takara Bio Inc.) to a vector fragment linearized by treating pGEK004 with a restriction enzyme with BamHI. , The plasmid pGE333 was obtained.
- the two DNA fragments obtained as described above are cyclized by ligating them in tandem using an In-Fusion cloning kit (Takara Bio Inc.) to a vector fragment linearized by treating pGEK004 with a restriction enzyme with BamHI. , The plasmid pGE322 was obtained.
- each recombinant coryneform bacterial strain was pre-cultured (test tube) in 5 mL of A medium, and 2 mL of each obtained pre-culture solution was placed in a 500 mL flask in NA medium (urea: 2 g, (NH 4 )).
- the results of the aspartic acid production test are shown in FIG. In the graph of FIG. 4, the vertical axis represents the aspartic acid concentration in the sample after the reaction. Further, Table 21 below shows the genotypes of the obtained recombinant coryneform bacteria and the aspartic acid production efficiency (%) calculated by the aspartic acid production test. The value of aspartic acid production efficiency (%) is the ratio of the produced aspartic acid to 0.5 mol of glucose taken up by the cells.
- Test Example 2 (Test procedure) For each of the corynebacterium-glutamicum gene-deficient strains GES168 ( ⁇ ldh), GES439 ( ⁇ ldh ⁇ sdhCAB), and GES524 ( ⁇ ldh ⁇ sdhCAB ⁇ poxB) produced in the above-mentioned item (1) by the above-mentioned electric pulse method, the above (2-2) The plasmid pGE333 (ppcD299N / K813S) constructed in the above section was transformed to obtain a recombinant coryneform bacterium. Using each of the obtained recombinant coryneform bacteria, a production test of aspartic acid was carried out by the same method as in Test Example 1.
- the results of the aspartic acid production test are shown in FIG. In the graph of FIG. 5, the vertical axis represents the aspartic acid concentration in the sample after the reaction. Furthermore, Table 22 below shows the genotypes of the obtained recombinant coryneform bacteria and the aspartic acid production efficiency (%) calculated by the aspartic acid production test. The value of aspartic acid production efficiency (%) is the ratio of aspartic acid actually produced to 0.5 mol of glucose taken up by the cells. This value is based on the fact that aspartic acid can theoretically produce 1 to 2 moles of glucose.
- the aspartic acid production efficiency is significant as shown in FIGS. 5 and 22. No significant improvement was seen.
- the ES439 / pGE333 strain which also has a mutant ppc gene having an amino acid substitution by the combination of D299N / K813S and lacks two genes, ldh gene and sdhCAB. As for, a remarkable improvement in aspartic acid production efficiency was observed.
- Test Example 3 In Test Examples 1 and 2, recombinant coryneform bacteria were previously grown under aerobic culture conditions using A medium and NA medium, the culture medium was removed by centrifugation, and the isolated somatic cells were placed. The aspartic acid production reaction was carried out by suspending the cells in a fixed amount of BT solution. On the other hand, in this test example, after the recombinant coryneform bacterium was grown under aerobic culture conditions using A medium and NA medium, the culture solution was prepared without forming somatic cells by centrifugation or the like. Aspartic acid production reaction was carried out using it as it was. The procedure is shown below.
- each sample culture solution was directly transferred to a 100 mL medium bottle containing a stir bar, and 5 mL of 50% glucose and 5 mL of 2M (NH 4 ) 2 CO 3 were further added.
- This medium bottle was placed in a constant temperature bath at 33 ° C. and allowed to stand, and the reaction was carried out while stirring with the above stirrer. After 24 hours, 0.5 mL of the reaction solution was collected, and the supernatant was collected by centrifugation, and the amount of glucose consumed and the amount of amino acids produced were measured.
- the amino acid analysis system Prominence was used for the identification and measurement of amino acids.
- the results of the aspartic acid production test in this test example are shown in FIG. In the graph of FIG. 6, the vertical axis represents the aspartic acid concentration in the sample after the reaction. Further, Table 23 below shows the genotypes of the obtained recombinant coryneform bacteria and the aspartic acid production efficiency (%) calculated by the aspartic acid production test. The value of the aspartic acid production efficiency (%) is, as described above, the ratio of the aspartic acid actually produced to 0.5 mol of glucose taken up by the cells.
- Test Examples 1 to 3 when the recombinant coryneform bacterium prescribed in the present invention is used, it is possible to improve the conversion efficiency of a starting substrate such as a saccharide into a target substance.
- a predetermined gene was disrupted in Escherichia coli according to the following procedure.
- the strain was pre-transformed with a bacteriophage recombinant expression vector pKD46 (Life Science Market).
- the obtained transformant was inoculated into 100 mL of LB medium (containing arabinose at a final concentration of 10 mM) and cultured at 30 ° C. until the medium turbidity OD600 was around 0.6.
- Competent cells were prepared by washing the obtained cells of recombinant Escherichia coli with 10% Glucerol three times and finally suspending them in 1 mL of 10% Glucerol.
- primers F14 and R14 shown in Table 24 below, a DNA fragment containing the kanamycin resistance gene coding region was amplified by PCR reaction using pKD13 as a template.
- primers F14 and R14 each contain nucleotide sequences homologous to the upstream and downstream regions of the pflB gene coding region in E. coli chromosomal DNA.
- the obtained PCR product was purified using NucleoSpin Gel and PCR Clean-up (Takara Bio Inc.).
- the obtained transformant contained 50 ⁇ g / mL of kanamycin.
- the growth strain was selected by growing on the LB agar medium contained in. Deletion of the pflB gene was confirmed by culturing the selected growth strain in a predetermined medium and performing organic acid analysis on the supernatant of the culture solution in which the bacterial cells were separated by centrifugation. That is, a strain in which formic acid production was not observed in the organic acid analysis was obtained as a pflB gene-deficient strain.
- the organic acid analysis was performed by HPLC analysis using a TSKgel OApak column (Tosoh).
- pCP20 (Life Science Market) was transformed into the BW251 13 ⁇ pflB :: Km strain obtained as described above at 30 ° C., and the obtained transformant was streaked onto an antibiotic-free LB medium plate at 42 ° C. Was cultured in.
- pCP20 is a plasmid vector designed to express Flp recombinase, which sheds a cassette of the kanamycin resistance gene under high temperature culture temperature conditions.
- a colony sensitive to kanamycin was selected and named BW25113 ⁇ pflB.
- the purified PCR product was gene-introduced into the above-mentioned competent cells to prepare an ldhA gene-deficient strain.
- the deletion of the ldhA gene was confirmed by culturing the transformant in a predetermined medium and analyzing the supernatant of the culture solution separated by centrifugation by organic acid analysis by the same method as described above. That is, a strain in which lactic acid production was not observed in the organic acid analysis was obtained as an ldhA gene-deficient strain.
- kanamycin resistance gene was also carried out by a method using pCP20 (Life Science Market) as described above, and colonies showing sensitivity to kanamycin were selected and named BW25113 ⁇ pflB ⁇ ldhA strain.
- the purified PCR product was gene-introduced into the above competent cells to prepare a frdA gene-deficient strain.
- the deletion of the frdA gene was confirmed by culturing the transformant in a predetermined medium and analyzing the supernatant of the culture solution separated by centrifugation by organic acid analysis by the same method as described above. That is, in the organic acid analysis, a strain in which production of succinic acid was not observed was obtained as a frdA gene-deficient strain.
- kanamycin resistance gene was also carried out by a method using pCP20 (Life Science Market) as described above, and colonies showing sensitivity to kanamycin were selected and named as BW25113 ⁇ pflB ⁇ ldhA ⁇ frdA strain.
- Test Example 4 By transforming the BW25113 ⁇ pflB ⁇ ldhA ⁇ frdA strain obtained as described above with pGEK004, pGE333 (ppcD229N / K813S) and pGE322 (ppcD229N / N917G) constructed in Test Example 1, respectively, the present invention can be recombined. Obtained a strain of Kori.
- Each of the above recombinant strains was pre-cultured in 5 mL of LB medium in vitro.
- the resulting preculture Quat medium in 500mL flask (Composition of medium 1L: Bacto tryptone 12g, yeast extract 24 g, glycerol 4mL, KH 2 PO 4 2.31g, K 2 HPO 4 12.54g) in 100mL
- the cells were inoculated and further cultured at 37 ° C. for 20 hours at 200 rpm with shaking. After culturing, the cells were centrifuged to remove the culture solution, and the obtained cells were suspended in 40 mL of BT solution, and the OD value of the suspension was adjusted to be around 15 to 20.
- the suspension was transferred to a 100 mL medium bottle containing a stir bar and an additional 5 mL of 50% glucose and 5 mL of 2M (NH 4 ) 2 CO 3 were added.
- This medium bottle was placed in a constant temperature bath at 33 ° C. and allowed to stand, and the reaction was carried out with stirring. After 20 hours, 0.5 mL of the reaction solution was collected from the medium bottle and centrifuged to obtain a supernatant, and the amount of glucose consumed and the amount of amino acids produced were measured.
- An amino acid analysis system (Shimadzu Corporation) was used for the identification and measurement of amino acids.
- the chromatograph obtained by amino acid analysis is shown in FIG. In the chromatograph shown in FIG. 7, the peak observed around 7 minutes is the peak of aspartic acid. Further, Table 27 below shows the genotype of the obtained recombinant Escherichia coli strain, the aspartic acid production efficiency (%) calculated by the aspartic acid production test, and the like. The value of aspartic acid production efficiency (%) is the ratio of aspartic acid actually produced to 0.5 mol of glucose taken up by the cells. This value is based on the fact that aspartic acid can theoretically produce 1 to 2 moles of glucose.
- aspartic acid as a target substance and a metabolite produced by a metabolic pathway derived from the aspartic acid are improved in production efficiency, and as a result, the yield of the target substance is improved. It was shown that it would be possible to improve the rate. That is, according to the present invention, it has been clarified that the conversion efficiency of a starting substrate such as a saccharide into a target substance can be improved, and as a result, energy saving of a bioprocess, cost reduction, and efficient substance production can be realized.
- cloning of various gene coding regions, promoter regions, etc. includes a step using an In-Fusion cloning kit (Takara Bio Inc.) as described above, but the primer pair used for PCR amplification is described. It is supplemented that the appropriate adapter sequence is added to each of the 5'ends of the forward / reverse primer according to the instructions of the cloning kit.
- the present invention has high industrial applicability in the fields of biotechnology, substance production, and the like.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
なお、本願は、2019年4月12日付けで日本国特許庁に提出された日本国特許出願No.JP2019-76629(特願2019-76629)に基いて優先権を主張するものであり、上記日本国特許出願の内容は、あらゆる目的において本明細書で援用される。
しかしながら、現在のアスパラギン酸の工業生産は、石油から大量に安価に合成されるフマル酸を原料にしているのが現状であり、バイオマス由来の糖を原料とした発酵技術によるアスパラギン酸の工業生産は未だ実現していない。
[1]下記の条件(I)、(II)及び(IV)のうちの少なくとも1つを充足し、かつ下記の条件(III)を充足する、遺伝子組換え微生物:
条件(I)上記遺伝子組換え微生物に対応する野生型微生物と比較して、コハク酸デヒドロゲナーゼ活性又はフマル酸還元酵素活性が低減され又は不活化されていること;
条件(II)上記野生型微生物と比較して、乳酸デヒドロゲナーゼ活性が低減され又は不活化されていること;
条件(III)野生型ホスホエノールピルビン酸カルボキシラーゼ活性におけるアスパラギン酸によるフィードバック阻害に対し抵抗性を示す改変型ホスホエノールピルビン酸カルボキシラーゼ活性、又は上記野生型微生物が示す野生型ホスホエノールピルビン酸カルボキシラーゼ活性よりもアスパラギン酸によるフィードバック阻害に対する抵抗性が高い外来性ホスホエノールピルビン酸カルボキシラーゼ活性を有すること;
条件(IV)上記野生型微生物と比較して、ピルビン酸:キノンオキシドレダクターゼ活性が低減され又は不活化されていること。
ここで、いくつか実施形態においては、条件(I)、(II)及び(IV)のうちの少なくとも2つの条件を充足してもよく、特定の実施形態においては、条件(I)及び(II)の両方、条件(I)及び(IV)の両方、又は条件(II)及び(IV)の両方を充足してもよい。
条件(I)上記遺伝子組換え微生物に対応する野生型微生物と比較して、コハク酸デヒドロゲナーゼ活性又はフマル酸還元酵素活性が低減され又は不活化されていること;
条件(II)上記野生型微生物と比較して、乳酸デヒドロゲナーゼ活性が低減され又は不活化されていること;
条件(III)野生型ホスホエノールピルビン酸カルボキシラーゼ活性におけるアスパラギン酸によるフィードバック阻害に対し抵抗性を示す改変型ホスホエノールピルビン酸カルボキシラーゼ活性、又は上記野生型微生物が示す野生型ホスホエノールピルビン酸カルボキシラーゼ活性よりもアスパラギン酸によるフィードバック阻害に対する抵抗性が高い外来性ホスホエノールピルビン酸カルボキシラーゼ活性を有すること。
なお、本発明においては、[4]において「細菌由来の変異型ホスホエノールピルビン酸カルボキシラーゼをコードする核酸」を「微生物、植物、原核生物又は細菌由来の外来性ホスホエノールピルビン酸カルボキシラーゼをコードする核酸」と読み替えることによる実施形態も採用され得る。
[6]上記変異型ホスホエノールピルビン酸カルボキシラーゼは、コリネバクテリウム属に属する細菌に由来するものである、[4]又は[5]に記載の遺伝子組換え微生物。
(a)第299番目のアスパラギン酸に相当するアミノ酸の所定のアミノ酸へのアミノ酸置換(ただし、置換後のアミノ酸はアスパラギン酸ではないものとし、好ましくはアラニン、アスパラギン、グリシン又はセリンへのアミノ酸置換である。);
(b)第653番目のリシンに相当するアミノ酸の所定のアミノ酸へのアミノ酸置換(ただし、置換後のアミノ酸はリシンではないものとし、好ましくはアラニン、アスパラギン、又はセリンへのアミノ酸置換である。);
(c)第813番目のリシンに相当するアミノ酸の所定のアミノ酸へのアミノ酸置換(ただし、置換後のアミノ酸はリシンではないものとし、好ましくはアラニン、アスパラギン、グリシン又はセリンへのアミノ酸置換である。);
(d)第869番目のセリンに相当するアミノ酸の所定のアミノ酸へのアミノ酸置換(ただし、置換後のアミノ酸はセリンではないものとし、好ましくはアラニン、アスパラギン、又はグリシンへのアミノ酸置換である。);
(e)第873番目のアルギニンに相当するアミノ酸の所定のアミノ酸へのアミノ酸置換(ただし、置換後のアミノ酸はアルギニンではないものとし、好ましくはアラニン、アスパラギン、グリシン又はセリンへのアミノ酸置換である。);及び
(f)第917番目のアスパラギンに相当するアミノ酸の所定のアミノ酸へのアミノ酸置換(ただし、置換後のアミノ酸はアスパラギンではないものとし、好ましくはアラニン、フェニルアラニン、グリシン又はセリンへのアミノ酸置換である。)、
ただし、上記(a)~(f)において、置換前のアミノ酸と置換後のアミノ酸とは異なるものとする。
(g)第299番目のアスパラギン酸に相当するアミノ酸のアスパラギンへのアミノ酸置換;
(h)第653番目のリシンに相当するアミノ酸のセリンへのアミノ酸置換;
(i)第813番目のリシンに相当するアミノ酸の所定のアミノ酸へのアミノ酸置換(ただし、置換後のアミノ酸はリシンではないものとし、好ましくはグリシン又はセリンへのアミノ酸置換である。);
(j)第869番目のセリンに相当するアミノ酸のグリシンへのアミノ酸置換;
(k)第873番目のアルギニンに相当するアミノ酸のグリシンへのアミノ酸置換;及び
(l)第917番目のアスパラギンに相当するアミノ酸の所定のアミノ酸へのアミノ酸置換(ただし、置換後のアミノ酸はアスパラギンではないものとし、好ましくはアラニン、フェニルアラニン、グリシン又はセリンへのアミノ酸置換である。)。
[10]上記変異型ホスホエノールピルビン酸カルボキシラーゼにおける上記少なくとも1つのアミノ酸変異は、上記(g)に示すアミノ酸置換と、上記(i)又は(l)に示すアミノ酸置換とを含む、[8]又は[9]に記載の遺伝子組換え微生物。
(A)配列番号2~13(好ましくは配列番号2~12、より好ましくは配列番号2~11)の何れか1つに示すアミノ酸配列に対して、上記少なくとも1つのアミノ酸置換を導入してなるアミノ酸配列;
(B)上記(A)に規定のアミノ酸配列において、1又は複数のアミノ酸が欠失、置換及び/又は付加されたアミノ酸配列(但し、上記少なくとも1つのアミノ酸置換は維持されているものとする。);
(C)上記(A)に規定のアミノ酸配列に対して少なくとも60%の配列同一性を有するアミノ酸配列(但し、上記少なくとも1つのアミノ酸置換は維持されているものとする。)。
[13]上記変異型ホスホエノールピルビン酸カルボキシラーゼは、配列番号2に示すアミノ酸配列に対して、上記少なくとも1つのアミノ酸置換を導入してなるアミノ酸配列を有する、[4]~[12]の何れか1つに記載の遺伝子組換え微生物。
該アミノ酸変異が、配列番号2に示すアミノ酸配列を基準として、
(g)第299番目のアスパラギン酸に相当するアミノ酸のアスパラギンへのアミノ酸置換と、
(i)第813番目のリシンに相当するアミノ酸の所定のアミノ酸へのアミノ酸置換(ただし、置換後のアミノ酸はリシンではないものとする。);又は
(l)第917番目のアスパラギンに相当するアミノ酸の所定のアミノ酸へのアミノ酸置換(ただし、置換後のアミノ酸はアスパラギンではないものとする。)と、
を少なくとも含み、
上記野生型ホスホエノールピルビン酸カルボキシラーゼのアミノ酸配列に対して、上記(g)、(i)又は(l)に規定のアミノ酸置換のみを有してなるタンパク質よりも、アスパラギン酸によるフィードバック阻害に対する抵抗性が高い、
変異型ホスホエノールピルビン酸カルボキシラーゼ。
ここで、[14]に係る変異型ホスホエノールピルビン酸カルボキシラーゼにおいては、上記(i)において、第813番目のリシンに相当するアミノ酸は、アラニン、アスパラギン、グリシン又はセリンに置換されることが好ましく、さらにグリシン又はセリンに置換されることがより好ましく、さらにセリンに置換されることが最も好ましい。さらに、上記(l)において、第917番目のアスパラギンに相当するアミノ酸は、アラニン、フェニルアラニン、グリシン又はセリンに置換されることが好ましく、フェニルアラニン又はグリシンに置換されることがより好ましい。
(J)配列番号2~13(好ましくは配列番号2~12、より好ましくは配列番号2~11)の何れか1つに示すアミノ酸配列において、上記アミノ酸置換を導入してなるアミノ酸配列;
(K)上記(J)に規定のアミノ酸配列において、1又は複数のアミノ酸が欠失、置換及び/又は付加されたアミノ酸配列(但し、上記アミノ酸置換は維持されているものとする。);
(L)上記(J)に規定のアミノ酸配列に対して少なくとも60%の配列同一性を有するアミノ酸配列(但し、上記アミノ酸置換は維持されているものとする。)。
[18]配列番号2~13(好ましくは配列番号2~12、より好ましくは配列番号2~11)の何れか1つに示すアミノ酸配列に対して、上記アミノ酸置換を導入してなるアミノ酸配列を有する、[14]~[17]の何れか1つに記載の変異型ホスホエノールピルビン酸カルボキシラーゼ。
[20]DNA断片である、[19]に記載の核酸。
条件(I)上記遺伝子組換え微生物に対応する野生型微生物と比較して、コハク酸デヒドロゲナーゼ活性又はフマル酸還元酵素活性が低減され又は不活化されていること;
条件(II)上記野生型微生物と比較して、乳酸デヒドロゲナーゼ活性が低減され又は不活化されていること;
条件(III)野生型ホスホエノールピルビン酸カルボキシラーゼ活性におけるアスパラギン酸によるフィードバック阻害に対し抵抗性を示す改変型ホスホエノールピルビン酸カルボキシラーゼ活性、又は上記野生型微生物が示す野生型ホスホエノールピルビン酸カルボキシラーゼ活性よりもアスパラギン酸によるフィードバック阻害に対する抵抗性が高い外来性ホスホエノールピルビン酸カルボキシラーゼ活性を有すること。
[24]条件(I)~(III)の全ての条件を充足する、[22]又は[23]に記載の遺伝子組換え微生物。
[27]グラム陽性菌に属する遺伝子組換え微生物である、[1]~[13]及び[21]~[26]の何れか1つに記載の遺伝子組換え微生物。
[28]コリネ型細菌に属する遺伝子組換え微生物である、[27]に記載の遺伝子組換え微生物。
[29]コリネバクテリウム属に属する遺伝子組換え微生物である、[28]に記載の遺伝子組換え微生物。
[30]コリネバクテリウム・グルタミカムの遺伝子組換え菌株である、[29]に記載の遺伝子組換え微生物。
[31]グラム陰性菌に属する遺伝子組換え微生物である、[1]~[13]及び[21]~[26]の何れか1つに記載の遺伝子組換え微生物。
[32]エシェリキア属に属する遺伝子組換え微生物である、[31]に記載の遺伝子組換え微生物。
[33]エシェリキア・コリの遺伝子組換え微生物である、[32]に記載の遺伝子組換え微生物。
[34]さらに、条件(V)として、上記野生型微生物と比較して、ピルビン酸ギ酸リアーゼ活性が低減され又は不活化されていることを充足する、[31]~[33]の何れか1つに記載の遺伝子組換え微生物。
(q)上記目的物質を回収すること、
を含む、目的物質を生産する方法。
[39]上記反応媒体(X)の酸化還元電位が、-200ミリボルトから-500ミリボルトの範囲にある所定の値である、[38]に記載の方法。
[40]上記反応媒体(X)が糖類を含む、[38]又は[39]に記載の方法。
[41]上記反応媒体(X)がグルコースを含む、[38]~[40]の何れか1つに記載の方法。
(p’)所定の培地(Y)中で、好気条件下に、上記遺伝子組換え微生物を培養し及び増殖させること、
をさらに含み、工程(p’)において増殖させた該遺伝子組換え微生物の菌体又はその菌体処理物を工程(p)に供試する、[37]~[41]の何れか1つに記載の方法。
[44]上記目的物質が、アスパラギン酸又はこれから誘導される代謝産物である、[37]~[43]の何れか1つに記載の方法。
[45]上記目的物質が、アスパラギン酸、ベータアラニン、又はアスパラギンである、[37]~[44]の何れか1つに記載の方法。
以下、本発明の態様においてさらに採用し得る実施形態ないし変形例を例示すると共に、本発明の利点及び効果についても言及する。
本発明の第一の態様によれば、以下の遺伝子組換え微生物が提供される。
下記の条件(I)、(II)及び(IV)のうちの少なくとも1つを充足し、かつ下記の条件(III)を充足する、遺伝子組換え微生物:
条件(I)上記遺伝子組換え微生物に対応する野生型微生物と比較して、コハク酸デヒドロゲナーゼ活性又はフマル酸還元酵素活性が低減され又は不活化されていること;
条件(II)上記野生型微生物と比較して、乳酸デヒドロゲナーゼ活性が低減され又は不活化されていること;
条件(III)野生型ホスホエノールピルビン酸カルボキシラーゼ活性におけるアスパラギン酸によるフィードバック阻害に対し抵抗性を示す改変型ホスホエノールピルビン酸カルボキシラーゼ活性、又は上記野生型微生物が示す野生型ホスホエノールピルビン酸カルボキシラーゼ活性よりもアスパラギン酸によるフィードバック阻害に対する抵抗性が高い外来性ホスホエノールピルビン酸カルボキシラーゼ活性を有すること;
条件(IV)上記野生型微生物と比較して、ピルビン酸:キノンオキシドレダクターゼ活性が低減され又は不活化されていること。
下記の条件(I)~(III)の全てを充足する、遺伝子組換え微生物:
条件(I)上記遺伝子組換え微生物に対応する野生型微生物と比較して、コハク酸デヒドロゲナーゼ活性又はフマル酸還元酵素活性が低減され又は不活化されていること;
条件(II)上記野生型微生物と比較して、乳酸デヒドロゲナーゼ活性が低減され又は不活化されていること;
条件(III)野生型ホスホエノールピルビン酸カルボキシラーゼ活性におけるアスパラギン酸によるフィードバック阻害に対し抵抗性を示す改変型ホスホエノールピルビン酸カルボキシラーゼ活性、又は上記野生型微生物が示す野生型ホスホエノールピルビン酸カルボキシラーゼ活性よりもアスパラギン酸によるフィードバック阻害に対する抵抗性が高い外来性ホスホエノールピルビン酸カルボキシラーゼ活性を有すること。
なお、以下、本発明の第一の態様に係る遺伝子組換え微生物と、発明の第二の態様に係る遺伝子組換え微生物とを、まとめて「本発明の遺伝子組換え微生物」又は「本発明に係る遺伝子組換え微生物」と言うことがある。
より詳細には、コリネ型細菌としては、コリネバクテリウム(Corynebacterium)属菌、ブレビバクテリウム(Brevibacterium)属菌、アースロバクター(Arthrobacter)属菌、マイコバクテリウム(Mycobacterium)属菌、マイクロコッカス(Micrococcus)属菌、マイクロバクテリウム(Microbacterium)属菌等が挙げられる。
コリネバクテリウム・グルタミカム(Corynebacterium glutamicum)(例えば、FERM P-18976株、ATCC13032株、ATCC31831株、ATCC13058株、ATCC13059株、ATCC13060株、ATCC13232株、ATCC13286株、ATCC13287株、ATCC13655株、ATCC13745株、ATCC13746株、ATCC13761株、ATCC14020株);
コリネバクテリウム・アセトグルタミカム(Corynebacterium acetoglutamicum)(例えばATCC15806株);
コリネバクテリウム・アセトアシドフィラム(Corynebacterium acetoacidophilum)(例えばATCC13870株);
コリネバクテリウム・メラセコラ(Corynebacterium melassecola)(例えばATCC17965株);
コリネバクテリウム・エフィシエンス(Corynebacterium efficiens)(例えばYS-314株、YS-314T株(NBRC100395T株));
コリネバクテリウム・アルカノリティカム(Corynebacterium alkanolyticum)(例えばATCC21511株);
コリネバクテリウム・カルナエ(Corynebacterium callunae)(例えばATCC15991株、NBRC15359株、DSM20147株);
コリネバクテリウム・リリウム(Corynebacterium lilium)(例えばATCC15990株);
コリネバクテリウム・サーモアミノゲネス(コリネバクテリウム・エフィシエンス)(Corynebacterium thermoaminogenes (Corynebacterium efficiens))(例えばAJ12340株、FERM BP1539株);
コリネバクテリウム・ハーキュリス(Corynebacterium herculis)(例えばATCC13868株);
コリネバクテリウム・アンモニアゲネス(コリネバクテリウム・スタティオニス)(Corynebacterium ammoniagenes(Brevibacterium ammoniagenes)(例えばATCC6871株、ATCC6872株、DSM20306株、NBRC12071T株、NBRC12072株、NBRC12612T株);
コリネバクテリウム・ポリュティソリ(Corynebacterium pollutisoli);
コリネバクテリウム・マリナム(Corynebacterium marinum)(例えばDSM44953株);
コリネバクテリウム・フミリドゥセンス(Corynebacterium humireducens)(例えばNBRC106098株);
コリネバクテリウム・ハロトレランス(Corynebacterium halotolerans)(例えばYIM70093株);
コリネバクテリウム・デザーティ(Corynebacterium deserti)(例えばGIMN1.010株);
コリネバクテリウム・ドオサネンス(Corynebacterium doosanense)(例えばCAU212株、DSM45436株);
コリネバクテリウム・マリス(Corynebacterium maris)(例えばDSM45190株)。
ブレビバクテリウム・ディバリカタム(Brevibacterium divaricatum)(例えばATCC14020株);
ブレビバクテリウム・フラバム(Brevibacterium flavum)[例えば、MJ-233(FERM BP-1497)株、MJ-233AB-41(FERM BP-1498)株、ATCC13826株、ATCC14067株、ATCC13826株];
ブレビバクテリウム・イマリオフィラム(Brevibacterium immariophilum)(例えばATCC14068株);
ブレビバクテリウム・ラクトファーメンタム(コリネバクテリウム・グルタミカム)(Brevibacterium lactofermentum (Corynebacterium glutamicum))(例えばATCC13869株);
ブレビバクテリウム・ロゼウム(Brevibacterium roseum)(例えばATCC13825株);
ブレビバクテリウム・サッカロリティカム(Brevibacterium saccharolyticum)(例えばATCC14066株);
ブレビバクテリウム・チオゲニタリス(Brevibacterium thiogenitalis)(例えばATCC19240株);
ブレビバクテリウム・アルバム(Brevibacterium album)(例えばATCC15111株);
ブレビバクテリウム・セリナム(Brevibacterium cerinum)(例えばATCC15112株)。
アースロバクター・グロビフォルミス(Arthrobacter globiformis)(例えば、ATCC8010株、ATCC4336株、ATCC21056株、ATCC31250株、ATCC31738株、ATCC35698株、NBRC3062株、NBRC12137T株)等が挙げられる。
マイクロバクテリウム属菌の具体例としては、マイクロバクテリウム・アンモニアフィラム(Microbacterium ammoniaphilum)(例えばATCC15354株)。
まず、条件(I)、(II)及び(IV)について説明する。
条件(I)における「遺伝子組換え微生物に対応する野生型微生物と比較して、コハク酸デヒドロゲナーゼ活性又はフマル酸還元酵素活性が低減され又は不活化されていること」とは、本発明に係る遺伝子組換え微生物を作製する上で、出発材料として使用される野生型微生物と比較して、コハク酸デヒドロゲナーゼ又はフマル酸還元酵素活性が有意に低減されているか、又は完全に不活化していることを意味する。なお、コリネバクテリウム属菌等の一部の細菌では、フマル酸還元酵素はもっておらず、コハク酸デヒドロゲナーゼがこの反応を触媒するが、大腸菌等の一部の細菌では、コハク酸デヒドロゲナーゼとフマル酸還元酵素の両方の酵素を有しており、主にフマル酸還元酵素が上記の反応を触媒する。
さらに、条件(II)における「野生型微生物と比較して、乳酸デヒドロゲナーゼ活性が低減され又は不活化されていること」とは、本発明に係る遺伝子組換え微生物を作製する上で、出発材料として使用される野生型微生物と比較して、乳酸デヒドロゲナーゼ活性が有意に低減されているか、又は完全に不活化していることを意味する。
さらに加えて、条件(IV)における「野生型微生物と比較して、ピルビン酸:キノンオキシドレダクターゼ活性が低減され又は不活化されていること」とは、本発明に係る遺伝子組換え微生物を作製する上で、出発材料として使用される野生型微生物と比較して、ピルビン酸:キノンオキシドレダクターゼ活性が有意に低減されているか、又は完全に不活化していることを意味する。
即ち、本発明において条件(I)を充足する実施形態が採用された場合、好気条件下では、コハク酸からフマル酸への変換が抑制されることから、より多量のクエン酸、cis -アコニット酸、D-イソクエン酸、α-ケトグルタル酸、スクシニルCoA、コハク酸又はこれから誘導される更なる代謝産物を効率的に産生させることができ、他方、還元条件又は嫌気条件下では、より多量のオキサロ酢酸、L-リンゴ酸、フマル酸又はこれから誘導される更なる代謝産物を効率的に産生させることができる。ここで、TCAサイクルにおける上記代謝産物から誘導される更なる代謝産物は、条件(I)を充足する本発明の遺伝子組換え微生物において、もともと野生型微生物が保持する代謝系を介して生合成されるものであってもよいし、さらに所定の遺伝子を導入することで新たに構築された代謝系を介して生合成されるものであってもよい。
本発明において、条件(V)の充足は必須ではないが、特定の実施形態において、本発明に係る遺伝子組換え微生物は、さらに、下記の条件(V)を充足する。
条件(V):野生型微生物と比較して、ピルビン酸ギ酸リアーゼ活性が低減され又は不活化されていること。
ここで、条件(V)における「野生型微生物と比較して、ピルビン酸ギ酸リアーゼ活性が低減され又は不活化されていること」とは、本発明に係る遺伝子組換え微生物を作製する上で、出発材料として使用される野生型微生物と比較して、ピルビン酸ギ酸リアーゼ活性が有意に低減されているか、又は完全に不活化していることを意味する。
(I)遺伝子組換え微生物のゲノム(染色体DNA)上において、各酵素活性を付与し得る酵素遺伝子コード領域が完全に又は部分的に破壊されていることにより、条件(I)及び/又は(II)及び/又は(IV)及び/又は(V)を充足する実施形態。
(II)遺伝子組換え微生物のゲノム上において、各酵素活性を付与し得る酵素遺伝子コード領域の上流に存在する遺伝子発現調節領域(例えばプロモーター領域)が完全に又は部分的に破壊されていることにより、条件(I)及び/又は(II)及び/又は(IV)及び/又は(V)を充足する実施形態。
(III) 遺伝子組換え微生物のゲノム上において、各酵素活性を付与し得る酵素遺伝子コード領域に対して、それぞれ、1又は複数のアミノ酸変異を誘発するヌクレオチド変異が導入されていることにより、条件(I)及び/又は(II)及び/又は(IV)及び/又は(V)を充足する実施形態。ここで、「1又は複数のアミノ酸変異」は、各酵素活性の低減又は不活化を生じ得るアミノ酸変異を意味する。
(IV)各酵素活性を付与し得る酵素タンパク質の酵素活性を活性化させる内因性アクチベーターが、上記実施形態(I)~(III)に記載の方法により不活化されることにより、条件(I)及び/又は(II)及び/又は(IV)及び/又は(V)を充足する実施形態。
(1)破壊すべき標的領域の決定と同領域のクローニング
Corynebacterium属菌、Escherichia属菌、Bacillus属菌、Clostridium属菌等の多くの細菌、さらにSaccharomyces cerevisiae、Yarrowia lipolytica等の各種菌類は、全ゲノム配列が決定されており、そのヌクレオチド配列並びに各遺伝子がコードするタンパク質のアミノ酸配列も既知である。
例えば、本発明において好ましく利用され得る微生物の1つであるCorynebacterium glutamicumについて言えば、ATCC13032株、R株、ATCC21831株、ATCC14067株等の多数の菌株において全ゲノム配列が決定されており、そのヌクレオチド配列等は既知である。さらに加えて、Corynebacterium efficiens YS-314株;Corynebacterium callunae DSM20147株;Corynebacterium ammoniagenes DSM20306株;Corynebacterium marinum DSM44953株;Corynebacterium humireducens NBRC106098株(DSM45392株);Corynebacterium halotolerans YIM70093株(DSM44683株);Corynebacterium deserti GIMN1.010株;Corynebacterium maris DSM45190株;Corynebacterium doosanense CAU212株(DSM45436株)等のコリバクテリウム属菌株について全ゲノム配列が決定されており、それらヌクレオチド配列等は既知である。さらに、全ゲノム配列が決定されていないにしても、条件(I)、(II)、(IV)及び(V)に係る各酵素活性を付与する各酵素遺伝子のヌクレオチド配列並びに該酵素のアミノ酸配が既知である微生物も存在する。
これら既知のヌクレオチド配列やアミノ酸配列は、ナショナル・センター・フォー・バイオテクノロジー・インフォメーション・サポート・センター(National Center for Biotechnology Information Support Center;NCBI)(アメリカ合衆国メリーランド州ベセスダ・ロックビルパイク8600)がインターネット上で公開するデータベース(URL:https://www.ncbi.nlm.nih.gov/)等の各種データベースから容易に入手可能である。
なお、細菌においては、コハク酸デヒドロゲナーゼ(Sdh)については、sdhC遺伝子にコードされる膜貫通タンパク質(サブユニットC)、sdhA遺伝子にコードされるフラビンタンパク質サブユニット(サブユニットA)、及びsdhB遺伝子にコードされるFe-Sタンパク質(サブユニットB)の3つのサブユニットタンパク質、並びに場合によってはSdhD(サブユニットD)から構成される複合体であり、これらサブユニットをコードする各遺伝子は、原核生物の場合、細菌ゲノム上でオペロンを構成している(例えば、図2B)。加えて、フマル酸還元酵素(Frd)は、例えばエシェリキア・コリ等の細菌では、サブユニットD、C、B、Aから構成される複合体であり、frdDCBA遺伝子(オペロン)によりコードされている。さらに、ピルビン酸ギ酸リアーゼ(Pfl)は、例えばエシェリキア・コリ等の細菌では、サブユニットA、B、C、Dから構成される複合体であり、pflABCD遺伝子(オペロン)によりコードされている。
次いで、条件(I)、(II)、(IV)及び(V)に係る酵素遺伝子の破壊に関し、相同組換え法を用いた遺伝子破壊株の作製方法について説明する。
まず、ゲノム上において破壊したい領域と相同組換えを生じ得る遺伝子破壊用プラスミドベクターを作製する必要がある。
なお、遺伝子組換え微生物におけるゲノム上の標的領域の破壊の確認は、PCR法やサザンハイブリダイゼーション法、各種酵素活性測定法等に基いて実施できる。
本発明に係る遺伝子組換え微生物は、さらに、条件(III)として「野生型ホスホエノールピルビン酸カルボキシラーゼ活性におけるアスパラギン酸によるフィードバック阻害に対し抵抗性を示す改変型ホスホエノールピルビン酸カルボキシラーゼ活性、又は上記野生型微生物が示す野生型ホスホエノールピルビン酸カルボキシラーゼ活性よりもアスパラギン酸によるフィードバック阻害に対する抵抗性が高い外来性ホスホエノールピルビン酸カルボキシラーゼ活性を有すること」を充足し得る。
まず、本発明において、「ホスホエノールピルビン酸カルボキシラーゼ活性」とは、具体的にはEC4.1.1.31に規定される反応を触媒する酵素活性を言い、多種多様な植物や微生物が広く保有するホスホエノールピルビン酸カルボキシラーゼ(PEPC)により発揮される酵素活性である。以下に、PEPCが触媒する代謝反応を示す。
即ち、上記の用語は、本発明に係る遺伝子組換え微生物が属する種に対応する野生型微生物、又は本発明に係る遺伝子組換え微生物を作製する上で出発材料として用いられる野生型微生物が保有する野生型ホスホエノールピルビン酸カルボキシラーゼが示す「アスパラギン酸によるフィードバック阻害に対する抵抗性」と比較して、アスパラギン酸によるフィードバック阻害に対する抵抗性がより高い外来性ホスホエノールピルビン酸カルボキシラーゼ活性を意味する。このような外来性ホスホエノールピルビン酸カルボキシラーゼ活性は、具体的には、上記「対応する野生型宿主微生物」とは異なる菌株系統又は生物種」が保有する異種性のホスホエノールピルビン酸カルボキシラーゼによって付与され得る。ここで、「野生型宿主微生物とは異なる生物種」は、微生物(例えば、菌類、個細菌や細菌等の原核生物)、植物、哺乳類等の動物などの各種生物種を含む。さらに、本発明に係る遺伝子組換え微生物における「外来性ホスホエノールピルビン酸カルボキシラーゼ活性」の付与は、より具体的には「野生型宿主微生物とは異なる菌株系統又は生物種」から単離されたPEPC遺伝子をコードする核酸の導入により実現できる。
加えて、本明細書においては、「ホスホエノールピルビン酸カルボキシラーゼ」を「PEPC」、又は「ppc」と表すことがある。
(i)野生型PEPCのアミノ酸配列に対して、1又は複数のアミノ酸の欠失、置換若しくは付加されてなる変異型PEPC。ここで、「1又は複数」の範囲は、例えば1から100個、1から50個、1から30個、好ましくは少なくとも2個以上、2から20個、より好ましくは2から10個、さらにより好ましくは2から5個、特に好ましくは2から4個、2から3個、例えば2個である。
(ii)2種以上の野生型PEPCのアミノ酸配列の一部を組合せて構成したキメラ型PEPC。
(a)第299番目のアスパラギン酸に相当するアミノ酸の所定のアミノ酸へのアミノ酸置換(ただし、置換後のアミノ酸はアスパラギン酸ではないものとし、好ましくはアラニン、アスパラギン、グリシン又はセリンへのアミノ酸置換である。);
(b)第653番目のリシンに相当するアミノ酸の所定のアミノ酸へのアミノ酸置換(ただし、置換後のアミノ酸はリシンではないものとし、好ましくはアラニン、アスパラギン、又はセリンへのアミノ酸置換である。);
(c)第813番目のリシンに相当するアミノ酸の所定のアミノ酸へのアミノ酸置換(ただし、置換後のアミノ酸はリシンではないものとし、好ましくはアラニン、アスパラギン、グリシン又はセリンへのアミノ酸置換である。);
(d)第869番目のセリンに相当するアミノ酸の所定のアミノ酸へのアミノ酸置換(ただし、置換後のアミノ酸はセリンではないものとし、好ましくはアラニン、アスパラギン、又はグリシンへのアミノ酸置換である。);
(e)第873番目のアルギニンに相当するアミノ酸の所定のアミノ酸へのアミノ酸置換(ただし、置換後のアミノ酸はアルギニンではないものとし、好ましくはアラニン、フェニルアラニン、グリシン又はセリンへのアミノ酸置換である。);及び
(f)第917番目のアスパラギンに相当するアミノ酸の所定のアミノ酸へのアミノ酸置換(ただし、置換後のアミノ酸はアスパラギンではないものとし、好ましくはアラニン、フェニルアラニン、グリシン又はセリンへのアミノ酸置換である。)、
ただし、上記(a)~(f)において、置換前のアミノ酸と置換後のアミノ酸とは異なるものとする。
なお、例えば、「第299番目のアスパラギン酸」を、アミノ酸の1文字表記を利用して「D299」と表し、「第299番目のアスパラギン酸のアスパラギンへのアミノ酸置換」を「D299N」と表すことがある。その他のアミノ酸及びアミノ酸置換も同様の方法で表記され得る。
(g)第299番目のアスパラギン酸に相当するアミノ酸のアスパラギンへのアミノ酸置換;
(h)第653番目のリシンに相当するアミノ酸のセリンへのアミノ酸置換;
(i)第813番目のリシンに相当するアミノ酸の所定のアミノ酸へのアミノ酸置換(ただし、置換後のアミノ酸はリシンではないものとし、好ましくはグリシン又はセリンへのアミノ酸置換である。);
(j)第869番目のセリンに相当するアミノ酸のグリシンへのアミノ酸置換;
(k)第873番目のアルギニンに相当するアミノ酸のグリシンへのアミノ酸置換;及び
(l)第917番目のアスパラギンに相当するアミノ酸の所定のアミノ酸へのアミノ酸置換(ただし、置換後のアミノ酸はアスパラギンではないものとし、好ましくはアラニン、フェニルアラニン、グリシン又はセリンへのアミノ酸置換である。)。
さらに、別の好ましい実施形態においては、上記変異型ホスホエノールピルビン酸カルボキシラーゼにおける上記少なくとも1つのアミノ酸変異は、上記(g)に示すアミノ酸置換と、上記(i)~(l)に示すアミノ酸置換のうちの少なくとも1つとを含む。
加えて、特に好ましい実施形態においては、上記変異型ホスホエノールピルビン酸カルボキシラーゼにおける上記少なくとも1つのアミノ酸変異は、上記(g)に示すアミノ酸置換と、上記(i)又は(l)に示すアミノ酸置換とを含む。
(A)配列番号2~13(好ましくは配列番号2~12、より好ましくは配列番号2~11)の何れか1つに示すアミノ酸配列において、上記(a)~(l)に示すアミノ酸置換からなる群から選択される少なくとも1つを導入してなるアミノ酸配列(ただし、置換前のアミノ酸と置換後のアミノ酸は異なるものとする。);
(B)上記(A)に規定のアミノ酸配列において、1又は複数のアミノ酸が欠失、置換及び/又は付加されたアミノ酸配列(但し、上記少なくとも1つのアミノ酸置換は維持されているものとする。);
(C)上記(A)に規定のアミノ酸配列に対して少なくとも60%の配列同一性を有するアミノ酸配列(但し、上記少なくとも1つのアミノ酸置換は維持されているものとする。)。
(D)配列番号2~13(好ましくは配列番号2~12、より好ましくは配列番号2~11)の何れか1つに示すアミノ酸配列において、上記(g)に示すアミノ酸置換と、上記(h)~(l)に示すアミノ酸置換のうちの少なくとも1つとを導入してなるアミノ酸配列(ただし、置換前のアミノ酸と置換後のアミノ酸は異なるものとする。);
(E)上記(D)に規定のアミノ酸配列において、1又は複数のアミノ酸が欠失、置換及び/又は付加されたアミノ酸配列(但し、上記各アミノ酸置換は維持されているものとする。);
(F)上記(D)に規定のアミノ酸配列に対して少なくとも60%の配列同一性を有するアミノ酸配列(但し、上記各アミノ酸置換は維持されているものとする。)。
(G)配列番号2~13(好ましくは配列番号2~12、より好ましくは配列番号2~11)の何れか1つに示すアミノ酸配列において、上記(g)に示すアミノ酸置換と、上記(i)~(l)に示すアミノ酸置換のうちの少なくとも1つとを導入してなるアミノ酸配列(ただし、置換前のアミノ酸と置換後のアミノ酸は異なるものとする。);
(H)上記(G)に規定のアミノ酸配列において、1又は複数のアミノ酸が欠失、置換及び/又は付加されたアミノ酸配列(但し、上記各アミノ酸置換は維持されているものとする。);
(I)上記(G)に規定のアミノ酸配列に対して少なくとも60%の配列同一性を有するアミノ酸配列(但し、上記各アミノ酸置換は維持されているものとする。)。
(J)配列番号2~13(好ましくは配列番号2~12、より好ましくは配列番号2~11)の何れか1つに示すアミノ酸配列において、上記(g)に示すアミノ酸置換と、上記(i)又は(l)に示すアミノ酸置換とを導入してなるアミノ酸配列(ただし、置換前のアミノ酸と置換後のアミノ酸は異なるものとする。);
(K)上記(J)に規定のアミノ酸配列において、1又は複数のアミノ酸が欠失、置換及び/又は付加されたアミノ酸配列(但し、上記各アミノ酸置換は維持されているものとする。);
(L)上記(J)に規定のアミノ酸配列に対して少なくとも60%の配列同一性を有するアミノ酸配列(但し、上記各アミノ酸置換は維持されているものとする。)。
加えて、上記(C)、(F)、(I)及び(L)において、「少なくとも60%」は、好ましくは少なくとも70%、より好ましくは少なくとも80%、さらにより好ましくは少なくとも85%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%と読み替えられる。
さらに加えて、上記(A)、(D)、(G)及び(J)において、「配列番号2~13(好ましくは配列番号2~12、より好ましくは配列番号2~11)の何れか1つに示すアミノ酸配列」は、「配列番号2に示すアミノ酸配列」(即ち、コリネバクテリウム・グルタミカムATCC13032株の野生型PEPCアミノ酸配列)と読み替える実施形態は、特に好ましい。
なお、上述の各実施形態において、上記(A)~(L)の何れかに規定のアミノ酸配列を有する変異型PEPCが、ホスホエノールピルビン酸カルボキシラーゼ活性を保持し、かつ条件(III)を充足せしめる趣旨であることに変わりは無い。
本発明の第三の態様によれば、以下の目的物質を生産する方法が提供される。
(p)本発明に係る遺伝子組換え微生物の菌体又はその菌体処理物を用いて目的物質を生成させること;並びに
(q)上記目的物質を回収すること、
を含む、目的物質を生産する方法。
さらに、より好ましい実施形態においては、本発明に係る方法は、工程(p)の前に、
(p’)所定の培地(Y)中で、好気条件下に、上記遺伝子組換え微生物を予め培養し及び増殖させること、をさらに含み、
工程(p’)において増殖させた該遺伝子組換え微生物の菌体又はその菌体処理物を工程(p)に供試する。
以下、工程(p’)、工程(p)、工程(q)の順に、これらの工程で採用され得る具体的構成及び要素について詳述する。
培地(Y)は、特に限定されるものではなく、方法において用いる遺伝子組換え微生物の種類に応じて、適当なもので選択して用いれば良い。具体的には、培地(Y)としては、炭素源、窒素源、無機塩類およびその他栄養物質等を含有する天然培地または合成培地を用いることができる。培地中に含まれる成分は、例えば以下のとおりである。
グルコース、フルクトース、マンノース、キシロース、アラビノース、ガラクトース等の単糖類;スクロース、マルトース、ラクトース、セロビオース、キシロビオース、トレハロースのような二糖類;セルロース,デンプン,グリコーゲン、アガロース、ペクチン、アルギン酸等の多糖類;糖蜜等;稲わら、林地残材、バガス、コーンストーバー等の非可食農産廃棄物や非可食性バイオマス(非可食性の草本植物や木本植物を原料とした資源);スイッチグラス、ネピアグラス、ミスキャンサス等のエネルギー作物を糖化酵素などで糖化したグルコースやキシロース等の複数の糖類を含む糖化液;マンニトール、ソルビトール、キシリトール、グリセリン等の糖アルコール;酢酸、クエン酵、乳酸、フマル酸、マレイン酸、グルコン酸等の有機酸;エタノール、プロパノール、ブタノール等のアルコール;ノルマルパラフィン等の炭化水素。
なお、炭素源は、1種を単独で、又は2種以上を混合して使用できる。
なお、窒素源は、1種を単独で又は2種以上を組合せて用いることができる。窒素源の培地中の濃度は、採用する遺伝子組換え微生物の種類やその性質、窒素化合物の種類等の条件に応じて適宜調製すればよく特に限定されるものでもないが、例えば約0.1~10w/v%とすることができる。
なお、無機塩は、1種を単独で又は2種以上を混合して使用できる。無機塩類の培地中の濃度は、採用する遺伝子組換え微生物の種類やその性質、無機塩類の種類等の条件に応じて適宜調製すればよく特に限定されるものでもないが、例えば約0.01~1(w/v%)とすればよい。
さらに加えて、必要に応じて、シリコーン系消泡剤やポリエーテル系消泡剤等の消泡剤を添加してもよく、細菌培地用の各種消泡剤が市販されているので、それらを利用してもよい。
なお、培地(Y)のpHは、採用する遺伝子組換え微生物が生育できる程度であれば特に限定されるものでもないが、約6~8が好ましい。
ここで、遺伝子組換え微生物の培養条件については、該遺伝子組換え微生物が十分に増殖し、十分な量の菌体又はその菌体処理物が得られるように適宜設定すれば足りる。具体的には、好気的条件下で培養温度を約25℃~38℃とし、培養時間を約12時間~48時間培養させることができる。さらに加えて、凍結乾燥や冷凍保存による菌体ストックについては、一度、固形培地上に播種し、該固形培地上で生育が確認されたコロニー等をさらに上述の培地(Y)に植菌することにより工程(p)に供試する遺伝子組換え微生物を調製することができる。
いくつかの実施形態においては、上述のとおり、工程(p’)において、培地(Y)中で遺伝子組換え微生物を培養及び増殖させた後、培地(Y)から遺伝子組換え微生物を回収又は分離することなく、該遺伝子組換え微生物を含む培地(Y)をそのまま、工程(p)に供試し、該遺伝子組換え微生物の菌体を用いて目的物質を生成させてもよい。さらに、工程(p)に先立ち、工程(p’)において取得した遺伝子組換え微生物を含む培地(Y)に、必要に応じて、後述の反応媒体(X)の成分となり得る炭素源(糖類)、窒素源、無機塩類、ビタミン類、還元剤等を追加し、工程(p)における目的物質の生成反応に供試してもよい。
本発明の反応媒体(X)の組成は、遺伝子組換え微生物が実質的に増殖せず、かつ遺伝子組換え微生物による目的物質の産生反応を進行させる還元条件下の反応媒体(X)を実現するものである限り、特に限定されるものではない。反応媒体(X)は、例えば炭素源、窒素源、及び無機塩類等を含有し、生物体等に由来する天然のものであってもよく、又は人工的に合成したものであってもよい。反応媒体(X)中に含まれる成分は、例えば以下のとおりである。
グルコース、フルクトース、マンノース、キシロース、アラビノース、ガラクトースのような単糖類;スクロース、マルトース、ラクトース、セロビオース、キシロビオース、トレハロースのような二糖類;セルロース,デンプン,グリコーゲン、アガロース、ペクチン、アルギン酸等の多糖類;糖蜜等;稲わら、林地残材、バガス、コーンストーバー等の非可食農産廃棄物や非可食性バイオマス(非可食性の草本植物や木本植物を原料とした資源);スイッチグラス、ネピアグラス、ミスキャンサス等のエネルギー作物を糖化酵素などで糖化したグルコースやキシロース等の複数の糖類を含む糖化液;マンニトール、ソルビトール、キシリトール、グリセリン等の糖アルコール;酢酸、クエン酵、乳酸、フマル酸、マレイン酸、グルコン酸等の有機酸;エタノール、プロパノール、ブタノール等のアルコール;ノルマルパラフィン等の炭化水素。
なお、窒素源は、1種を単独で又は2種以上を組合せて用いることができる。窒素源の反応液中の濃度は、用いる遺伝子組換え微生物の種類や、所望の目的物質の種類や性状、反応条件、窒素化合物の種類等の条件に応じて適宜調整すればよく、特に限定されるものでもないが、例えば、約0.1~10(w/v%)に調整することができる。
なお、無機塩類は、1種を単独で又は2種以上を組合せて用いることができる。無機塩類の反応液中の濃度は、用いる遺伝子組換え微生物の種類や、所望の目的物質の種類や性状、反応条件、無機塩類の種類等の条件に応じて適宜調整すればよく、特に限定されるものでもないが、例えば約0.01~1(w/v%)とすればよい。
加えて、具体的な好ましい反応媒体(X)の基本組成としては、上述のBT培地等が挙げられ、これらの培地の組成をベースとして、上述のとおり、炭素源(糖類)の濃度、ニコチン酸及びその誘導体のうち少なくとも1つの濃度(xn)、ビオチン濃度(xb)等を適宜調整することにより反応媒体(X)を調製することができる。
コリネ型細菌が実質的に増殖しない還元条件とは、字義どおりに解釈して遺伝子組換え微生物が実質に増殖しない程度に反応媒体が還元状態にあることを意味するが、より具体的には反応媒体の酸化還元電位で規定される。反応媒体(X)の酸化還元電位は、約-200mV~-500mVが好ましく、約-250mV~-500mVがより好ましい。
なお、反応媒体(X)の酸化還元電位は、酸化還元電位計を用いて測定することができる。酸化還元電位計は、市販品も存在することから、本発明にける反応媒体(X)の酸化還元電位の測定には、それら市販品を利用してもよい。
即ち、反応媒体の溶媒として、蒸留水等の代わりに反応液用水溶液を使用してもよく、反応液用水溶液の調整方法は、例えば硫酸還元微生物などの絶対嫌気性微生物用の培養液調整方法(Pfennig, N. et al., (1981) : The dissimilatory sulfate-reducing bacteria,In The Prokaryotes,A Handbook on Habitats Isolation and Identification of Bacteria,Ed.by Starr,M.P.et al., p926-940, Berlin,Springer Verlag.)や「農芸化学実験書 第三巻、京都大学農学部 農芸化学教室編、1990年第26刷、産業図書株式会社出版」などが参考となり、所望の還元条件下の水溶液を得ることができる。
さらに、適当な還元剤(例えば、チオグリコール酸、アスコルビン酸、システィン塩酸塩、メルカプト酢酸、チオール酢酸、グルタチオン、硫化ソーダ等)を添加して還元条件の反応液用水溶液を調整することもできる。
これらの方法を適宜組み合わせることも有効な還元条件の反応液用水溶液の調整方法である。
工程(p)における反応温度は、所望の目的物質を生成する範囲であればよく、採用する遺伝子組換え微生物の性質等に応じて適宜に設定すればよく、特に限定されるものではない。典型的には、約20~50℃、好ましくは約25~47℃であり、より好ましくは約27~37℃であり、このような温度範囲であれば効率良く目的物質を製造できる。
反応時間も、所望の目的物質が得られるように適宜調整すればよく、特に限定されるものでもないが、例えば約1時間~約7日間、より効率的な目的物質の観点から約1時間~約3日間が好ましく、例えば約1時間~48時間とすることができる。
工程(p)において目的物質を生成させた後、工程(q)として、目的物質を回収する。ここで、工程(q)において、「目的物質を回収する(こと)」と言う用語は、目的物質を含有する遺伝子組換え微生物及び/又は培養液若しくは反応媒体のものを採取することにより、目的物質を回収することを包含する概念である。
さらに、本発明の方法は、任意に目的物質を洗浄し、乾燥し、破砕し、粉体化又は粒状化し、及び/又は梱包する等の工程をさらに含んでも良い。
本発明の方法においては、本発明に係る遺伝子組換え微生物を利用して、様々な目的物質を収率良く生産することができる。採用する遺伝子組換え微生物の種類に応じて目的物質の種類は様々であるが、具体的には、核酸関連化合物(例えば、アデニン、グアニン、シトシン、チミン、ウラシル、5'-グアニル酸、アデノシン、ATP,CDP-コリン);ホルモン用物質等の各種生理活性物質;炭水化物や糖類;ビタミン関連物質及び補酵素(例えば、ビタミンC、ビタミンB2、B12、ソルボース、NAD,FAD、コエンザイムA);タンパク質、ペプチド、アミノ酸;L-3,4-ジヒドロキシフェニルアラニン(L-DOAP)、5-ヒドロキシトリプトファン、ピロリドンカルボン酸等のアミノ酸誘導体;エタノール、ブタノール、イソプロパノール等のアルコール類;フェノール、カテコール、4-ヒドロキシ安息香酸、4-アミノ安息香酸、アントラニル酸、没食子酸、コハク酸、フマル酸、リンゴ酸、シキミ酸、3-デヒドロシキミ酸、3-デヒドロキナ酸、プロトカテク酸、コリスミ酸等の各種有機化合物等が挙げられる。
さらに加えて、L-アミノ酸の誘導体は、具体的には、遺伝子組換え微生物の代謝系において、L-アミノ酸から誘導される代謝産物である。
さらに、本発明において、目的物質は、L-アスパラギン酸又はこれから誘導される代謝産物であることがこのましい。L-アスパラギン酸から誘導される代謝産物には、L-スレオニン、L-リシン、L-アルギニン、L-ホモセリン等のアミノ酸やアミノ酸誘導体が含まれる。
さらに別の実施形態においては、目的物質は、オキサロ酢酸、リンゴ酸又は生合成経路上これらの化合物を経由する代謝産物である。
好ましい実施形態においては、目的物質は、アスパラギン酸又はこれから誘導される代謝産物である。より好ましい実施形態においては、目的物質は、アスパラギン酸、ベータアラニン、又はアスパラギンである。
本発明の第四の態様によれば、下記の変異型ホスホエノールピルビン酸カルボキシラーゼが提供される。
コリネ型細菌に属する微生物が保有する野生型ホスホエノールピルビン酸カルボキシラーゼのアミノ酸配列に対して、該野生型ホスホエノールピルビン酸カルボキシラーゼ活性におけるアスパラギン酸によるフィードバック阻害を低減し得るアミノ酸変異を有し、
該アミノ酸変異が、配列番号2に示すアミノ酸配列を基準として、
(g)第299番目のアスパラギン酸に相当するアミノ酸のアスパラギンへのアミノ酸置換と、
(i)第813番目のリシンに相当するアミノ酸の所定のアミノ酸へのアミノ酸置換(ただし、置換後のアミノ酸はリシンではないものとする。);又は
(l)第917番目のアスパラギンに相当するアミノ酸の所定のアミノ酸へのアミノ酸置換(ただし、置換後のアミノ酸はアスパラギンではないものとする。)と、
を少なくとも含み、
上記野生型ホスホエノールピルビン酸カルボキシラーゼのアミノ酸配列に対して、上記(g)、(i)又は(l)に規定のアミノ酸置換のみを有してなるタンパク質よりも、アスパラギン酸によるフィードバック阻害に対する抵抗性が高い、
変異型ホスホエノールピルビン酸カルボキシラーゼ。
(J)配列番号2~13(好ましくは配列番号2~12、より好ましくは配列番号2~11)の何れか1つに示すアミノ酸配列において、上記(g)に示すアミノ酸置換と、上記(i)又は(l)に示すアミノ酸置換とを導入してなるアミノ酸配列(ただし、置換前のアミノ酸と置換後のアミノ酸は異なるものとする。);
(K)上記(A)に規定のアミノ酸配列において、1又は複数のアミノ酸が欠失、置換及び/又は付加されたアミノ酸配列(但し、上記各アミノ酸置換は維持されているものとする。);
(L)上記(A)に規定のアミノ酸配列に対して少なくとも60%の配列同一性を有するアミノ酸配列(但し、上記各アミノ酸置換は維持されているものとする。)。
加えて、上記(L)において、「少なくとも60%」は、好ましくは少なくとも70%、より好ましくは少なくとも80%、さらにより好ましくは少なくとも85%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%と読み替えられる。
さらに加えて、上記(J)において、「配列番号2~13(好ましくは配列番号2~12、より好ましくは配列番号2~11)の何れか1つに示すアミノ酸配列」は、「配列番号2に示すアミノ酸配列」(即ち、コリネバクテリウム・グルタミカムATCC13032株の野生型PEPCアミノ酸配列)と読み替える実施形態は、特に好ましい。
本発明の第五の態様によれば、第四の態様に係る変異型ホスホエノールピルビン酸カルボキシラーゼをコードする核酸が提供される。
加えて、本発明に係る核酸は、必ずしも必須ではないが、特定の微生物の細胞内で自律複製可能となるように複製起点等を含み、プラスミドの形態で提供されてもよい。さらに加えて、本発明に係る核酸においては、当該変異型PEPCコード配列に加え、微生物の細胞内で本発明に係る変異型PEPCが発現可能となるように、プロモーター配列やシャイン・ダルガノ配列等の遺伝子制御配列を含んでもよい。に当該変異型PEPCコード領域を含んでもよい。
なお、本発明において「含む」及び「有する」の語はそれぞれ、特に断わりのない限り、これらの語が目的語として言及する要素以外の要素の存在を排除するものではなく、これらの用語は混用される。加えて、本願の優先権主張の基礎とされる日本国特許出願No.JP2019-76629(特願2019-76629)の内容に加え、本明細書において言及される各文献の内容は、本明細書の一部を構成するものとしてここに援用される。
出発材料としてコリネバクテリウム・グルタミカムATCC13032株を用い、遺伝子破壊の手法により所定の酵素活性を不活化し、かつ所定のアミノ酸置換を有する変異型ホスホエノールピルビン酸カルボキシラーゼ遺伝子を導入した組換えコリネ型細菌を作出した。以下に、その手順を示す。
まず、PCR法により、プラスミドpNIC-Bsa4(Source BioScience社)を鋳型とし、以下の表12に示すプライマーのペアーを用い、SacB遺伝子断片を増幅させた。
さらに、PCR反応により、コリネバクテリウム・グルタミカムATCC13032株のゲノムDNAを鋳型として、ldh遺伝子コード領域上流の約1000bpの領域と、該遺伝子コード領域下流の約1000bpの領域とをそれぞれ増幅させた。
なお、これらPCR反応では、上流領域についてはプライマーF2及びR2のペアーを用い、下流領域についてはプライマーF3及びR3を用いた(表13)。
なお、図2Aに、各プライマーと遺伝子コード領域との位置関係が模式的に示されている。
即ち、コリネバクテリウム・グルタミカムATCC13032株のゲノムDNAを鋳型として、sdhCAB遺伝子コード領域上流の約1000bpの領域と、該遺伝子コード領域下流の約1000bpの領域とをそれぞれ増幅させた。
なお、これらPCR反応では、上流領域についてはプライマーF4及びR4のペアーを用い、下流領域についてはプライマーF5及びR5を用いた(表14)。加えて、上述のとおり、sdhCABは、sdhCコード領域、sdhAコード領域、sdhBコード領域により、ゲノム上でオペロンを構成しているが、各プライマーと、各コード領域の位置関係は、図2Bに示されている。
即ち、コリネバクテリウム・グルタミカムATCC13032株のゲノムDNAを鋳型として、poxB遺伝子コード領域上流の約1000bpの領域と、該遺伝子コード領域下流の約1000bpの領域とをそれぞれ増幅させた。
なお、これらPCR反応では、上流領域についてはプライマーF6及びR6のペアーを用い、下流領域についてはプライマーF7及びR7を用いた(表15)。
なお、図2Cに、各プライマーと遺伝子コード領域との位置関係が模式的に示されている。
コリネバクテリウム菌の複製起点に係るDNA断片は、PCR法により、pBL1(和地正明博士より贈与、ヌクレオチド配列GenBankID:AF092037.1)を鋳型として、表16に示すプライマーF8及びR8のペアーを用いて増幅させた。さらに、大腸菌の複製起点に係るDNA断片は、PCR法により、pMW119(タカラバイオ株式会社)を鋳型として、表16に示すプライマーF9及びR9のペアーを用いて増幅させた。さらに、カナマイシン耐性遺伝子DNA断片は、PCR法により、pHSG299(タカラバイオ株式会社)を鋳型として、表16に示すプライマーF10及びR10のペアーを用いて増幅させた。
次いで、PCR反応をベースとした部位特異的変異導入法に基づき、各種アミノ酸置換を有する変異型ホスホエノールピルビン酸カルボキシラーゼ遺伝子DNA断片を増幅させ、それらDNA断片がそれぞれ、上記シャトルベクターpGEK004に挿入されてなるプラスミドを構築した。
構築したプラスミドの名称及びPEPCのアミノ酸置換の内容を、以下の表17に示す。
(2-2-1)pGE320(ppcD299N遺伝子)について
まず、PCR反応により、コリネATCC13032株のゲノムDNAを鋳型とし、表18に示すプライマーF11及びR11のペアーを用いて、コリネ型細菌で機能可能なプロモーターであるgapA遺伝子プロモーター領域を含むDNA断片を増幅させた。
ここで、PEPCのN末端側断片の増幅に用いたプライマーR12-1(リバースプライマー)と、PEPCのC末端側断片の増幅に用いたプライマーF13-1(フォワードプライマー)とは、PEPCのコード領域においてオーバラップしており、かつD299Nに係る変異コドン(表18にそれぞれ下線で示す「GTT」/「AAC」)を含んでいる。なお、相応する野生型コドンは「GAC」(センス鎖)である。
まず、pGE320の作製時と同様にして、PCR反応により、gapA遺伝子プロモーター領域を含むDNA断片を増幅させた。
さらに、PEPCコード領域については、まず、PCR法により、ATCC13032株ゲノムDNAを鋳型として、表18に示すプライマーF12と表19に示すプライマーR12-2とのペアーを用いることにより、PEPCのN末端側に相当する約2430bpの領域を増幅すると共に、同じくATCC13032株ゲノムDNAを鋳型として、表19に示すプライマーF13-2と表18に示すプライマーR13とのペアーを用いることによりPEPCのC末端側領域を含む約530bpの領域を増幅した。
まず、pGE320の作製時と同様にして、PCR反応により、gapA遺伝子プロモーター領域を含むDNA断片を増幅させた。
さらに、PEPCコード領域については、まず、PCR法により、ATCC13032株ゲノムDNAを鋳型として、表18に示すプライマーF12と表20に示すプライマーR12-3とのペアーを用いることにより、PEPCのN末端側に相当する約2430bpの領域を増幅すると共に、同じくATCC13032株ゲノムDNAを鋳型として、表20に示すプライマーF13-3と表18に示すプライマーR13とのペアーを用いることによりPEPCのC末端側領域を含む約530bpの領域を増幅した。
PCR法により、上述のプラスミドpGE320を鋳型として、プライマーF12とプライマーR13-2とのペアーを用い、gapA遺伝子プロモーター領域とppc遺伝子N末端側領域に相当するDNA断片を増幅させた。さらに、同じくPCR法により、プライマーF-14-2とプライマーR14とのペアーを用い、ppc遺伝子C末端側と3’下流域に相当するDNA断片を増幅させた。
上述のとおり取得したDNA断片2つを、pGEK004をBamHIで制限酵素処理することにより線状化したベクター断片に、In-Fusion cloning kit(タカラバイオ株式会社)を用いてタンデムに連結させて環状化し、プラスミドpGE333を取得した。
PCR法により、上述のプラスミドpGE320を鋳型として、プライマーF12とプライマーR13-3とのペアーを用い、gapA遺伝子プロモーター領域とppc遺伝子N末端側領域に相当するDNA断片を増幅させた。さらに、同じくPCR法により、プライマーF-14-3とプライマーR14とのペアーを用い、ppc遺伝子C末端側と3’下流域に相当するDNA断片を増幅させた。
上述のとおり取得したDNA断片2つを、pGEK004をBamHIで制限酵素処理することにより線状化したベクター断片に、In-Fusion cloning kit(タカラバイオ株式会社)を用いてタンデムに連結させて環状化し、プラスミドpGE322を取得した。
[試験例1]
(試験手順)
上述の電気パルス法により、上記(1)の項で作出したコリネバクテリウム ・グルタミカム遺伝子欠損株GES439(ATCC13032ΔldhΔsdhCAB株)に対して、上記(2-2)の項で構築したプラスミドpGEK004、pGE320、pGE343、pGE321、pGE333、pGE322をそれぞれ形質転換し、組換えコリネ型細菌を取得した。
アスパラギン酸生産試験の結果を、図4に示す。図4のグラフにおいて、縦軸は、反応後の試料におけるアスパラギン酸濃度を表す。さらに、以下の表21に、取得した組換えコリネ型細菌の遺伝子型、並びにアスパラギン酸生産試験により算出したアスパラギン酸生産効率(%)を示す。アスパラギン酸生産効率(%)の値は、菌体に取り込まれたグルコース0.5モルに対する生成アスパラギン酸の割合である。
(試験手順)
上述の電気パルス法により、上記(1)の項で作出したコリネバクテリウム ・グルタミカム遺伝子欠損株GES168(Δldh)、GES439(ΔldhΔsdhCAB)、GES524(ΔldhΔsdhCABΔpoxB)それぞれに対して、上記(2-2)の項で構築したプラスミドpGE333(ppcD299N/K813S)を形質転換し、組換えコリネ型細菌を取得した。
取得した各組換えコリネ型細菌を用いて、試験例1と同様の方法により、アスパラギン酸の生産試験を行った。
アスパラギン酸生産試験の結果を、図5に示す。図5のグラフにおいて、縦軸は、反応後の試料におけるアスパラギン酸濃度を表す。さらに、以下の表22に、取得した組換えコリネ型細菌の遺伝子型、並びにアスパラギン酸生産試験により算出したアスパラギン酸生産効率(%)を示す。アスパラギン酸生産効率(%)の値は、菌体に取り込まれたグルコース0.5モルに対する実際に生成されたアスパラギン酸の割合である。この値は、アスパラギン酸が、理論上、グルコース1モルから2モルできることに基く値である。
試験例1及び2では、組換えコリネ型細菌を、予め、A培地及びNA培地を用いて好気培養条件下に増殖させた後、遠心分離により培養液を取り除き、分離した菌体細胞を所定量のBT液に懸濁させてアスパラギン酸の生産反応を行った。これに対して、本試験例では、組換えコリネ型細菌をA培地及びNA培地を用いて好気培養条件下に増殖させた後に、遠心操作などにより菌体細胞はせずに、培養液をそのまま用いてアスパラギン酸生産反応を行った。以下に、その手順を示す。
なお、アミノ酸の同定及び測定には、アミノ酸分析システムProminence(株式会社島津製作所)を用いた。
本試験例におけるアスパラギン酸生産試験の結果を図6に示す。図6のグラフにおいて、縦軸は、反応後の試料におけるアスパラギン酸濃度を表す。
さらに、以下の表23に、取得した組換えコリネ型細菌の遺伝子型、並びにアスパラギン酸生産試験により算出したアスパラギン酸生産効率(%)を示す。アスパラギン酸生産効率(%)の値は、上述のとおり、菌体に取り込まれたグルコース0.5モルに対する実際に生成されたアスパラギン酸の割合である。
次に、エシェリキア・コリ(大腸菌)を用いて、本発明に係る組換え微生物及び該組換え微生物を用いてアスパラギン酸生産を行った例を示す。
(1)pflB遺伝子の破壊
まず、Datsenko and Wanner (Proc Natl Acad Sci U S A 2000, 97:6640-6645.)に記載されるBW25113株(lacIq rrnBT14 ΔlacZwj16 hsdR514 ΔaraBADAH33 ΔrhaBADLD78)を、当該文献に記載される方法に従い作製した。
上述のとおり取得したBW25113ΔpflB株に、再び、pKD46(Life Science Market)を形質転換し、得られた形質転換体について、上記同様の方法によりコンピテントセルを調製した。
次に、下記の表25に示すプライマーF15及びR15のペアーを用い、PCR反応により、pKD13を鋳型として、カナマイシン耐性遺伝子コード領域を含むDNA断片を増幅させた。ここで、プライマーF15及びR15はそれぞれ、大腸菌染色体DNAにおいてldhA遺伝子コード領域の上流域と下流域と相同なヌクレオチド配列を含む。
上述のとおり取得したBW25113ΔpflBΔldhA株に、再び、pKD46(Life Science Market)を形質転換し、得られた形質転換体について、上記同様の方法によりコンピテントセルを調製した。
次に、下記の表26に示すプライマーF16及びR16のペアーを用い、PCR反応により、pKD13を鋳型として、カナマイシン耐性遺伝子コード領域を含むDNA断片を増幅させた。ここで、プライマーF16及びR16はそれぞれ、大腸菌染色体DNAにおいてfrdA遺伝子コード領域の上流域と下流域と相同なヌクレオチド配列を含む。
上述のとおり取得したBW25113ΔpflBΔldhAΔfrdA株に、試験例1で構築したpGEK004、pGE333(ppcD229N/K813S)、pGE322(ppcD229N/N917G) をそれぞれ、定法により形質転換することにより、本発明所定の各種組換えエシェリキア・コリ菌株を取得した。
アミノ酸分析により得られたクロマトグラフを図7に示す。なお、図7に示すクロマトグラフにおいて、7分あたりに見られるピークがアスパラギン酸のピークである。さらに、以下の表27に、取得した組換えエシェリキア・コリ菌株の遺伝子型、アスパラギン酸生産試験により算出したアスパラギン酸生産効率(%)等を示す。アスパラギン酸生産効率(%)の値は、菌体に取り込まれたグルコース0.5モルに対する実際に生成されたアスパラギン酸の割合である。この値は、アスパラギン酸が、理論上、グルコース1モルから2モルできることに基く値である。
実施例において、各種遺伝子コード領域、プロモーター領域等のクローニングには上述のとおりIn-Fusion cloning kit(タカラバイオ株式会社)を利用した工程もあるが、PCR増幅の際に使用したプライマーペアーについては、フォワード/リバースプライマーの5’末端にはそれぞれ、上記クローニングキットの指示に従い適切なアダプター配列が付加されたものであることを補足する。
Claims (26)
- 下記の条件(I)~(III)の全てを充足する、遺伝子組換え微生物:
条件(I)上記遺伝子組換え微生物に対応する野生型微生物と比較して、コハク酸デヒドロゲナーゼ活性又はフマル酸還元酵素活性が低減され又は不活化されていること;
条件(II)上記野生型微生物と比較して、乳酸デヒドロゲナーゼ活性が低減され又は不活化されていること;
条件(III)野生型ホスホエノールピルビン酸カルボキシラーゼ活性におけるアスパラギン酸によるフィードバック阻害に対し抵抗性を示す改変型ホスホエノールピルビン酸カルボキシラーゼ活性、又は上記野生型微生物が示す野生型ホスホエノールピルビン酸カルボキシラーゼ活性よりもアスパラギン酸によるフィードバック阻害に対する抵抗性が高い外来性ホスホエノールピルビン酸カルボキシラーゼ活性を有すること。 - さらに、条件(IV)として、上記野生型微生物と比較して、ピルビン酸:キノンオキシドレダクターゼが低減され又は不活化されていることを充足する、請求項1に記載の遺伝子組換え微生物。
- (p)請求項1又は2に記載の遺伝子組換え微生物の菌体又はその菌体処理物を用いて目的物質を生成させること;並びに
(q)上記目的物質を回収すること、
を含む、目的物質を生産する方法。 - 工程(p)において、上記遺伝子組換え微生物が実質的に増殖しない還元条件下の反応媒体(X)中で、該遺伝子組換え微生物の菌体又はその菌体処理物を反応させることにより目的物質を生成させる、請求項3に記載の方法。
- 上記反応媒体(X)の酸化還元電位が、-200ミリボルトから-500ミリボルトの範囲にある所定の値である、請求項4に記載の方法。
- 上記反応媒体(X)が糖類を含む、請求項4又は5に記載の方法。
- 上記反応媒体(X)がグルコースを含む、請求項4~6の何れか1項に記載の方法。
- 工程(p)の前に、
(p’)所定の培地(Y)中で、好気条件下に、上記遺伝子組換え微生物を予め培養し及び増殖させること、
をさらに含み、工程(p’)において増殖させた該遺伝子組換え微生物の菌体又はその菌体処理物を工程(p)に供試する、請求項3~7の何れか1項に記載の方法。 - 上記目的物質が、オキサロ酢酸、リンゴ酸又は生合成経路上これらの化合物を経由する代謝産物である、請求項3~8の何れか1項に記載の方法。
- 上記目的物質が、アスパラギン酸又はこれから誘導される代謝産物である、請求項3~9の何れか1項に記載の方法。
- 上記目的物質が、アスパラギン酸、ベータアラニン、又はアスパラギンである、請求項3~10の何れか1項に記載の方法。
- コリネ型細菌に属する微生物が保有する野生型ホスホエノールピルビン酸カルボキシラーゼのアミノ酸配列に対して、該野生型ホスホエノールピルビン酸カルボキシラーゼ活性におけるアスパラギン酸によるフィードバック阻害を低減し得るアミノ酸変異を有し、
該アミノ酸変異が、配列番号2に示すアミノ酸配列を基準として、
(g)第299番目のアスパラギン酸に相当するアミノ酸のアスパラギンへのアミノ酸置換と、
(i)第813番目のリシンに相当するアミノ酸の所定のアミノ酸へのアミノ酸置換ただし、置換後のアミノ酸はリシンではないものとする。);又は
(l)第917番目のアスパラギンに相当するアミノ酸の所定のアミノ酸へのアミノ酸置換(ただし、置換後のアミノ酸はアスパラギンではないものとする。)と、
を少なくとも含み、
上記野生型ホスホエノールピルビン酸カルボキシラーゼのアミノ酸配列に対して、上記(g)、(i)又は(l)に規定のアミノ酸置換のみを有してなるタンパク質よりも、アスパラギン酸によるフィードバック阻害に対する抵抗性が高い、
変異型ホスホエノールピルビン酸カルボキシラーゼ。 - 下記の(J)、(K)及び(L)の何れか1つに示すアミノ酸配列を有する、請求項12に記載の変異型ホスホエノールピルビン酸カルボキシラーゼ:
(J)配列番号2~13の何れか1つに示すアミノ酸配列において、上記(g)に示すアミノ酸置換と、上記(i)又は(l)に示すアミノ酸置換とを導入してなるアミノ酸配列;
(K)上記(J)に規定のアミノ酸配列において、1又は複数のアミノ酸が欠失、置換及び/又は付加されたアミノ酸配列(但し、上記各アミノ酸置換は維持されているものとする。);
(L)上記(J)に規定のアミノ酸配列に対して少なくとも60%の配列同一性を有するアミノ酸配列(但し、上記各アミノ酸置換は維持されているものとする。)。 - 上記(J)に規定のアミノ酸配列は、配列番号2に示すアミノ酸配列に対して、上記アミノ酸置換を導入してなるアミノ酸配列である、請求項13に記載の変異型ホスホエノールピルビン酸カルボキシラーゼ。
- 配列番号2~13の何れか1つに示すアミノ酸配列に対して、上記アミノ酸置換を導入してなるアミノ酸配列を有する、請求項12~14の何れか1項に記載の変異型ホスホエノールピルビン酸カルボキシラーゼ。
- 請求項12~15の何れか1項に記載の変異型ホスホエノールピルビン酸カルボキシラーゼをコードする核酸。
- DNA断片である、請求項16に記載の核酸。
- 請求項16又は17に記載の核酸が導入された、遺伝子組換え微生物。
- 下記の条件(I)~(III)の全てを充足する、請求項18に記載の遺伝子組換え微生物:
条件(I)上記遺伝子組換え微生物に対応する野生型微生物と比較して、コハク酸デヒドロゲナーゼ活性又はフマル酸還元酵素活性が低減され又は不活化されていること;
条件(II)上記野生型微生物と比較して、乳酸デヒドロゲナーゼ活性が低減され又は不活化されていること;
条件(III)野生型ホスホエノールピルビン酸カルボキシラーゼ活性におけるアスパラギン酸によるフィードバック阻害に対し抵抗性を示す改変型ホスホエノールピルビン酸カルボキシラーゼ活性、又は上記野生型微生物が示す野生型ホスホエノールピルビン酸カルボキシラーゼ活性よりもアスパラギン酸によるフィードバック阻害に対する抵抗性が高い外来性ホスホエノールピルビン酸カルボキシラーゼ活性を有すること。 - さらに、条件(IV)として、上記野生型微生物と比較して、ピルビン酸:キノンオキシドレダクターゼが低減され又は不活化されていることを充足する、請求項19に記載の遺遺伝子組換え微生物。
- グラム陽性菌に属する遺伝子組換え微生物である、請求項1及び2並びに請求項18~20の何れか1項に記載の遺伝子組換え微生物。
- コリネ型細菌に属する遺伝子組換え微生物である、請求項21に記載の遺伝子組換え微生物。
- グラム陰性菌に属する遺伝子組換え微生物である、請求項1及び2並びに請求項18~20の何れか1項に記載の遺伝子組換え微生物。
- エシェリキア属に属する遺伝子組換え微生物である、請求項23に記載の遺伝子組換え微生物。
- さらに、条件(V)として、上記野生型微生物と比較して、ピルビン酸ギ酸リアーゼ活性が低減され又は不活化されていることを充足する、請求項23又は24に記載の遺伝子組換え微生物。
- 請求項3~11の何れか1項に記載の方法であって、工程(p)における上記遺伝子組換え微生物が、請求項18~25の何れか1項に記載の遺伝子組換え微生物である方法。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201980069550.XA CN112888776B (zh) | 2019-04-12 | 2019-09-06 | 生产目标物质的方法 |
US17/602,998 US20220177924A1 (en) | 2019-04-12 | 2019-09-06 | Genetically modified microorganism and method for producing target substance using same |
CN202310343756.5A CN116445387A (zh) | 2019-04-12 | 2019-09-06 | 生产目标物质的方法、转基因微生物及核酸的应用 |
KR1020217036600A KR20210151897A (ko) | 2019-04-12 | 2019-09-06 | 유전자 재조합 미생물 및 이를 이용한 목적 물질의 생산방법 |
EP19924352.8A EP3954756A4 (en) | 2019-04-12 | 2019-09-06 | GENETICALLY MODIFIED MICRO-ORGANISM AND METHOD OF PRODUCTION OF A TARGET SUBSTANCE USING THE SAME |
JP2021513154A JP7360741B2 (ja) | 2019-04-12 | 2019-09-06 | 遺伝子組換え微生物及びこれを用いた目的物質の生産方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019076629 | 2019-04-12 | ||
JP2019-076629 | 2019-04-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020208842A1 true WO2020208842A1 (ja) | 2020-10-15 |
Family
ID=72751049
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2019/035286 WO2020208842A1 (ja) | 2019-04-12 | 2019-09-06 | 遺伝子組換え微生物及びこれを用いた目的物質の生産方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20220177924A1 (ja) |
EP (1) | EP3954756A4 (ja) |
JP (1) | JP7360741B2 (ja) |
KR (1) | KR20210151897A (ja) |
CN (2) | CN112888776B (ja) |
WO (1) | WO2020208842A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023068295A1 (ja) * | 2021-10-21 | 2023-04-27 | 伊藤忠商事株式会社 | バイオプロセス、微生物を培養する方法及び標的物質を製造する方法並びにバイオプロセス装置 |
JPWO2023095896A1 (ja) * | 2021-11-26 | 2023-06-01 | ||
KR20240024116A (ko) | 2021-06-29 | 2024-02-23 | 디아이씨 가부시끼가이샤 | 아스파라긴산 조성물, 폴리숙신이미드 조성물, 폴리아스파라긴산 조성물, 및 가교 폴리아스파라긴산 조성물 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116286364B (zh) * | 2022-09-08 | 2023-11-10 | 杭州秀川科技有限公司 | 一种促进厌氧微生物分离和培养的复合物及其应用 |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0870860A (ja) | 1993-08-24 | 1996-03-19 | Ajinomoto Co Inc | 変異型ホスホエノールピルビン酸カルボキシラーゼとその遺伝子及びアミノ酸の製造方法 |
JP2001190297A (ja) * | 1999-12-10 | 2001-07-17 | Degussa Huels Ag | 遺伝子sdhA、sdhBおよびsdhCをコードする新規ヌクレオチド配列 |
JP2003503064A (ja) | 1999-06-29 | 2003-01-28 | アーカー−ダニエルズ−ミッドランド カンパニー | 炭素同化の調節 |
JP2006000091A (ja) * | 2004-05-20 | 2006-01-05 | Mitsubishi Chemicals Corp | オキザロ酢酸またはオキザロ酢酸誘導体の製造方法 |
JP2006254795A (ja) | 2005-03-17 | 2006-09-28 | Shimane Univ | アスパラギン酸脱水素酵素、アラニン脱水素酵素、l−アスパラギン酸製造方法、および、d−リンゴ酸製造方法 |
JP2006254730A (ja) | 2005-03-15 | 2006-09-28 | Univ Of Tokushima | 新規なアスパラギン酸デヒドロゲナーゼ |
JP2006320278A (ja) * | 2005-05-20 | 2006-11-30 | Research Institute Of Innovative Technology For The Earth | コリネ型細菌による高効率なジカルボン酸の製造方法 |
JP2007043947A (ja) | 2005-08-09 | 2007-02-22 | Research Institute Of Innovative Technology For The Earth | コリネ型細菌を用いる還元条件でのアミノ酸の製造方法 |
JP2007514436A (ja) * | 2003-12-18 | 2007-06-07 | ビーエーエスエフ アクチェンゲゼルシャフト | 発酵による精密化学物質の製造方法 |
JP2008513023A (ja) * | 2004-09-17 | 2008-05-01 | ライス ユニバーシティー | 高コハク酸生産細菌 |
JP2010183860A (ja) | 2009-02-11 | 2010-08-26 | Shimane Univ | 常温型アスパラギン酸脱水素酵素およびl−アスパラギン酸製造方法 |
JP2016506738A (ja) * | 2013-02-07 | 2016-03-07 | ティアンジン インスティテュート オブ インダストリアル バイオテクノロジー、チャイニーズ アカデミーオブ サイエンシーズTianjin Institute Of Industrial Biotechnology, Chinese Academy Of Sciences | 5−アミノレブリン酸の高生産株及びその製造方法と使用 |
JP2016516435A (ja) | 2013-04-23 | 2016-06-09 | シージェイ チェイルジェダン コーポレーションCj Cheiljedang Corporation | L−アルギニン産生能が向上したコリネバクテリウム属微生物およびこれを用いたl−アルギニンの産生方法 |
JP2019076629A (ja) | 2017-10-26 | 2019-05-23 | アップリカ・チルドレンズプロダクツ合同会社 | 子守帯 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62109133A (ja) | 1985-11-08 | 1987-05-20 | Nec Corp | マイクロプログラム制御装置 |
RU2010101135A (ru) | 2010-01-15 | 2011-07-20 | Закрытое акционерное общество "Научно-исследовательский институт "Аджиномото-Генетика" (ЗАО АГРИ) (RU) | Бактерия семейства enterobacteriaceae - продуцент l-аспартата или метаболитов, производных l-аспартата, и способ получения l-аспартата или метаболитов, производных l-аспартата |
EP2495317A1 (en) * | 2011-03-01 | 2012-09-05 | Technische Universität Hamburg-Harburg | Modified phosphoenolpyruvate carboxylase from Corynebacterium glutamicum and uses thereof |
-
2019
- 2019-09-06 WO PCT/JP2019/035286 patent/WO2020208842A1/ja unknown
- 2019-09-06 CN CN201980069550.XA patent/CN112888776B/zh active Active
- 2019-09-06 CN CN202310343756.5A patent/CN116445387A/zh active Pending
- 2019-09-06 JP JP2021513154A patent/JP7360741B2/ja active Active
- 2019-09-06 EP EP19924352.8A patent/EP3954756A4/en active Pending
- 2019-09-06 KR KR1020217036600A patent/KR20210151897A/ko not_active Application Discontinuation
- 2019-09-06 US US17/602,998 patent/US20220177924A1/en active Pending
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0870860A (ja) | 1993-08-24 | 1996-03-19 | Ajinomoto Co Inc | 変異型ホスホエノールピルビン酸カルボキシラーゼとその遺伝子及びアミノ酸の製造方法 |
JP2003503064A (ja) | 1999-06-29 | 2003-01-28 | アーカー−ダニエルズ−ミッドランド カンパニー | 炭素同化の調節 |
JP2001190297A (ja) * | 1999-12-10 | 2001-07-17 | Degussa Huels Ag | 遺伝子sdhA、sdhBおよびsdhCをコードする新規ヌクレオチド配列 |
JP2007514436A (ja) * | 2003-12-18 | 2007-06-07 | ビーエーエスエフ アクチェンゲゼルシャフト | 発酵による精密化学物質の製造方法 |
JP2006000091A (ja) * | 2004-05-20 | 2006-01-05 | Mitsubishi Chemicals Corp | オキザロ酢酸またはオキザロ酢酸誘導体の製造方法 |
JP2008513023A (ja) * | 2004-09-17 | 2008-05-01 | ライス ユニバーシティー | 高コハク酸生産細菌 |
JP2006254730A (ja) | 2005-03-15 | 2006-09-28 | Univ Of Tokushima | 新規なアスパラギン酸デヒドロゲナーゼ |
JP2006254795A (ja) | 2005-03-17 | 2006-09-28 | Shimane Univ | アスパラギン酸脱水素酵素、アラニン脱水素酵素、l−アスパラギン酸製造方法、および、d−リンゴ酸製造方法 |
JP2006320278A (ja) * | 2005-05-20 | 2006-11-30 | Research Institute Of Innovative Technology For The Earth | コリネ型細菌による高効率なジカルボン酸の製造方法 |
JP2007043947A (ja) | 2005-08-09 | 2007-02-22 | Research Institute Of Innovative Technology For The Earth | コリネ型細菌を用いる還元条件でのアミノ酸の製造方法 |
JP2010183860A (ja) | 2009-02-11 | 2010-08-26 | Shimane Univ | 常温型アスパラギン酸脱水素酵素およびl−アスパラギン酸製造方法 |
JP2016506738A (ja) * | 2013-02-07 | 2016-03-07 | ティアンジン インスティテュート オブ インダストリアル バイオテクノロジー、チャイニーズ アカデミーオブ サイエンシーズTianjin Institute Of Industrial Biotechnology, Chinese Academy Of Sciences | 5−アミノレブリン酸の高生産株及びその製造方法と使用 |
JP2016516435A (ja) | 2013-04-23 | 2016-06-09 | シージェイ チェイルジェダン コーポレーションCj Cheiljedang Corporation | L−アルギニン産生能が向上したコリネバクテリウム属微生物およびこれを用いたl−アルギニンの産生方法 |
JP2019076629A (ja) | 2017-10-26 | 2019-05-23 | アップリカ・チルドレンズプロダクツ合同会社 | 子守帯 |
Non-Patent Citations (20)
Title |
---|
"Bargeys Manual of Determinative Bacteriology", 1974, pages: 599 |
"GenBank", Database accession no. AF092037.1 |
"Nogeikagaku Jikkensho (Agricultural Chemistry Experiments Book", vol. 3, 1990, SANGYO TOSHO PUBLISHING CO. |
BIOINFORMATICS, vol. 23, 1 November 2007 (2007-11-01), pages 2947 - 2948 |
CHEN Z ET AL.: "Deregulation of feedback inhibition of phosphoenolpyruvate carboxylase for improved lysine production in Corynebacterium glutamicum", APPL. ENVIRON. MICROBIOL., vol. 80, no. 4, 2014, pages 1388 - 1393, XP055550364, DOI: 10.1128/AEM.03535-13 * |
CHEN ZBOMMAREDDY RRFRANK DRAPPERT SZENG AP, APPL ENVIRON MICROBIOL, vol. 80, no. 4, February 2014 (2014-02-01), pages 1388 - 93 |
DATSENKOWANNER, PROC NATL ACAD SCI U S A, vol. 97, 2000, pages 6640 - 6645 |
INUI, M ET AL.: "Metabolic analysis of Corynebacterium glutamicum during lactate and succinate productions under oxygen deprivation conditions", J. MOL. MICROBIOL. BIOTECHNOL., vol. 7, 2004, pages 182 - 196, XP009070835, DOI: 10.1159/000079827 |
LITSANOV BKABUS ABROCKER MBOTT M, MICROB BIOTECHNOL., vol. 5, no. 1, January 2012 (2012-01-01), pages 116 - 28 |
MITSUHASHI S ET AL.: "Disruption of malate: quinone oxidoreductase increases L-lysine production by Corynebacterium glutamicum", BIOSCI. BIOTECHNOL. BIOCHEM., vol. 70, no. 11, 2006, pages 2803 - 2806, XP002566301, DOI: 10.1271/bbb.60298 * |
OMUMASABA, C.A. ET AL.: "Corynebacterium glutamicum glyceraldehyde-3-phosphate dehydrogenase isoforms with opposite, ATP-dependent regulation", J. MOL. MICROBIOL. BIOTECHNOL., vol. 8, 2004, pages 91 - 103, XP009510178, DOI: 10.1159/000084564 |
PFENNIG, N: "The Prokaryotes, A Handbook on Habitats Isolation and Identification of Bacteria", 1981, SPRINGER VERLAG., article "The dissimilatory sulfate-reducing bacteria", pages: 926 - 940 |
SAMBROOK ET AL.: "Molecular Cloning", 1989, COLD SPRING HARBOR LABORATORY PRESS |
TOKUYAMA K ET AL.: "Application of adaptive laboratory evolution to overcome a flux limitation in an Escherichia coli production strain", BIOTECHNOL. BIOENG., vol. 115, no. 6, 2018, pages 1542 - 1551, XP055747460 * |
VAN DER REST ET AL., APPL. MICROBIOL BIOTECHNOL, vol. 52, 1999, pages 541 - 545 |
WADA M ET AL.: "Effects of phosphoenolpyruvate carboxylase desensitization on glutamic acid production in Corynebacterium glutamicum ATCC 13032", J. BIOSCI. BIOENG., vol. 121, no. 2, 2016, pages 172 - 177, XP029378597 * |
WADA MSAWADA KOGURA KSHIMONO YHAGIWARA TSUGIMOTO MONUKI AYOKOTA A, J BIOSCI BIOENG, vol. 121, no. 2, February 2016 (2016-02-01), pages 172 - 7 |
YANO M ET AL.: "The replacement of Lys620 by serine desensitizes Escherichia coli phosphoenolpyruvate carboxylase to the effects of the feedback inhibitors L-aspartate and L-malate", EUR. J. BIOCHEM., vol. 247, no. 1, 1997, pages 74 - 81, XP055747455 * |
YANO MLIZUI K, EUR J BIOCHEM., vol. 247, no. 1, 1 July 1997 (1997-07-01), pages 74 - 81 |
YOSHINAGA, TIZUI, KKATSUKI, H, J. BIOCHEM, vol. 68, 1970, pages 747 - 750 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20240024116A (ko) | 2021-06-29 | 2024-02-23 | 디아이씨 가부시끼가이샤 | 아스파라긴산 조성물, 폴리숙신이미드 조성물, 폴리아스파라긴산 조성물, 및 가교 폴리아스파라긴산 조성물 |
WO2023068295A1 (ja) * | 2021-10-21 | 2023-04-27 | 伊藤忠商事株式会社 | バイオプロセス、微生物を培養する方法及び標的物質を製造する方法並びにバイオプロセス装置 |
JPWO2023068295A1 (ja) * | 2021-10-21 | 2023-04-27 | ||
JPWO2023095896A1 (ja) * | 2021-11-26 | 2023-06-01 | ||
WO2023095896A1 (ja) * | 2021-11-26 | 2023-06-01 | Dic株式会社 | 遺伝子組換え微生物、及びアスパラギン酸を生産する方法 |
Also Published As
Publication number | Publication date |
---|---|
CN112888776B (zh) | 2023-05-26 |
US20220177924A1 (en) | 2022-06-09 |
EP3954756A1 (en) | 2022-02-16 |
EP3954756A4 (en) | 2022-11-30 |
JP7360741B2 (ja) | 2023-10-13 |
JPWO2020208842A1 (ja) | 2020-10-15 |
CN112888776A (zh) | 2021-06-01 |
KR20210151897A (ko) | 2021-12-14 |
CN116445387A (zh) | 2023-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107034250B (zh) | 谷氨酸类l-氨基酸的制造方法 | |
JP7360741B2 (ja) | 遺伝子組換え微生物及びこれを用いた目的物質の生産方法 | |
JP4427878B2 (ja) | 析出を伴う発酵法によるl−グルタミン酸の製造法 | |
TWI573869B (zh) | 導入有二氧化碳固定循環之微生物 | |
JP4595506B2 (ja) | L−アミノ酸生産菌及びl−アミノ酸の製造方法 | |
JP6881448B2 (ja) | アルデヒドの製造方法 | |
KR100674401B1 (ko) | L-글루탐산-생성 세균 및 l-글루탐산 제조 방법 | |
JP7380768B2 (ja) | アルデヒドの製造方法 | |
KR20140091742A (ko) | 발효법에 의한 목적 물질의 제조법 | |
EP3109318B1 (en) | Microorganisms for producing putrescine or ornithine and process for producing putrescine or ornithine using them | |
AU2016297226B2 (en) | Microorganisms for producing putrescine or ornithine and process for producing putrescine or ornithine using them | |
JP7074133B2 (ja) | 目的物質の製造方法 | |
JP2022082679A (ja) | 目的物質の製造方法 | |
WO2014115815A1 (ja) | 二酸化炭素固定回路を導入した微生物 | |
JPWO2020208842A5 (ja) | ||
JP3921866B2 (ja) | L−グルタミン酸生産菌及びl−グルタミン酸の製造法 | |
JP4144131B2 (ja) | L−グルタミン酸生産菌及びl−グルタミン酸の製造法 | |
JP2017518759A (ja) | L−トリプトファン生産能を有するエシェリキア属微生物及びこれを用いたl−トリプトファンの製造方法 | |
JP2017216881A (ja) | ジカルボン酸の製造方法 | |
US20150111261A1 (en) | L-threonine-producing escherichia coli and method for producing l-threonine using the same | |
RU2672323C2 (ru) | Микроорганизм для продуцирования диамина и способ получения диамина с его использованием | |
RU2696504C2 (ru) | Микроорганизм для продуцирования диамина и способ получения диамина с его использованием | |
WO2022092018A1 (ja) | L-アミノ酸の製造法 | |
WO2023095896A1 (ja) | 遺伝子組換え微生物、及びアスパラギン酸を生産する方法 | |
US20150118720A1 (en) | Process for producing amino acid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19924352 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2021513154 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20217036600 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2019924352 Country of ref document: EP Effective date: 20211112 |